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The use of a cystine binding protein assay to establish the diagnosis of cystinosis was 
investigated. The assay has a lower limit of detection of 0.0314mol/l, is linear to a 
concentration of 1.5, umol/I and has a coefficient of variation of 1.7 and 15.0% 
between 0.05 and 0.614mol/l. In 32 patients the mean ± SD pre-treatment leucocyte 
cystine concentration was 5.78 ± 2.49 nmol 1/2 cystine per mg protein (controls 0.10 
± 0.05). The median polymorphonuclear leucocyte cystine concentration in a group 
of 24 obligate heterozygotes was 0.55 (range 0.23 - 1.79) nmol 1/2 cystine per mg 
protein (controls 0.10, range 0.04 - 0.38). 
The effects of single doses of phosphocysteamine solution, rectal cysteamine gel, 
intravenous cysteamine and a cysteamine capsule were studied in 10 patients with 
cystinosis. No significant diurnal variation in leucocyte cystine was found. Compared 
with the intravenous dose, cysteamine was poorly absorbed from rectal gel (21 % 
bioavailability) but well absorbed after administration of either oral 
phosphocysteamine solution (73% bioavaflability) or a cysteamine capsule (50% 
bioavailability). oral phosphocysteamine (10mg/kg cysteamine base), intravenous 
cysteamine (5mg/kg) and cysteamine capsule (15mg/kg) significantly reduced the 
mean leucocyte cystine with maximal depletion 1-3 hours after the dose. At 12 hours 
the mean leucocyte cystine was significantly lower than the pre-treatment level in each 
of these studies. Rectal cysteamine did not significantly reduce the mean leucocyte 
cystine concentration. In conclusion, phosphocysteamine suspension may be 
administered 12 hourly. Rectal cysteamine administration is feasible but higher doses 
are required before efficacy can be judged. A cysteamine capsule may prove to be a 
viable alternative to oral phosphocysteamine. 
59 patients have received cysteamine and/or phosphocysteamine in the UK up to May 
1990. In the 44 pre-transplant patients, cysteamine did not prevent a decline in 
glomerular renal function but a normal growth rate was maintained. The inability to 
demonstrate a significant reduction in leucocyte cystine concentrations suggests that 
monitoring of therapy needs to be improved. 
P2 
Errata 
Page 32: MgCL should be MgC12, 
Page 33: Units of hexosaminidase activity should be per minute per unit 
hexosaminidase. 
Page 103: Structures of cystine and cysteine are incorrect. See page 25 for correct 
versions. 
Page 108: Units for PRCIO should be (mg/dl)-'. 
Page 115: Data are shown as mean ± SEM. 
Page 120: Figure 6.1 refers to data from 34 patients (and not 36 as stated). 
The regression equation should read: y= -0.0018x + 0.019. 
Page 137: A blood sample was taken at 20.00h and not 22.00h as stated. 
Page 187: Duration of therapy was incorrectly calculated in one patient, giving the 
impression that she started therapy at 9 months. This does not affect the 
statistical analysis. 
Page 192: The data for PMN leucocyte cystine concentrations are not normally 
distributed and should be log transformed. The means for the log 
transformed PMN cystines in the normal controls and obligate 
heterozygotes are 0.13 and 0.57nmol 1/2 cys/mg protein respectively. 
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Chapter 1: Introduction 
Cystinosis is a rare metabolic disorder inherited in an autosomal recessive manner. It 
causes renal dysfunction and growth failure in early childhood. The underlying 
biochemical abnormality is a defect in lysosomal cystine transport which leads to 
intracellular cystine accumulation. The proximal renal tubule appears to be 
particularly sensitive to cystine toxicity. 
Children present with features of the renal Fanconi syndrome (polyuria, polydipsia, 
poor growth and rickets). Without specific treatment, patients progress into end-stage 
renal failure by the end of the first decade of life. With the advent of successful renal 
transplantation, patients are now able to survive into adulthood. However, although 
the donor kidney does not develop features of cystinosis, widespread cystine 
accumulation in other organs leads to multisystem disease. Thus older transplanted 
patients can develop endocrine, visual and neurological dysfunction. Despite 
transplantation, growth continues to be poor and short stature is universal in adults. 
Cystinosis has an approximate incidence of 1/175,000 births in Europe but there 
remain cases who are not diagnosed until after their death. Older methods of diagnosis 
relied on the demonstration of cystine crystals in biopsy specimens. This invasive and 
specialised procedure meant that confirmation of the diagnosis was difficult and 
restricted to centres of excellence. In the 1960's Schneider et al. demonstrated that the 
cystine content of leucocytes was increased in children with cystinosis (Schneider et 
al., 1967). Determination of the leucocyte cystine concentration became the most 
convenient biochemical method- of diagnosis. In the UK, leucocyte cystine 
concentrations have traditionally been measured on an amino acid analyzer. However 
this method is relatively slow, insensitive and expensive. Oshima et al. described an 
assay for measuring cystine in a variety of biological specimens, utilising a specific 
bacterial cystine, binding protein (Oshima et al., 1974). This method was in 
widespread use in North America but there was no clinical experience of the technique 
in the United Kingdom. Thus the first step in this research project on cystinosis was 
to set up and further characterise this assay. Once in place, cystine levels were 
determined in leucocytes, chorion villous samples, amniocytes and tissue samples. 
Determination of the cystine content of a purified polymorphonuclear leucocyte pellet 
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led to the ability to distinguish heterozygotes for cystinosis from normal individuals 
(Smolin et al., 1987). 
The treatment of cystinosis involves replacement of fluid and electrolyte losses, good 
nutrition and vitamin D supplements. The discovery of cysteamine, an agent that 
depletes cystine both in vitro and in vivo, led to a new era in the management of the 
condition. Cysteamine acts by reacting with cystine to form a mixed disulphide which 
is transported out of the lYsosome. Cysteamine treatment slows the progression of 
renal glomerular disease and improves growth. However, the drug has a foul taste, 
frequently causes nausea & vomiting and leads to the unpleasant smell of free 
sulphides on the breath. Despite the use of cysteamine and its pro-drug, 
phosphocysteamine, for over 14 years, the pharmacokinetics and pharmacodynamics 
of the drugs have not been reported. The second aim of this project was to undertake 
such studies in an effort to improve the efficacy and tolerability of these compounds. 
As part of this investigation, new routes and formulations of the drug were studied. 
A postal survey of paediatric nephrologists in the UK revealed that there are 
approximately 80 patients with cysfinosis in this country. Many of these have received 
cysteamine in the last 14 years but there has been no formal review of the efficacy of 
their therapy. A retrospective study of the experience of cysteamine treatment in the 
UK was therefore undertaken. These data have formed part of an application by North 
American paediatricians to the United States Government Food and Drug 
Administration to produce cysteamine under the Orphan Drug Program. 
Although cysteamine has made-a ma or impact on the course of cystinosis, a greater 
understanding of the molecular basis of the condition is still required. The site of the 
cystinosis gene is not known, indeed there is not yet chromosomal localisation. There 
is marked clinical heterogeneity in cystinosis. In addition, there are rarer late-onset 
and adult (benign) forms of the disorder. Identification of the gene will lead to a 
better understanding of the pathogenesis of cystinosis and mutation analysis will help 
to explain the heterogeneity of patients. Ultimately there will be the prospect of gene 
therapy. 
The search for the cystinosis gene is a major undertaking. The first steps have been 
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addressed in this project. Other groups have tried to isolate the human cystine binding 
protein. These efforts have, so far, been unsuccessful. A group has therefore been 
established at Guy's Hospital to undertake a search of every autosome to look for 
linkage between markers and the cystinosis gene. A reliable method of determining 
heterozygote status greatly increases the linkage content of each family.. A number of 
highly informative families in the UK, with 2 affected children and/or consanguinity, 
have been studied. 
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Chapter 2: Biochemical aspects of cystinosis 
Description of cystine 
The first description of cystine was made by William Hyde Wollaston in a paper read 
on July 5th, 1810 and subsequently published in the Philosophical Transactions of the 
Royal Society (Wollaston WH, 1810). Wollaston trained as a physician but later 
became more famous for his contribution to physical chemistry and optics. He had 
developed an interest and expertise in the study of urinary calculi. 
As a result of this interest, he received from Dr. Reeve in Norwich, a portion of 
calculus removed from Dr. Reeve's brother at the age of 5 years. Another calculus of 
the same nature was sent to him by Mr. Lucas, a surgeon at Guy's Hospital, who had 
removed it from the bladder of a 36 year old man called William Small (Wollaston 
WH, 1810). This latter calculus can still be viewed in the Gordon Museum at Guy's 
Hospital. It is likely that both these patients suffered from cystinuria. Wollaston 
performed various physical and chemical analyses upon these two calculi: "Under the 
blow-Pipe it may be distinguished ftom uric acid by the smell, which at no period 
resembles that ofprussic acid; but in addition to the usual smell of burned animal 
substances, there is a peculiarfoetor, of which I cannot give a correct idea, as I know 
of no smell which it can be said to resemble". 
He described the characteristic hexagonal crystals of cystine and attempted to dissolve 
portions of the calculi in several fluids including water, alcohol, various acids and 
alkalies: " 7he combination of this substance with acids, may be made to crystallize 
without difficulty, and they form*slender spicula radiatingfrom a center [sic] ....... 
Wollaston's Test, as performed in laboratories today, involves adding hydrochloric 
acid to a tissue sample in which there are suspected crystals of cystine. Wollaston 
concludes: "From the ready disposition of this substance to unite with both acids and 
alkalies, it would appear to be an oxide ..... and since both calculi that have yet been 
observed have been takenfirom the bladder, it may be convenient to give it the name 
of cystic oxide... ". Although Wollaston himself expressed the hope that the name 
would not be altered, it has come to be shortened to cystine. 
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Chemistry 
Cystine is a dibasic amino acid with a molecular weight of 240.3. It is the disulphide 



















Cystine is very insoluble in water but the addition of weak acid or alkali increases 
solubility. It is insoluble in alcohol, a property used diagnostically in the 
histochemical preparation of tissue to demonstrate cystine crystals. 
Metabotism of cysteine 
Synthesis: trans-sulphuration pathway 
Cysteine results firstly from hydrolysis of protein and secondly, from de novo, 
synthesis via the metabolism of methionine in the trans-sulphuration pathway. 
This pathway describes the conversion of methionine, an essential amino acid, to 
cysteine. A full description of the pathway has been published elsewhere (Mudd et al., 
1989). 
S-adenosylmethionine (SAM) is formed by the transfer of an adenosyl moiety of ATP 
to methionine, catalysed. by methionine adenosyl transferase. The adenosyl moiety is 
linked via a sulphonium bond, making S-adenosylmethionine a "high energy" 
compound, ie. each substituent is capable of participating in transfer reactions. This 
allows SAM to act as a methyl donor in many reactions, yielding the next compound 
in the pathway, S-adenosylhomocysteine (SAH). SAH is cleaved by a hydrolase 
enzyme to hornocysteine and adenosine. 
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Homocysteine may be methylated to methionine either with betaine, catalysed by 
betaine-homocysteine methyltransferase or using 5-methyltetrahydrofolate as a methyl 
donor. Alternatively homocysteine may condense with serine to form cystathionine, 
catalysed by cystathionine B synthetase. Cystathionine is then cleaved to cysteine and 
ketobutyrate by cystathionase. 
Whilst cysteine is not normally an essential amino acid, deficiencies of the enzymes 
converting homocysteine to cysteine will make it an obligatory requirement. Thus a 
deficiency of cystathionine 8 synthetase (in cases of homocystinuria) or of 
cystathionase (deficient in foetal tissue and in cases of cystathionuria) will make 
cysteine an essential amino acid. 
Degradation 
Approximately two-thirds of ingested cysteine is oxidised, mainly to inorganic 
sulphate and to taurine. Oxidation of the sulphur atom gives cysteinesulphinic acid, 
which is metabolised to sulphite either directly yielding alanine or after 
transamination, yielding pyruvate. Sulphite is converted by sulphite oxidase to 
sulphate which is excreted in the urine. Decarboxylation of cysteinesulphinic acid 
gives hypotaurine which is further oxidised to taurine, both steps being pyridoxine 
dependent. 
Conversion to cystine 
Cysteine spontaneously oxidises to the disulphide form, cystine, in aerobic and 
alkaline conditions. An acid pH slows but does not prevent oxidation. In the cytosol, 
the presence of glutathione and-reductases maintain cystine in its reduced state. Most 
reactions of cysteine occur when it is in its reduced state. 
Metabolic defect in cystinosis 
Cystine metabolism 
No defect in cystine reduction or cysteine metabolism has been consistently 
demonstrated in cystinosis (Gahl et al., 1989). The enzyme systems described in the 
preceding sections exist outside the lysosome (which is the major site of cystine 
storage, see "Site of cystine accumulation"). Since there are multiple pathways by 
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which cysteine may be metabolised, a single enzyme block would be unlikely to 
account for significant cystine accumulation. 
Site of cystine accumulation 
Cystine crystals have been demonstrated in many tissues from patients with cystinosis 
(see Gahl et al., 1989 for review). Cystine concentrations in many cystinotic tissues 
are markedly elevated compared with normals (Gahl et al., 1989; see also chapter 4, 
"Clinical course and longterm manifestations"). 
Early workers suggested that phagocytosis led to the occurrence of cystine crystals 
within reticuloendothelial cells. Baar and Bickel presented evidence that cystine 
crystallisation occurred intracellularly in reticuloendothelial cells (Baar and Bickel, 
1952). They found similarities between the storage of cystine in cystinosis and the 
accumulation of storage material in Gaucher's and in Niemann-Pick diseases (which 
were subsequently shown to be lysosomal storage disorders). Although they 
incorrectly attributed cystine accumulation to a disorder of protein metabolism, it took 
a further 15 years to improve on their knowledge of the site of cystine storage. 
Plasma cystine concentrations 
Crawhall et al. measured plasma cystine concentrations in 6 children with cystinosis 
and 4 healthy children (Crawhall et al., 1968). They found no significant difference in 
either the cystine concentrations or the plasma cystine/cysteine ratios. Since previous 
workers had demonstrated high cystine concentrations in tissues (Patrick, 1965), 
Crawhall et al. concluded that the tissue cystine could not be in equilibrium with the 
extracellular fluid and plasma. This was supported by the finding that a reduction in 
plasma cystine (achieved by treatment with penicillamine or a low cystine diet) had no 
effect on cystine storage (Crawhall et al., 1968). Cystinosis is therefore due to 
intracellular accumulation of cystine. 
Intracellular cystine concentrations 
The increased concentration of free cystine in leucocytes was first demonstrated by 
Schneider et al. (Schneider et al., 1967). The mean leucocyte cystine concentration in 
9 cystinosis children was 6.44 ± 2.76 Amol 1/2 cystine per gm protein, compared with 
0.08 ± 0.06 in controls. Heterozygotes were found to have an intermediate level of 
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0.49 ± 0.28. N-ethylmaleimide was used to trap free cysteine during the assay, but 
Schneider et al. were unable to detect any cysteine-NEM in normal, cystinotic or 
heterozygote leucocyte preparations. This suggested that cystine might be localised in 
subcellular compartments, inaccessible to the cellular reduction systems. Sub-cellular 
fractionation of normal and cystinotic leucocytes was performed and the majority 
(75%) of the intracellular cystine was found to be in the granular fraction (as 
demonstrated by acid-phosphatase activity). Addition of a detergent (Triton X-100) to 
disrupt lipid membranes, led to an increase in cystine content of the granular 
fractions. This further suggested that the cystine storage was compartmentalised within 
the granular fraction. 
Morphological evidence of cystine compartmentatisation 
Patrick and Lake examined a lymph node taken from a5 year old boy with cystinosis 
(Patrick and Lake, 1968). Using electron microscopy, they demonstrated that the 
intracellular cystine crystals were delineated by intact membranes and that acid- 
phosphatase reactivity was localised. to the periphery of the cystine crystals. 
Schulman et al. treated tissue from 2 conjunctival biopsies (one from a cystinosis 
patient and one control) with ferritin (Schulman et al., 1970a). Ferritin is readily 
phagocytosed and concentrated in lysosomes. Electron microcopy revealed negative 
images of the cystine crystals surrounded by a dense accumulation of ferritin. This 
work demonstrated the presence of crystals in conjunctiva and also provided further 
evidence that lysosomes are the site of cystine accumulation. Hummeler et al. 
demonstrated cystine crystals in the lamina propria cells of rectal biopsies from two 
cystinotic patients (Hummeler et al., 1970). Cells that were stained for acid 
phosphatase showed enzyme activity around the crystal inclusions. 
Soume of cystine 
Oshima et al. studied IIS-Cystine incorporation in cystinotic and normal fibroblasts 
(Oshima et al., 1976). Following treatment with cysteamine (a cystine depleting agent, 
see chapter 5: "Mechanism of action of cysteamine") cystinotic fibroblasts 
reaccumulated 30 to 50% of the original cystine after 24 hours in a cystine-free 
medium. Cystine therefore accumulates from an intracellular source, even in the 
absence of extracellular free cystine. Further work investigated whether cystine 
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reaccumulated in this model in the presence of labelled methionine, cystathionine or 
serine-enriched medium. In no case did cystine reaccumulate suggesting that these 
extracellular thiols were not the source of cystine (Crawhall et al., 1977; Thoene et 
al., 1977). Thoene et al. also demonstrated that glutathione was not a source of 
cystine reaccumulation (Thoene et al., 1977). 
Evidence that cystine was derived from protein came from the observation that 
cysteamine-treated cystinotic fibroblasts did not reaccumulate cystine in the presence 
of cycloheximide (an inhibitor of protein synthesis) or chloroquine (an inhibitor of 
protein degradation) (Thoene et al., 1977). Subsequent work has shown that cellular 
protein degradation involves both cytoplasmic and lysosomal systems. Extracellular 
protein and "long-lived" cellular proteins are degraded within lysosomes, and serve as 
a source of cystine (Thoene et al., 1985). 
Free extracellular cystine (as opposed to that associated with protein) may also serve 
as a source of intralysosomal cystine accumulation (Thoene and Lemons, 1982). 
Thoene and Lemons presented evidence suggesting that pinocytosis of free cystine or 
incorporation of cystine into "short-lived" cellular proteins were unlikely to be the 
major mechanisms of entry of cystine into the lysosome. Forster et al. examined the 
effects of colchicine (an inhibitor of pinocytosis) and glutamate (a competitive 
inhibitor of plasma membrane cystine transport), on cystine reaccumulation (Forster et 
al., 1990). Glutamate but not colchicine inhibited cystine reaccumulation suggesting 
that cystine can enter cells by transport across the plasma membrane. Forster et al. 
concluded that cytosolic cystine is reduced by glutathione to cysteine in which form it 
enters the lysosome (Forster et-al., 1990). The cystine that accumulates in cystinotic 
lysosomes is cystine therefore derived either from the degradation of protein or from 
transport of extracellular free cystine. 
Studies of lysosomal transport 
The evidence described so far suggested that the lysosome is the site of cystine 
accumulation and that there is no defect in cystine metabolism. An alternative 
explanation was that there was a defect in lysosomal, cystine transport. 
Schulman and Bradley demonstrated that the concentrations of amino acids (other than 
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cystine) were normal in preparations of cystinotic lysosomal fractions (for review, see 
Schulman and Bradley, 1972). These workers investigated the effects of incubating 
human fibroblasts with D-isomers of various amino acids and with a series of mixed 
disulphides. The test compound enters the lysosome by endocytosis and is then 
available to be metabolised or to cross the lysosomal membrane. If the 
* 
substance is 
not cleared it accumulates within the lysosome leading to osmotic swelling and 
vacuolation. Schulman and Bradley observed that the lysosomal membrane seemed to 
have an apparent impermeability to molecules with a molecular weight greater than 
220-230. Cystinotic but not normal cells underwent vacuolation when incubated with 
cysteine-penicillamine disulphide (MW 269 similar to cystine, MW 240). This 
suggested that the cystinotic lysosomes could not clear cystine. 
There remained difficulties in studying lysosomal cystine transport. Firstly, cystinotic 
cells contained a large amount of cystine within the lysosomal membrane. Secondly, 
any cystine that was transported out of the lysosome would immediately be reduced to 
cysteine. Reeves reported a method for studying amino acid efflux from lysosomes 
(Reeves, 1979). Amino acid methyl esters diffuse passively into the lysosome where 
they are hydrolysed to the free amino acid. Lysosomal amino acid accumulation could 
be induced against a concentration gradient. The rate of efflux of the amino acid from 
the pre-accumulated lysosome could then be studied. 
Demonstmtion of a defect in lysosomal cystine tmnsport 
Steinherz et al. loaded isolated lysosomes from normal and cystinotic cells with 
cystine and leucine methylesters (Steinherz et al., 1982a). Whereas the rate of efflux 
of leucine was normal in cystino*tic lysosomes, the rate of cystine efflux was much 
slower in both cystinotic and normal preparations (Steinherz et al., 1982a). The same 
workers repeated the work with in= leucocytes and with much lower concentrations 
of radioactive cystine dimethyl ester (CDME) (Steinherz et al., 1982b). Using this 
method, normal and cystinotic leucocytes accumulated cystine to high but non-toxic 
concentrations. Cystine loading did not affect lysosomal membrane integrity or alter 
the intracellular concentration of other amino acids. Fractionation experiments and 
electron microscopy demonstrated that the cystine loading had occurred within the 
lysosomal fmction. The cystinotic cells lost radioactive cystine more slowly than the 
normal cells. The work was repeated and confirmed with nonradioactive CDME. 
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Jonas et al. incubated normal, heterozygous and cystinotic fibroblasts with 30mM 
cysteine-glutathione mixed disulphide and achieved modestly elevated lysosomal 
cystine accumulation. When placed in cystine-free medium, there was rapid loss of the 
accumulated cystine from the normal and heterozygote but not from the cystinotic 
fibroblasts (Jonas et al., 1982a). 
Gahl et al. confirmed that cystine exodus from cystinotic lysosomes pre-loaded with 
"S-Cystine or nonradioactive cystine was markedly slower than in normal preparations 
and was intermediate in heterozygotes (Gahl et al., 1982a; Gahl et al., 1982b). 
Cystinotic lysosomes showed no abnormality in the transport of methionine or 
tryptophan. These workers also demonstrated that cystine recovery inside and outside 
the lysosomes was unaffected by the addition of N-ethylmaleimide (which traps 
cysteine) to the medium. This suggested that cystine was lost from the lysosome in the 
disulphide form and not first reduced to cysteine. Gahl et al. studied the kinetics of 
cystine efflux in normal, heterozygote and cystinotic lysosomal fractions (Gahl et al., 
1982b). They found that the velocity of cystine efflux was zero in cystinotic 
preparations, saturable in normal cells and approximately half normal in 
heterozygotes. 
Another series of experiments demonstrated that lysosomal cystine transport was 
carrier-mediated (Gahl et al., 1983b). The occurrence of counter-transport (or trans- 
stimulation) constitutes classical proof that a transmembrane movement is mediated by 
a carrier. Counter-transport exists if tracer quantities of a radioactive substance cross 
a membrane at an increased rate in the presence of a substantial concentration of the 
non-radioactive substance on the opposite side of the membrane (Gahl et al., 1983b). 
Normal leucocyte granular fractions pre-loaded with cystine (by CDME) demonstrated 
increased uptake of IH-cystine compared to those that had not been loaded. The rate 
of uptake was proportional to the intralysosomal cystine load. Cystinotic fractions 
showed no uptake and heterozygote fractions half the normal counter-transport. This 
work proved conclusively that lysosomal cystine transport was carrier-mediated. - 
Speciricity of lysosomal cystine counter-transport 
Studies of counter-transport also provided infomation on the specificity of the 
lysosomal cystine transporter (Gahl et al., 1983b). The results showed that the carrier 
P 31 
is stereospecific to L-cysfine and does not transport other amino acids such as arginine 
or glutamate. This suggested that the lysosomal carrier is distinct from the plasma 
membrane cystine transporter which can also carry arginine (in intestinal and renal 
tubular cells) and glutamate (in fibroblasts). 
Many workers have investigated the effects of nucleotides, lysosomal acidification, 
potassium, magnesium and altered temperature on cystine lysosomal transport (ATP, 
Mg, KCI in leucocytes: Gahl et al., 1982b; ATP, protonisation in lymphoblasts: Jonas 
et al., 1982b and Jonas et al., 1983; acidification of leucocyte lysosomes: Gahl and 
Tietze, 1985a; effects of pH and cations in rat liver lysosomes: Jonas, 1986; effects of 
Mg and NEM on leucocytes: Greene et al., 1987). Variable results were obtained in 
these studies, partly because of methodological differences (Greene et al., 1987). 
Further, the addition of a substance can have more than one effect, eg. ATP provides 
energy but also affects lysosomal acidification (Gahl and Tietze, 1985a). Finally, 
Ebstein-Barr transformed lymphoblasts and rat liver lysosomes behaved differently 
from polymorphonuclear leucocytes (Gahl et al., 1982b; Jonas et al., 1982b; Jonas, 
1986). In leucocytes, normal cystine transport was stimulated by the addition of ATP 
(in the presence of MgCl and KCI) (Gahl et al., 1982b). The presence of a proton 
translocator, an alkalinising agent, an inhibitor of ATP-dependent acidification or an 
anion transport inhibitor (all of which reduce the proton gradient across the lysosomal 
membrane) had no effect on cystine transport (Gahl and Tietze, 1985a). In 
lymphoblasts the addition of a proton translocator or an ATP analogue inhibited 
normal cystine transport (Jonas et al., 1982b). Jonas et al. went on to demonstrate that 
there is no abnormality of ATP-dependent acidification and ATP-ase activity in 
cystinotic lysosomes (Jonas et al., 1983). 
Lysosomal cystine concentrations and transport In the variant forms of cystinosis 
Schneider et al. demonstrated that the leucocyte cystine concentrations were generally 
higher in patients with infantile nephropathic cystinosis (range 4-14 umol 1h cystine 
per gni protein) compared to those with the adult ("benign") form (range 1-4 jimol 1/2 
cystine per gni protein), (Schneider et al., 1968). 
Goldman et al. found that mean cystine concentrations in fibroblasts from infantile and 
adolescent patients were 10.8 and 6.6 pmol/gm protein respectively (compared to 0.2 
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in normal cells), (Goldman et al., 1971). They also found that leucocyte cystine 
concentrations in the adolescent-type patients were intermediate between those from 
the adult and those from the infantile forms of cystinosis. Smolin et al. confirmed 
some of these findings in preparations of both mixed leucocytes and 
polymorphonuclear leucocytes (Smolin et al., 1987). 
Gahl and Tietze studied lysosomal cystine efflux and counter-transport in variant 
forms of cystinosis (Gahl and Tietze, 1987b). A patient with intermediate 
("adolescent") cystinosis was found to have a cystine concentration in his cultured 
fibroblasts of 14 nmol 1/2 cystine per mg protein (within the range for the infantile 
form). The mean velocity of cystine efflux from his cells was 0.2 pmol 1/2 cystine per 
minute unit of hexosaminidase, compared to normal cells (4.8 ± SEM 1.0) and 
infantile cystinotic cells (I. I±0.3). A second boy, with benign ("adult") cystinosis 
had a leucocyte cystine concentration of 2.85 nmol 1/2 cystine per mg protein and 
between 9 and 29% of the normal amount of cystine counter-transport (compared to 0- 
5% in the infantile form). These data suggested that the variant forms for cystinosis 
were also due to a defect in lysosomal cystine transport, although not so severe as in 
the infantile form. . 
Further characterisation of lysosomal cystine transport 
There is no animal model of cystinosis; however various workers have studied cystine 
transport in other species in an attempt to further characterise the lysosomal carrier. 
One of the aims of these studies was to identify substances that might bind to the 
cystine carrier and thus be used to differentiate cystinotic and normal cells. 
Other species 
1. Mouse 
Mouse L-929 fibroblasts have a specific lysosomal carrier for cystine which, like the 
human transporter, exhibits counter-transport (Greene et al., 1990). Greene et al. 
measured rates of counter-transport at different external substrate concentrations. 
Kinetic modelling suggested that the results could best be fitted to a model containing 
a saturable and a second, non-saturable component. The authors speculated that the 
second component might well have been saturable at higher cystine concentrations in 
the external medium. The presence of two lysosomal transport systems for cystine 
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could explain the observation that cystinotic cells do not accumulate cystine 
indefinitely. 
A variety of substances were tested for competitive inhibition of cystine counter- 
transport in the mouse model. Greene et al. found that the mouse lysosomal 
transporter exhibited specificity for L-isomers and could be best inhibited by DL- 
selenocystine, LL-lanthionine and L(+)-cystathionine. Comparing these results with 
those for other potential inhibitors, they deduced that the presence of a amino groups 
was more important than carboxyl groups in terms of binding. Substitution of the 
sulphur atom for a carbon or selenium atom had little effect on binding inhibition. 
2. Bacteria 
A bacterial cystine binding protein (CBP) can be isolated from Escherichia coli by an 
osmotic shock and purification procedure (Berger and Heppel, 1972). Two transport 
systems exist. A specific system recognises cystine, selenocystine and cystathionine. A 
general system is also inhibited by lanthionine, diaminopimelate, 3-hydroxy and 4- 
methyl-diaminopiMelate. Oshima et al. studied this further by incubating a range of 
potential inhibitors with 14 C-Cystine and CBP. The mixture was then filtered and the 
percentage of bound radioactivity determined. DL-Lanthionine (9% radioactivity 
bound), DL-Diaminopimelic acid (23%) and cystathionine were all potent inhibitors at 
a concentration of 91umol/l. No significant inhibition was found for cysteic acid, 
carboxymethylcysteine, cysteine-N-ethylmaleimide, methionine, taurine and 
glutathione. 
The patterns of inhibition of the bacterial general cystine transport system and the 
mouse fibroblast system are thus very similar, suggesting that there may be homology 
for the binding site between the two species. 
3. Yeast 
Idriss and Jonas described a cystine transport system in the yeast acidic vacuole 
(prepared from Saccharomyces cerevisiae), analogous to the mammalian lysosome 
(Idriss and Jonas, 1990). Cystine uptake had a pH optimum of 7.5, was dependent on 
ATP and Mg and was highly specific. Study of this transport system may provide 
evidence of homology of the cystine transporter and aid in its identification. 
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The effect of altered incubation temperature on cystine transport in vitro 
Lemons et al. have investigated the effects of increasing the incubation temperature on 
the cystine content of cystinotic fibroblasts (Lemons et al., 1986). When cells were 
cultured at 40*C or 43"C for 48 hours, the cystine contents were reduced to 40% and 
20%, respectively, of the control cells, without any change in cell viability. These 
results were unexpected since the rate of proteolysis increases with temperature. The 
authors speculated that the increased temperature might alter the structural specificity 
of the cystine transporter, thereby allowing cystine efflux. Forster et al. performed the 
opposite experiment (Forster et al., 1989). They hypothesised that the increased 
incubation temperature could increase in vitro activity of the lysosomal cystine 
transporter by improving membrane fluidity. They demonstrated that a reduction in 
incubation temperature from 37'C to 28*C led to a reversible further accumulation of 
cystine in cystinotic fibroblasts. A second alternative is that a'second lysosomal 
cystine transporter might exist which is responsible for the presumed efflux of cystine 
from cystinotic cells. Forster. et al argued that the effects of temperature alteration on 
cystine content demonstrated in their paper might be explained by altered membrane 
fluidity in this second transport system. 
Cystine accumulation and transport in other lysosomal diseases 
Lysosomal cystine transport studies have been undertaken in two other lysosomal 
diseases, mucoliPidosis type II (ML-II, I-cell disease) and Salla disease (Greene et al., 
1985; Tietze et al., 1986; Renlund et al., 1986). Greene et al. demonstrated increased 
cystine levels in cultured fibroblasts but not leucocytes nor liver tissue from 4 patients 
with ML-II. As with cystinotic cells, the cystine was localised in the lysosomes. 
Cystine efflux from ML-II cells *was slower than from normal cells but not to the 
degree seen in cystinotic lysosomes. Tietze et al. reported similar results. 
ML-II is caused by a reduced activity of N-acetylglucosamine I-phosphotransferase 
which catalyses the addition of a mannose-6-phosphate marker to enzymes targeted for 
the lysosomes. The abnormality of cystine transport in ML-II may be due to the 
cystine transporter also lacking a mannose-6-phosphate residue or may be a secondary 
phenomenon of impaired lysosomal proteinase function (Tietze et al., 1986). 
Renlund et al. studied the lysosomal efflux of sialic acid in Salla disease. Fibroblasts 
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from normal and Salla disease individuals were loaded with sialic acid by incubating 
them with N-acetylmannosamine (the precursor of N-acetyl neuraminic acid, NANA, 
which accumulates to abnormal amounts in this disorder). Whereas normal cells 
cleared NANA, the rate of NANA efflux from Salla cells was minimal, suggesting 
that the disorder is due to an abnormality of lysosomal NANA transport. Salla 
fibroblasts were then loaded with cystine using CDME (see "Studies of lysosomal 
transport"). There was no abnormality of cystine efflux from Salla fibroblasts 
indicating that the defect in Salla disease is restricted to NANA rather than being a 
generalised lysosomal transport disorder. 
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The Renal Fanconi Syndrome 
The renal Fanconi syndrome consists of generalised proximal tubular dysfunction and 
rickets. The proximal tubular dysfunction leads to a reduced reabsorption of amino 
acids, glucose, phosphate, bicarbonate, urate, sodium and thus water. There are also 
excessive losses of other substances including potassium, calcium, magnesiumo low 
molecular weight proteins and enzymes. The syndrome may be an isolated 
phenomenon, occur as part of an inherited metabolic disorder or be secondary to 
toxins or disease (see table 2.1 below): 
Table 2.1: Causes of the Renal Fanconi Syndrome 
Idiopathic: Sporadic or familial 
Inherited: Cystinosis 
Lowe's syndrome 
Hereditary fructose intolerance 
Tyrosinaemia type I 
Galactosaernia 
Wilson's disease 
Glycogen storage disease (some forms) 
Mitochondrial disorders (some) 
Acquired: Drugs: 6-mercaptopurine 
Aminoglycosides 
Outdated tetracyclines 
Toxins: Heavy metals (Cd, Hg, Pb, PI) 
Paraquat, toluene 
Renal: Nephrotic syndrome 
Renal transplantation 
Interstitial nephritis (antiTBM Ab) 
Multiple myeloma/ dysproteinaemias 
Pathogenesis of the Fanconi syndrome 
The mechanisms whereby the conditions listed above lead to the Fanconi syndrome 
are not yet clear. Since there are multiple carriers for active transport of amino acids, 
glucose, phosphate etc., it is unlikely that genetic mutations will separately affect each 
carrier. It is more likely that the mutation or disorder causes a defect in a process 
common to all of the carrier systems. Such a defect might involve inhibition of NaK 
ATPase or a reduction in cellular ATP. Alternatively or in addition, there might be an 
increase in the efflux of molecules from the tubular cell to the lumen, perhaps as a 
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result of an increased permeability of the brush border membrane. Detailed reviews of 
experimental models and mechanisms of the Fanconi syndrome have been published 
(Bergeron and GouGoux, 1989; Gonick and Buckalew, 1985). 
MechanLqm of cystine toxicity in cystinosis 
There is no animal model of cystinosis and the exact mechanism whereby cystine 
accumulation leads to cellular dysfunction remains unknown. The effects of cystine 
toxicity have been best studied in the kidney. Foreman et al. created a mild 
experimental Fanconi syndrome by administering a course of intraperitoneal CDME to 
rats. Treated rats showed an increase in urine volume, excretion of phosphate, glucose 
and amino acids compared with untreated rats (Foreman et al., 1987). The creatinine 
clearance was unaffected. They also demonstrated that in vitro incubation of renal 
cortical tubule suspensions with CDME led to intracellular cystine concentrations 
comparable to those found in renal tissue removed from patients with cystinosis. Such 
cystine-loaded tubules showed a reduction in solute uptake. In later experiments, rat 
brush border membrane vesicles isolated from cystine-loaded cells showed identical 
uptake of proline compared with non-loaded controls (Foreman and Benson, 1990). 
Thus cystine loading did not affect the transport of proline across the brush border. 
These results suggested that the abnormality in renal tubular function induced by 
cystine loading, was not due to a direct effect on apical membrane transporters. 
Salmon and Baum set up in vitro microperfusion studies in isolated rabbit proximal 
convoluted tubules loaded with cystine by incubation with CDME (Salmon and Baum, 
1990). Cystine loading led to a dramatic reduction in volume absorption, glucose and 
bicarbonate transport. There was no change in the permeability of the tubules to 
mannitol or to bicarbonate, suggesting that the decrease in transport was due to 
inhibition of active transport. These effects were not seen with methyl esters of 
leucine or tryptophan. Since CDME loading had led to an increase in intracellular 
cysteine concentration, the effect of cysteine methyl ester was also studied. At higher 
concentrations than the cystine dimethyl ester (2mM vs 0.5mM), the cysteine loading 
also had inhibitory effects on tubular transport. 
These workers then studied the effects of CDME loading on ATP and NaK ATPase 
activity in the same in vitro model (Coor et al., 1991). Cystine loading led to a 60% 
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reduction in intracellular ATP. In addition, the reduction in volume absorption could 
be partly negated by the addition of exogenous ATP to the culture medium. However 
cystine loading had no effect on the Idnetics of NaK ATPase even at twice the normal 
CDME concentration. 
Sakarcan et al. found that basal oxygen consumption in isolated cystine-loaded 
proximal tubules was significantly decreased compared with control tubules (12.1 
0.6 vs. 20.6 ± 0.5 nmol oxygen per min per mg protein), (Sakarcan et al., 1992). 
When the cystine-loaded and control tubular preparations were incubated with ouabain 
which inhibits NaK ATPase activity, oxygen consumption was reduced to 11.4 ± 1.0 
and 10.2 ± 0.7 nmol oxygen per min per mg protein respectively. Thus inhibition of 
NaK ATPase accounts for virtually all of the decrease in oxygen consumption seen 
when tubules are loaded with cystine. The results of these studies suggest that 
increased intracellular cystine concentrations do not affect membrane permeability but 
lead to a fall in intracellular ATP and to inhibition of NaK ATPase. Both these 
mechanisms would lead to a reduction in active transport processes and therefore a net 
increase in excretion of solute and water. 
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Chapter 3: The determination of cystine and cysteamine 
The determination of cystine in biological samples 
Introduction 
Cystinosis results from the intra-lysosomal accumulation of the disulphide, cystine. 
The plasma cystine concentration is normal in patients with cystinosis (see chapter 2: 
"Plasma cystine concentrations"). An assay for intracellular cystine is therefore 
required for biochemical confirmation of the diagnosis. 
The traditional method of determining cystine in biological samples relies on 
colorimetric analysis after reaction with ninhydrin, using an amino acid analyser. This 
method is relatively slow, with a capacity of between 5-8 samples per day (RN 
Dalton, personal communication). Many methods exist for the determination of thiols. 
These can be used to measure total cyst(e)ine, however they are subject to interference 
from the many other compounds containing sulphydryl groups (eg. glutathione). 
Oshima et al. developed an assay for cystine in physiological samples, utilising a 
cystine binding protein derived from Escherichia coli (Oshima et al., 1974). The 
cystine binding protein (CBP) can be isolated from Escherichia coli by an osmotic 
shock and purification procedure (Berger and Heppel, 1972; Willis et al., 1974). CBP 
is stable and its binding interaction remains relatively constant over a range of ionic 
strength and ph (Oshima et al., 1974). Berger and Heppel investigated the binding and 
found there to be general specificity for a, a'- diamino-dicarboxylic acids with a3 to 
4 carbon atom chain length between the 2 a-carbon atoms (Berger and Heppel, 1972). 
Oshima et al. studied this further by incubating a range of potential inhibitors with 
"C-Cystine and CBP. The mixture was then filtered and the percentage of bound 
radioactivity determined. DL-lanthionine (9% radioactivity bound), DL- 
diaminopimelic acid (23%) and cystathionine were all potent inhibitors at 9lumol/l 
concentration. No significant inhibition was found for cysteic acid, carboxymethyl- 
cysteine, cysteine-N-ethylmaleimide, methionine, taurine and glutathione. Cystinotic 
fibroblasts, treated with lmM dithiothreitol (DM to reduce cystine to cysteine and 
then reacted with N-ethylmaleimide to trap cysteine and free DIT, showed no 
detectable cystine. This demonstrated that there were no other interfering compounds 
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present in any significant quantity in the cystinotic samples (Oshima et al., 1974). 
Since the defect in cystinosis is an intraceflular accumulation of cystine, and 
leucocytes derived from a peripheral blood sample are the most accessible source of 
cells, the measurement of leucocyte cystine is the most practical means of confirming 
the diagnosis biochemically. 
A mixed leucocyte cell preparation can be made by allowing whole blood to separate 
in an acid citrate dextrose - dextran (ACD) mixture (Smolin et al., 1987). 
Measurement of the cystine concentration within such a cell preparation provides an 
excellent separation between patients affected with cystinosis and normal people (see 
chapter 4: "Confirmation of the diagnosis" for results). The effects of treatment with 
the cystine depleting agents, cystearnine and phosphocysteamine, can also be 
accurately followed with mixed leucocyte cystine concentrations (see chapter 8: 
"Monitoring of leucocyte cystine concentrations" for results). 
The establishment of a method for determining the leucocyte cystine concentration 
using the cystine binding protein assay, was clearly necessary prior to starting 
research in cystinosis. Professor Schneider, during a visit to Europe in 1988, spent 
one month at Guy's Hospital introducing the methodology. 
Although the mean mixed leucocyte cystine concentration in a group of heterozygotes 
is elevated by a factor of six compared with normal people (Schneider et al., 1967)o 
individual results show some overlap. It is not possible to distinguish any individual as 
normal or heterozygous by this*method. Schulman et al. reported that the cystine in 
cystinotic leucocytes is primarily located in polymorphonuclear leucocytes rather than 
in lymphocytes (Schulman et al., 1970b). Smolin et al. measured the cystine 
concentrations in polymorphonuclear leucocyte pellets prepared from a group of 29 
parents of children with cysfinosis (ie. obligate heterozygotes) (Smolin et al., 1987). 
This group reported no overlap between the heterozygote cystine concentrations and 
those in a group of normal people. 
The determination of cystine therefore requires several steps: 
L Isolation, purification and lysis of a cell pellet of the tissue to be studied (eg. 
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leucocytes). 
2. Deproteinisation and separation of the protein-free supernatant. 
3. Determination of the protein-free cystine concentration. 
4. Determination of the protein content of the pellet to 
account for variation in cell recovery. 
These steps are detailed in appendix 1. 
The assay can be used to determine the cystine concentration not only in leucocytes 
but also a variety of other tissues including the following: 
- cultured skin fibroblasts and amniocytes, 
- chorion villous biopsy or placental tissue, 
- post mortem or tissue biopsy specimens. 
Although the methods were in use in several North American laboratories, there 
remained unanswered questions about the assay. It was important to establish the 
sensitivity, specificity, linearity and coefficient of variation of the assay in our own 
laboratory. Secondly, the effect of storing the blood sample prior to preparation of the 
leucocyte pellet had not been studied. This is of importance since many nephrology 
centres do not have on-site facilities for the cell preparation. Studies on the 
characteristics of the assay were therefore undertaken. 
Studies on the measurement of cystine 
1. Lower timit of detection 
The lower limit of detection of the cystine binding protein assay was determined by 
running 6 blank ("0") standards and calculating the mean and standard deviation of the 
results. The lower limit of detection is generally taken as 3 standard deviations of the 
mean of the zero result. In this assay the lower limit of detection was calculated to be 
0.03 jAmol/l. 
2. Linearity 
A standard curve over the range 0-0.6, umol/I was performed for each assay. A 
typical curve, with the calculated line of regression of CpNý.. /CPM,,, b. on Standard 
cystine concentration, is shown in figure 3.1. To establish the linear range of the 
assay, cystine standards were measured in duplicate over the concentration range 0- 
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5.014mol/I (see figure 3.2). A line of regression of the data between 0 and 0.6ptmol/l 
was plotted. At cystine concentrations of > 1.5, umol/l, values of CPM=x/CPM,, b, fall 
away from this line indicating saturation of binding (see figure 3.2). Thus to ensure 
that clinical samples fell within the linear range, they were diluted to fall between 
0.2 - OAAmol/l. 
3. Specificity 
Specificity was assessed by running cystine standards of 0.2 and 0.5 /Amol/I to which 
had been added Amino Acid Calibration Standards (containing 39 components) diluted 
to 25 14mol/l, with cystine standards to which water had been added as a control. 
Table 3.1 shows the mean (SD) results of 4 samples: 






0.20 0.20(0.01) 0.20(0.01) 
0.50 0.48(0.02) 0.49(0.02) 
CBP specifically binds cystine. Oshima et al. advocated the use of N-ethylmaleimide 
(NEM) to trap free thiol groups and thus prevent them from cross-reacting with CBP, 
during the leucocyte pellet preparation (Oshima et al., 1974). To investigate whether 
free thiols did affect cystine binding, a 40ml blood sample was taken from an adult 
cystinosis patient who was on phosphocysteamine treatment. From this sample, 6 
leucocyte pellets were prepared with the addition of lOmM NEM in dipotassium 
hydrogen phosphate buffer and, as a control, 6 pellets were prepared with the addition 
of distilled water. The mean (SD) leucocyte cystine concentration for the 6 pellets 
prepared with NEM was 0.45 (0.11) nmol 1/2 cystine per mg protein compared with a 
value of 0.48 (0.08) for the pellets prepared with water. 
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4. Coefficient of variation 
a. Cystine binding protein assay 
The coefficient of variation (CoV) was assessed by assaying 6 spiked cystine standards 
at each of the following concentrations: 0,0.05,0.1,0.2,0.3,0.4,0.5 and 
0.6jAmol/l. The results (mean ± SD) are shown in table 3.2 below: 






0 -0.02 0.01 35.3 
0.05 0.05 0.01 15.0 
0.1 0.10 0.00 2.7 
0.2 0.22 0.01 5.0 
0.3 0.32 0.02 5.6 
0.4 0.42 0.01 2.3 
0.5 0.46 0.01 2.9 
0.6 0.61 0.01 1.7 
b. Protein assay 
The coefficient of variation was assessed by determining, in duplicate, the protein 
concentration of 10 aliquots of a protein standard (Sigma, 1mg/ml) using the methods 
in appendix I ("Detemination of the protein concentration"). The result is factored so 
that lmg/mI gives a result of 50OAg in the cuvette. The mean (SD) protein content 
was 500.7 (5.1) pg per cuvette, giving a coefficient of variation of 1.0 %- 
c. Mixed leucocyte cystine preparation 
The coefficient of variation for the mixed leucocyte cystine preparation was assessed 
by taking a 15-18ml blood sample from each of 4 individuals (3 cystinosis patients, 
two of whom were receiving cysteamine and one unaffected healthy adult). Mixed 
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leucocyte cystine concentrations were determined as detailed in appendix 1. 
Table 3.3: Coefficient of variation of the determination of mixed leucocyte cystine 
concentration 
Concentration 





0.06 6 24.7 
1.30 5 8.1 
3.54 6 6.0 
8.47 6 15.2 
d. Polymorphonuclear leucocyte cystine preparation 
The coefficient of variation was assessed by preparing 6 polymorphonuclear leucocyte 
cystine pellets from a 30ml blood sample taken from a healthy volunteer. The mean 
(SD) leucocyte cystine concentration was 0.10 (0.03) nmol Ih cystine per mg protein. 
The coefficient of variation at this concentration is 33%. 
5. Comparison of two different forms of leucocyte peHet preparation 
LeucoPREP cell separation tubes (Becton Dickinson Labware) have been designed to 
provide a convenient separation of mononuclear cells from whole blood. The tubes 
contain a gel layer through which neutrophils, red cells and platelets but not 
mononuclear cells pass during centrifugation. Since this system is much more 
convenient, a comparison of leucocyte cystine concentrations obtained from blood 
processed by the LeucoPREP and standard ACD methods was made. Blood samples 
from two healthy adults and nine cystinosis patients (receiving various doses of 
phosphocysteamine) were simultaneously prepared by the two methods. (After cells 
were obtained from the LeucoPREP tube the pellet preparation was by standard 
methods). The results (see figure 3.3, overleaf) indicate that there is no correlation 
between cystine concentrations obtained by standard methods and those derived from 
LeucoPREP cell separation. The LeucoPREP system cannot therefore be utilised in 
the determination of leucocyte cystine concentration. 
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Figure 3-3: Comparison of two methods of leucocyte pellet preparation on 
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6. Composition of mixed and polymorphonuclear leucocyte peUets 
Blood samples (40mls) were taken from two healthy adult volunteers for leucocyte 
pellet preparation and for whole blood leucocyte differential count. Six mixed 
leucocyte pellets were prepared from one volunteer and six polymorphonuclear (PMN) 
leucocyte pellets from the other. After the last cell wash in each preparation, 0.25mls 
were removed for differential leucocyte count using a Coulter counter. The remainder 
of the specimen was prepared in the usual way. Differential counting was possible in 
every mixed leucocyte preparation and in 4 of the 6 polymorphonuclear specimens. 
No red blood cells were detected in any of the leucocyte preparations. Table 3.4 
shows the whole blood leucocyte counts and the mean (SD) from each preparation. 
Table 3.4: Composition of mixed and polymorphonuclear leucocyte pellets 
Total leucocyte Lymphocytes Neutrophils 
count M M 
I 
(X 1000/, Ul) I I 
Whole blood 8.6 28 62 
(Subject 1) 
Mixed leucocyte pellet 2.5(0.7) 23(2) 51 (4) 
(Subject 1) 
Whole blood 7.6 31 64 
(Subject 2) 
PMN leucocyte pellet 3.3(0.8) 4(l) 91 (2) 
(Subject 2) 1 
- 
1 
Fractionation of blood on acid citrate dextran solution leads to a mixed leucocyte 
preparation with a differential count similar to that in whole blood. When blood is 
added to Ficoll Hypaque gradients a highly purified polymorphonuclear leucocyte 
pellet is obtained. To determine whether the different leucocyte count in each 
preparation affected the leucocyte cystine concentration, mixed leucocyte and 
polymorphonuclear leucocyte cystine concentrations were simultaneously determined 




Table 3.5: Comparison of mixed and polymorphonuclear leucocyte cystine 
concentraflons 
Subject Mixed leucocyte 
cystine concentration 
(nmol Ih cys/mg protein) 
PMN leucocyte 
cystine concentration 
(nmol 'A cys/mg protein) 
1 0.08 0.11 
2 0.05 0.11 
3 0.05 0.10 
4 0.03 0.07 







Although the polymorphonuclear leucocyte cystine concentrations are generally higher 
than the mixed leucocyte levels, there is no statistically significant difference (paired 
one sample t test, p>0.05). 
7. Effect of storage of the blood sample on leucocyte cystine concentration 
The effect of storage of the blood sample was assessed in two experiments. In the 
first, blood freshly obtained from each of 5 patients (none on cystine depleting agents) 
were added either to a tube containing ACD or to each of two lithium heparin tubes. 
After mixing, blood from one lithium tube was decanted into a second ACD tube. The 
other lithium tube was roller-mixed for 4 hours and then the blood added to an ACD 
tube. Leucocyte cystine concentrations were determined in duplicate by standard 
methods. Table 3.6 (below) shows leucocyte cystine concentrations prepared by the 
three different methods. There is no significant difference between the values obtained 
conventionally and those obtained from samples placed or stored in lithium heparin 
tubes (paired one sample t test, p>0.05 for each comparison). 
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Table 3.6: Effect of storage of blood sample for 4 hours on leucocyte cystine 
concentration 
Patient Standard ACD Lithium heparin 4h lithium heparin 
1 4.34 5.05 4.11 
2 7.80 7.95 7.09 
3 9.06 9.79 10.03 
4 6.55 4.04 3.89 









The effects of storage were further investigated by comparing the mixed leucocyte 
cystine concentration from 6 samples prepared immediately after venepuncture with 6 
samples left in either acid citrate dextran or in a lithium heparin tube at room 
temperature for 24h, 48h or 7 days. Leucocyte pellets could not be prepared from any 
of the samples that had stood for 7 days. Figure 3.4 shows the results of the 24 and 
48 hour studies. The mean (SD) values are shown in table 3.7. 




rin Lithium heparin 
tube 
[F24 
hour study 2.35(1.45) 2.62(1.43) 
] 
2.23(1.13) 
48 48 hour study 2.17(1.72) 2.34(0.96) 2.47(0.80) 
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There were no statistically significant differences between the control values and those 
obtained after storage for 24 or 48 hours (paired one sample t test, p>0.05 for each 
comparison). There were some technical difficulties (mainly poorer fractionation) in 
preparing pellets from some of the samples stored for such long periods. Blood 
samples should not therefore be routinely stored prior to leucocyte pellet preparation. 
However, centres unable to prepare leucocyte pellets could send blood in a lithium 
heparin tube through the post to a specialised centre without undue loss of accuracy. 
Discussion of determination of leucocyte cystine concentration 
Determination of leucocyte cystine concentration using the methods described, has 
proven to be feasible and reliable. The cystine binding protein assay is sensitive, 
specific, reproducible and versatile. The assay has a lower limit of detection of 
0.03jAmol/1 cystine and is linear to a concentration of 1.5/Amol/l. No interference was 
found after the addition of Amino Acid Calibration Standards, demonstrating the 
specificity of binding to cystine binding protein. Incubation with n-ethylmaleimide also 
had no effect on the results thus indicating that cysteine and other free thiols do not 
bind to CBP. 
The differential leucocyte count in mixed leucocyte pellets is broadly similar to that in 
the whole blood from which the pellets were prepared. In contrast, the purified 
polymorphonuclear (PMN) leucocyte pellets contained a mean of 91 % neutrophils 
compared with a value of 64% neutrophils in the whole blood sample. The double 
Ficoll gradient preparation of PMN pellets is therefore very effective. However, in 
normal subjects, the PMN leucbcyte cystine is not significantly different to the mixed 
leucocyte value. 
The preparation of a mixed leucocyte pellet takes approximately 11/2 hours from the 
time of venepuncture. Experience has shown that up to 6 samples can be prepared at 
any one time. However, laboratories at hospitals with only one or two cystinosis 
patients may not be able to direct resources to such a time consuming method. For 
this reason, the effect of storage of blood samples on leucocyte cystine concentration 
was studied. No significant difference was found between samples prepared 
immediately and those stored for up to 48 hours in either acid citrate dextrose-dextran 
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solution or in lithium heparin tubes. However pellet preparation was more difficult in 
samples stored for 48 hours and such storage cannot normally be recommended. 
Shorter durations of storage have not been associated with such problems. Therefore 
smaller laboratories can send the blood sample to a specialised centre to be prepared. 
It is hoped that such work will make the diagnosis and therapeutic monitoring of 
cystinosis more accessible. This is of importance since the prognosis is clearly related 
to the age at which treatment is started. 
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Determination of plasma cysteamine 
Introduction 
The determination of plasma cysteamine was based on the methods of Smolin and 
Schneider (Smolin and Schneider, 1988). Plasma was first reduced with sodium 
borohydride to convert disulphides to thiols. The samples were then applied to a high- 
performance liquid chromatography system and the analytes detected 
electrochemically. The method was modified for use on a Coulochern electrochemical 
detection system. This required the determination of the optimal conditions for the 
new system (specifically, pH of the mobile phase, operating potentials and the effect 
of a screen electrode). 
The methods and principles of electrochemical detection are detailed in appendix 2. 
Studies on the measurement of plasma cysteamine 
1. Recovery of cysteamine foHowing reduction 
The recovery of cysteamine was studied by reducing cysteamine standards prepared in 
water, 1.4% bovine albumin solution and plasma taken from a healthy adult volunteer. 
These were compared with freshly prepared cystearnine standards that were not 
reduced. Recovery was assessed at 1,10,50 and 1001M cysteamine. The results are 
shown in table 3.8. 
Table 3.8: Recovery of cysteamine following reduction 






0 121 60 
10 61 108 94 
so 43 86 81 
100 47 90 83 
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These results demonstrate that protein is required as some form of supporting matrix 
during derivatisation. In subsequent patient studies, cystearnine standards were 
prepared in an aliquot of the patient's pre-dose plasma. 
2. Determination of the optimal working and screen potentials 
Since the combination of analyte, mobile phase and electrochemical cell was new, it 
was necessary to define the optimal working potential for the two electrodes. 
Electrode I was set at 0. IOV and electrode 2 at OV. The mean background current 
and response obtained after duplicate injections of 100, umol/I Cysteamine standard 
were noted. The potential applied to electrode 1 was increased by 0.05V and the 
injections repeated. A hydrodynamic voltammogram was constructed by continuing 
this process until the response had levelled out (see figure 3.5). Likewise a 
hydrodynamic voltammogram was constructed for electrode 2 (with electrode 1 set at 
OV), see figure 3.5. Although the response from electrode I is far superior to that 
from electrode 2, the resulting background current is also much greater and becomes 
prohibitively high. The maximal response from electrode 2 was seen at an applied 
potential of 0.60V and at this setting there was negligible increase in background 
current (see figure 3.6). 
The two electrodes in the Coulochem cell allow the first to be set in a Screen mode. 
In order to define the best combination of electrode potentials in this mode, the 
response obtained after injecting the 10014mol/I Cysteamine standard was assessed with 
electrode 2 set at 0.60V and the potential applied to the Screen electrode, varied. The 
results of duplicate injections are shown in figure 3.7. These data suggest that there is 
negligible loss of response when the Screen electrode is set at 0.1 OV. Background 
current was however, markedly reduced by the use of the Screen mode. 
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3. Lower limit of detection, linearity and coefficient of variation 
Cysteamine standards were prepared in bovine serum albumin at 0,1,5,20 and 
100jimol/I and derivatised as detailed in the methods. Samples were injected 6 times 
and the mean response calculated. The results (see figure 3.8) demonstrate that the 
assay is linear over this range of concentrations. The lower limit of detection is 
generally taken as 3 standard deviations of the mean of the zero result. In this assay 
the lower limit of detection is therefore 0.42 ; tmol/l. The coefficient of variation at 
each concentration is shown in table 3.9 (see below). 










Discussion of determination of plasma cysteamine 
The development of an assay for plasma cysteamine led to the ability to study the 
pharmacoldnetics of cysteamine and phosphocysteamine. The methodology of the 
assay described in this thesis is based on that developed by Smolin and Schneider, 
1988. However, since a different electrode was used, new operating potentials needed 
to be ascertained. In addition the recovery of cysteamine standard from water, 
albumin and plasma was studied. These results suggested that the presence of protein 
in the sample acted as a support matrix for cysteamine. The cysteamine assay was 
found to have a lower limit of detection of 0.42timol/I and was linear over a 
concentration range of I- 10014moVI. 
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Samples were batched for analysis of plasma cysteamine. Prior to running each batch, 
there were commonly difficulties in re-establishing the optimal working conditions of 
the system. These are difficulties common to most electrochemical detection systems. 
Further work is required to improve the determination of cysteamine in biological 
samples so that new formulations of the drug can be studied. 
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Chapter 4: CHnical features of cystinosis 
Introduction 
Children with early onset cystinosis present with manifestations of the renal Fanconi 
syndrome usually in the second half of infancy (Gahl et al., 1989). Without specific 
treatment to reduce the toxic effects of cystine accumulation, patients develop 
progressive renal glomerular failure and require renal replacement therapy (usually a 
renal transplant) at the end of their first decade. Even if this is successful, the 
metabolic defect remains in non-renal tissues and longterm manifestations of cystinosis 
supervene. 
Patients with the rarer late-onset (or intermediate) form of cystinosis present after 18 
months of age, usually with proteinuria and chronic renal impairment (Goldman et al., 
1971). Benign cystinosis is extremely rare and is diagnosed in individuals who have 
no renal pathology but have corneal crystal deposition seen on slit lamp examination 
(Cogan et al., 1957). Such individuals are entirely asymptomatic. 
Historical perspective 
Abderhalden is credited with the first description of a patient with cystinosis (see 
McCune et al., 1943, for review). Abderhalden described a boy of 21 months who 
had died of "inanition", whose kidneys, intestines, liver, spleen and mesenteric glands 
contained "chalky foci" in which he identified cystine crystals. This boy, two 
brothers, the father and the grandfather were all described as having "cystinuria". 
Several independent authors (including Lignac, Fanconi, de Toni and Debrd) reported 
the association of severe rickets, dwarfism, glycosuria and albuminuria. (see McCune 
et al., 1943, for review). Fanconi suggested the concept of tubular damage as opposed 
to glomerular dysfunction and gave this the name of "nephrotic-glycosuric dwarfism 
with hypophosphataemic rickets. " The authors mentioned above were credited with the 
eponym but McCune et al. shortened it to the now familiar "Fanconi syndrome". 
The association between cystine storage and the Fanconi syndrome was seen in II of 
39 children with rickets and glycosuria, reviewed by McCune et al., (McCune et al., 
1943). Freudenberg reviewed 17 previously published cases of cystinosis and noted 
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the similarities between this disorder and the Fanconi syndrome (Freudenberg, 1949). 
Cystinosis remains the commonest inherited cause of the Fanconi syndrome although 
there are many other causes (see chapter 2: "The renal Fanconi syndrome"). 
The demonstration of cystine in the urine and tissues of Abderhalden's patient led 
workers to believe that cystinuria and cystine storage disease were due to the same 
basic abnormality of cystine metabolism. Lignac described a boy of 3 years age with 
rickets, glycosuria and cystine deposits in the renal cortex (McCune et al., 1943). 
Russell and Barrie described 3 children with renal failure, two of whom had cystine 
crystals in the liver, the third having cystinuria (Russell and Barrie, 1936). The first 
child had polyuria, glycosuria, severe renal rickets and was extremely small (height 
91cms, weight 18.49kg at 12 years). She died from the complications of renal failure 
at 12 years of age. The second child was described as having rickets as a young child 
(but had no skeletal abnormality at the time of his death at 16 years), polyuria, 
glycosuria and again died in renal failure. The last child had had 2 operations to 
remove cystine calculi from the bladder and right ureter. He also died from terminal 
renal failure at the age of 13 years. With hindsight, it would seem that the first of 
Russell and Barrie's cases had infantile cystinosis and followed a typical course. Their 
second case did not have severe rickets and there is no comment on whether his 
stature was small. Noting also that he died of renal failure at 16 years (considerably 
later than at 10 years, the mean age of onset of end-stage renal failure for infantile 
cystinosis) it is possible he might have had "late onset" cystinosis. Russell and Barrie, 
considering all the above cases, conclude: "there can be little doubt that cystinuria 
and cystinosis are due to one and the same disturbance ofprotein metabolism". They 
argued that renal rickets in thege cases could be explained by damage to the kidney by 
continued excessive excretion of cystine in the urine and speculated that "the 
deposition of cystine in tissues might be regarded as a secondary retention 
phenomenon". 
This confusion between cystinuria and cystinosis may be explained in two ways. 
Firstly, children with cystinosis have a generalised aminoaciduria, of which cYstine is 
one part. The excessive excretion of dibasic amino acids (cystine, lysine, ornithine 
and arginine) seen in cystinuria, was not however, observed. Secondly, children with 
cystinuria in whom calculus formation leads to urinary obstruction and infection, will 
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suffer progressive renal damage unless the condition is treated. It is thus not 
surprising that early workers reported children with cystinuria, dying from renal 
failure. 
Major advances in the description and understanding of the pathogenesis of cystinosis 
were made by Bickel et al. in a review of the clinical, biochemical and pathological 
features of 14 cases (Bickel et al., 1952). These workers found that the arninoaciduria 
in cystinosis was generalised and therefore different to that in cystinuria. Bickel 
stated: "cystine storage in Lignac-Fancon! disease is the result neither of renal 
damage nor of cystinuria alone. " Secondly, Bickel's group correctly surmised that 
cystine accumulated at the site of its production from protein hydrolysis: "7he 
intracellular localisation of cystine crystals is stressed, and histopathological and 
experimental evidence is given for the assumption that cystine storage is not due to 
phagocytosis, but that cystine crystallizes at the site of its formation, namely in a 
certain part of the reticuloendothelial system. " 
Subsequently the site of cystine storage was found to be the lysosome and the 
underlying biochemical abnormality a defect in cystine transport (see chapter 2: 
"Demonstration of a defect in lysosomal cystine transport"). Coincident with these 
advances were improved methods of diagnosis. Traditional methods relied on the 
demonstration of cystine crystals in fissue biopsies, usually from conjunctiva or lymph 
node. Schneider et al. published evidence that the leucocyte cystine concentrations 
were significantly elevated in patients with cystinosis (Schneider et al., 1967). This 
allowed easy diagnosis and provided a means of therapeutic monitoring when cysfine- 
depleting agents were discoverea. 
Presentation of early-onset (infantile) cystinosis 
Symptoms 
Patients with cystinosis appear normal at birth (Gahl et al., 1989) and grow well for 
the first few months of life. Symptoms usually become prominent in the second half 
of infancy although some parents note abnormal symptoms at a much earlier age. In a 
recent review of 59 patients with cystinosis in the UK, the median age of onset of 
symptoms was II months (range 4- 176), (see chapter 6: "Results: patients") . 
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Typical symptoms include poor weight gain or weight loss, inadequate and fussy 
feeding, vomiting, constipation, lethargy, weakness, excessive thirst, polydipsia and 
polyuria. Direct questioning may reveal that the child has a dislike of bright light as a 
result of corneal cystine deposition (see below). Large quantities of dilute urine are 
passed each day and parents may comment on the need for "double nappies" or on the 
fact that bedclothes are dripping wet from urine. A history of the child drinking two 
to three 500ml. bottles of water at night is not uncommon. Recurrent episodes of 
fever and dehydration may occur (see chapter 4: "Miscellaneous findings"). The 
weakness may be profound and can lead to an inability to bear weight or walk. One 
child under the care of Guy's Hospital, presented having "gone off his feet". A 
common finding is that children with cystinosis like salty and spicy foods even whilst 
still in infancy (Gahl et al., 1989). Two of the children recently referred to Guy's 
Hospital had a habit of dipping their fingers into salt pots or jars of Marmite. Such 
behaviour led in one case to the family being referred for psychiatric counselling 
before the diagnosis of cystinosis was made. Another child at Guy's Hospital 
presented to their local hospital at the age of 18 months with a femur fractured after a 
minor injury and was subsequently found to have rickets secondary to cystinosis. 
Some children die before a diagnosis can be made. In one case a child presented to a 
paediatric department in a state of collapse at the age of 16 months (N Mann, personal 
communication). She was extremely small (weight and length << 3rd centile) and in 
a state of cardiovascular collapse. Despite aggressive treatment she died 5 hours after 
admission. Urinalysis had shown proteinuria and ketonuria, radiographs showed 
florid rickets and post mortem histology demonstrated crystalline deposits in lymph 
node, spleen and liver. These wire subsequently shown to be cystine crystals, 
confirming the diagnosis of cystinosis. Early reviews of cystinosis contained many 
reports of such cases, diagnosed only at post mortem examination (Worthen and 
Good, 1958). 
Examination 
The most striking feature on examination of children with cystinosis is their short 
stature and wasting. The mean height standard deviation score of 6 children aged 0.67 
- 1-94y) presenting to Guy's Hospital since 1989, was -3.10 (range -2.09 to -3.9 1). 
Thus normal growth parameters in a newly presenting case make the diagnosis of 
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infantile cystinosis unlikely. 
Cystinosis is not associated with dysmorphic features although the patient's appearance 
can be characteristic. Typically, there is frontal bossing, blond hair and a protuberant 
abdomen. Most Caucasian patients have a fair complexion and light or blond hair 
although the presence of dark hair does not exclude the diagnosis. A cause for the 
paler skin and hair has yet to be found, although Gahl et al. has speculated that it may 
be related to impaired melanosome function since melanosomes are the melanocyte 
counterparts of lysosomes (Gahl et al., 1989). At the time of diagnosis, hair may be 
sparse and thin. Following rehydration, electrolyte replacement and treatment with 
cysteamine, parents often comment that hair growth improves and that it also darkens. 
Children of other racial groups (eg. African, Middle Eastern, Pakistani) have a 
complexion identical to their unaffected siblings. 
Skeletal changes 
Head circumference is not affected by the growth failure. Frontal bossing secondary 
to rickets is commonly seen and may persist throughout childhood. Other more 
marked signs of rickets may be noted, including swelling of the wrists (due to 
metaphyseal widening), "rachitic rosary" (swelling of the costo-chondral junctions) 
and genu valgum. As noted above one patient presented after sustaining a fractured 
femur. 
Radiological changes, best seen in the rapidly growing distal ends of the ulna and 
radius, include rarefaction, fraying of the provisional zone of calcification and 
widening and concavity of the metaphyses. Cupping of the end of the shaft is an 
advanced feature. In the longterm, angulation deformities (eg. genu valgum/varum) 
can occur due to displacement of the epiphyseal cartilage during the active growth 
stage (Silverman, 1993). The bone age is delayed with respect to chronological age. 
In the above series of 6 patients presenting to Guy's Hospital, the mean bone age 
delay was 0.76y (range 0.17 to 1.11 y). 
Ocular manifestations 
Photophobia is the earliest symptom of ocular involvement and is due to deposition of 
cystine crystals within the cornea. Demonstration of corneal crystals requires slit lamp 
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examination by an experienced ophthalmologist. Crystals are not present in the 
neonatal period but can usually be seen by one year of age (Wong, 1972). Thus the 
inability to see corneal crystals does not exclude the diagnosis of cystinosis in an 
infant whilst their demonstration is virtually pathognomonic. The crystals are fusiform 
or needle-shaped and are found in the stroma beneath the epithelium. In adults a 
similar appearance is seen in patients with myeloma (Wong, 1972). Slit-lamp 
examination of the conjunctiva reveals a ground-glass appearance, again due to crystal 
deposition. 
Fundoscopy may reveal a patchy depigmentation of the retina with peripheral clumps 
of pigment. The retinal changes may precede the corneal features and have been 
observed as early as 5 weeks of age (Wong, 1972). In addition the retina may be 
generally hypopigmented (the "blond fundus"). Longterm ocular manifestations of 
cystinosis are described later in this chapter. 
Plasma and urine biochemistry 
In most newly-presenting patients the abnormalities on routine urinalysis and/or 
plasma biochemistry provide the first clues to the diagnosis since they will reveal 
features of the renal Fanconi syndrome. The results from a nine month old child who 
recently presented to Guy's Hospital illustrate the abnormalities: 
Urine: 
pH 6, glycosuria, trace proteinuria 
Blood: 
Sodium 132mmol/l, potassium 1.7mmol/l, chloride 107mmol/l, urea 2.1 mmol/l, 
creatinine 50, umol/l, calcium 2.63mmol/l, phosphate 0.61mmol/l, magnesium 
0.96mmol/l, albumin 51g/l, total bilirubin lOjAmol/l, aspartate transaminase 17iu/1, 
alkaline phosphatase 711 iu/1. 
pH 7.49, PaC02 2.64kPa, Standard bicarbonate 15.3mmol/l, base deficit - 9. Ommol/l. 
This patient therefore had hyponatraemia (with vascular contraction suggested by the 
increased albumin level), severe hypokalaemia and hypophosphataemia. Such volume 
contraction would lead to secondary hyperaldosteronism causing further urine loss of 
potassium. The standard bicarbonate was low, compensated by a low PaCO2but the 
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degree of hyponatracmia, volume contraction and hypokalaernia was so severe that the 
pH was elevated, reflecting a metabolic alkalosis. 
Urinary pH is often paradoxically high unless the depletion of bicarbonate is so severe 
as to reduce the tubular luminal bicarbonate concentration below the threshold for 
reabsorption. In this case urinary pH may be less than 5. Urinary osmolality is low 
(< 300 mosmol/1), (Gahl et al., 1989). There is a generalised aminoaciduria, 
contrasting with cystinuria in which only the dibasic amino acids (cystine, lysine, 
ornithine and arginine) are excreted in excess. 
Rarely cystinosis can present with features of Bartter's syndrome (Lemire et al., 
1978), nephropathic diabetes insipidus or pseudohypoaldosteronism (Lemire and 
Kaplan, 1984). 
There are no abnormalities of plasma bilirubin or transaminases in cystinosis children 
presenting in infancy. Abnormal biochemical indices of hepatic function would suggest 
an alternative cause of the Fanconi syndrome (eg. tyrosinaemia or fructosaemia). 
Glomerular filtration rate at diagnosis 
The plasma creatinine is often within the normal range at the time of diagnosis (unless 
the diagnosis is either very late, eg. over 3-4 years of age, or the child has "late- 
onset" cystinosis - see below). However if the child is very dehydrated, there may be 
a fall in plasma creatinine concentration with fluid and electrolyte therapy. 
Formal measurement of glomerular filtration rate, using a single injection inulin 
clearance method, was therefore undertaken in 6 children, mean age 15.3months 
(range 8- 23), newly-presenting to Guy's Hospital (for methods, see Montini et al., 
1989). All the children were in a stable state of hydration and the test was performed 
after an overnight fast. Table 4.1 shows the results of these studies: 
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Table 4.1: Glornerular filtration rate in newly-diagno patients 
Patient Inutest GFR 
(mls/min/1.73m) 
Estimated GFR (Schwartz et 
al., 1976) 
MD 95 55 
DC 34 38 
RH 63 54 
LE 46 43 
Rj 60 51 
I OB 1 112 1 80 1 
Mean ± SD 68 ± 30 
1 54 ± 15 
Metabolic bone disease and mineral homeostasis 
In the 9 month old newly-presenting patient whose results are detailed above, the 
parathyroid hormone (iPTH) concentration was below the limit of detection (< I 
ng/1). Presumably the severe hypophosphatemia (0.61mmol/1) led to an increase in 25- 
(OH)DO-a-hydroxylation, increasing bone resorption and intestinal calcium 
absorption. The slightly increased plasma calcium (2.63mmol/1) would serve to 
suppress PTH secretion. 
Correction of the acidosis with sodium bicarbonate and of the hypophosphataemia with 
phosphate supplements, led to this child developing frank tetany approximately 1-2 
weeks after admission. This sequence of events was seen in five of the last eight 
children admitted in a state of dehydration. Hypomagnesaemia can also contribute to 
the occurrence of tetany. 
The serum alkaline phosphatase is usually raised at the time of diagnosis, reflecting 
active rickets. Vitamin D metabolism has been studied in a group of 10 cystinosis 
patients with varying degrees of renal impairment (Steinherz et al., 1983). None were 
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receiving cysteamine or phosphocysteamine but they were all talcing bicarbonate and 
Vitamin D supplements. No evidence of total calcidiol (25-hydroxyvitamin D) 
deficiency was found although levels of 24,25-dihydroxyvitamin D and 1,25- 
dihydroxyvitamin D were low in some patients, in proportion to their renal 
parenchymal damage. Deficient 25-(OH)D3-1-a-hydroxylation is also a potential cause 
of reduced 1,25-dihydroxyvitamin D levels. 
Haematology 
Haematological indices may be normal or may show a mild anaemia, variable 
leucocyte count and high platelet count (Gahl, 1986a). The anaemia may initially be 
due to iron deficiency but in an older child with cystinosis, may have a variety of 
causes (Gahl et al., 1989). The erythrocyte sedimentation rate and platelet count can 
be high and remain so, although no explanation has been given for these findings 
(Gahl, 1986a). 
Thyroid function tests 
Thyroid function tests are usually normal at the time of presentation (Gahl, 1986a) 
although one patient presenting at Guy's Hospital at the age of 9 months already had 
an abnormally high TSH level with a free T4 concentration at the lower limit of the 
normal range. In the second and third decades of life, abnormalities of thyroid 
function become increasingly common (see below "Endocrine function in cystinosis"). 
Urinary excretion of low molecular weight proteins 
The excretion of low molecular weight (LMW) proteins and tubular enzymes are 
increased in cystinosis. LMW proteins such as retinol. binding protein (RBP) and 82, 
microglobulin 02-M), are freely filtered through the glomerulus, reabsorbed by 
endocytosis in the proximal tubule and catabolised in the tubular cell lysosomes. In 
healthy Iddneys, the reabsorption of LMW proteins is estimated to be 99.9% complete 
(Tomlinson, 1992). Even minor degrees of proximal tubular dysfunction may 
therefore be associated with an increased LMW protein excretion. 
Random urine samples from 10 newly-diagnosed patients, aged 8-25 months, were 
collected prior to cysteamine therapy. The mean glomerular filtration rate, estimated 
in 7 patients, either using the Inutest (n = 6) or chromium-EDTA (n = 1) single 
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injection method, was 68 mis/min/1.73e. 
The concentrations of retinol binding protein (RBP), B2-microglobulin 02-M), albumin 
(Alb), N-acetylglucosaminidase (NAG) and alanine aminopeptidase (AAP) were 
determined using standard methods (Tomlinson et al., 1990; Marulin, 1976; Jung and 
Scholz, 1980). 82-microglobulin is unstable in acid urine, however all the samples in 
the above series had a pH > 7. Table 4.2 shows the median results and ranges, with 
normal geometric mean values (Tomlinson et al., 1990; Tomlinson et al., in press): 
Table 4.2: Urinary excretion of low molecular weight proteins in newly-diagnosed 
patients 
Protein/enzyme Normal range Cystinosis 
RBP (n=8) 8.1 84,586 
(mg/mol creat) (< 1-24.5) (54,289-136,904) 
82-m (n=3) 9.8 90,642 
(mg/mol creat) (6-40.7) (71,651-97,424) 
Alb (n = 8) 0.52 143 
(g/mol creat) (0.014-1.17) (89-231) 
NAG (n=10) 6.8 3460 
(mmol. /pNP/h/mol creat) (1.8-25) (831-6618) 
AAP (n=5) 0.94 19.1 
(u/mol creat) (0.17-1.62) (8.4-36.7) 
Note: n= number of patients analysed for each urine marker 
These data confirm the grossly elevated excretion of LMW proteins and tubular 
enzymes in cystinosis (for review, see Waldmann et al., 1972). Data on the increased 
excretion of alanine aminopeptidase in cystinosis have not previously been reported. 
The excretion of albumin was also increased, but to a lesser extent. 
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Urinary camitine excretion 
The reabsorption of carnitine from the proximal tubule is also impaired. Bernadini et 
al found that the fractional excretion of free and acyl carnitine in children with 
cystinosis was increased (32 and 27% respectively) compared to normal controls (2.8 
and 5.3% respectively) (Bernadini et al., 1985). This led to a deficiency of plasma 
free carnitine. In two cystinosis patients who underwent muscle biopsies, the levels of 
total and free carnitine were reduced compared to normal controls. 
Confirmation of the diagnosis 
There is often a substantial delay between the onset of symptoms and confirmation of 
the diagnosis of cystinosis. In a recent review of 58 patients in the UK (see chapter 
6), the median age at which the diagnosis was made was 19.6 months (range 0-100) 
giving a median delay between onset of symptoms and diagnosis of 6 months (0-100). 
There is evidence in North America that paediatricians have an increased awareness of 
the condition, based on a reduction in the age of diagnosis from 51.3 ± 12.3 (SEM) 
months for children born between 1958 and 1964, to 27.6 ± 4.1 months for those 
born between 1970 and 1974 (Gahl et al., 1986b). 
The best method of confirming the diagnosis clinically is by the demonstration of 
corneal cystine crystals using a slit-lamp. This requires an experienced 
ophthalmologist but is non-invasive and diagnostic. However crystals may not be 
apparent in infancy and can easily be missed (see above: "Ocular manifestations"). 
Failure to demonstrate crystals in an infant does not therefore exclude the diagnosis. 
All children in whom the diagnosis is suspected should therefore have the leucocyte 
cystine concentration determined. This requires a 3ml venous blood sample, processed 
according to the methods detailed in appendix I ("Mixed leucocyte cell pellet 
preparation; Determination of the cystine concentration"). When necessary a result can 
be given within 24 hours. For centres unable to prepare a leucocyte pellet, blood can 
be sent by courier to the appropriate laboratory. Figure 4.1 shows the leucocyte 
cystine concentrations in 32 patients (prior to treatment with cysteamine) either 
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referred to Guy's Hospital or for whom a leucocyte pellet/blood was sent for this 
assay, compared with those of 14 controls (healthy volunteers or patients with other 
diagnoses). The mean (SD) leucocyte cystine concentration in this group was 5.78 ± 
2.49 nmol Ih cystine per mg protein (median 5.62, range 1.57-11.84). For the control 
group the mean value was 0.10 ± 0.05 nmol 1/2 cystine per mg protein (median 0.10, 
range 0.03-0.18). An elevated cystine concentration can also be found in skin 
fibroblasts. This is, however, an inconvenient method of diagnosis since it is more 
invasive and requires several weeks of cell culture before the assay can be performed. 
Prior to the advent of a reliable assay for leucocyte cystine concentration, a variety of 
other methods were used to confirm the diagnosis. Cystine is found in abundance in 
hair in normal and in cystinosis patients. Analysis of hair amino acids after acid 
hydrolysis showed no differences between samples from children with cystinosis and 
those from normals (Vellan et al., 1969). In contrast, infra-red spectroscopy of 
cystinosis hair samples gives a spectrum sufficiently different from normals for the 
method to be used as a means of diagnosis (Lubec et al., 1983). 
Demonstration of cystine crystals in biopsy tissue was a frequent method of diagnosis. 
Crystals can be seen in biopsies of the kidney (see below), lymph node (Patrick and 
Lake, 1968), conjunctiva (Schulman et al., 1970c), rectum (Holtzapple et al., 1969) 
and in bone marrow aspirates (Schneider et al., 1969). 
Pre-symptomatic diagnosis 
With the advent of cysteamine therapy, many North American parents with an 
affected child no longer wish to have prenatal diagnosis for subsequent pregnancies 
(Schneider JA, personal communication). For such couples, pre-symptomatic 
diagnosis of the newborn baby is possible using either umbilical cord blood or samples 
of the placenta (Smith et al., 1989). 
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Clinical course and longterm manifestations of cystinosis 
Introduction 
Although children with cystinosis present with features of renal tubular dysfunction, 
cystinosis is a multisystem disorder. An illustration of this is given by the cystine 
concentrations determined in post mortem tissue samples taken from a9 year old child 
(SM) with cystinosis who died from fungal septicaernia during intensive 
immunosuppression after renal transplantation. Samples were analysed as described in 
appendix 1 and the results (in nmot 1h cystine per mg wet weight) are shown together 
with results from other groups, in table 4.3 below. Published values are mainly from 
post mortern studies of a 25 year old woman with cystinosis (Jonas et al., 1987). 
Kidney 
Change in glomerular filtration rate 
Without treatment glomerular damage progresses inexorably but at a variable rate. 
The plasma creatinine concentration may remain stable for several years but will then 
increase exponentially as the child develops chronic glomerular failure. Plasma 
creatinine concentration may not however be as good a guide to glomerular filtration 
rate as in other some renal conditions since children with cystinosis often have severe 
muscle wasting. Progression to end-stage renal failure has been observed to occur as 
early as 30 months (Schnaper et al., 1992) but usually occurs at the end of the first 
decade. In a review of 205 patients with cystinosis, studied before the advent of 
cysteamine, the mean age of renal death was 9.2 years (Gretz et al., 1982). In a 
review of British children with cystinosis, cross-sectional analysis of the patients' 
reciprocal creatinine concentrations at the start of cysteamine therapy plotted against 
age revealed a linear relationship with a calculated age of renal death of approximately 
. 10 years (see chapter 6: "Results"). A similar age of renal death was calculated in an 
earlier North American review (Gahl et al., 1990). 
As the child's glomerular filtration rate falls so the urinary fluid and electrolyte losses 
are also reduced. Less electrolyte supplements are required and the child appears to be 
"getting better". As chronic renal impairment progresses, salt, water, potassium and 
phosphate restriction is required. Renal transplantation is discussed in chapter 5. 
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Table 4.3: Tissue cystine concentrations 
Tissue Patient SM Other groups Normal values 
Cerebral cortex 1.1 10 0.25 
Cerebellum 0.6 11 0.38 
Pituitary 135 154 0.19 
Thyroid 105 
Parathyroid 88 
Adrenal 1210 137 
Pancreas 1080 102 0.37 
Ovary 225 47 0.54 
Uterus 97 60 0.10 
Heart muscle 23 50 0.02 
Skeletal muscle 15 11 0.02 
Aorta 48 100 0.31 
Skin 135 65 1.3 
Liver 413 537 0.43 
Spleen 191 0 427 
Kidney 820 124 0.25 
Lymph node 900 62 0.33 
(Units: nmol 1/2 cystine per mg protein) 
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The mechanism whereby cystine accumulation leads to tubular damage is discussed in 
chapter 2 ("Mechanisms of cystine toxicity in cystinosis"). The cause of progressive 
glomerular failure in cystinosis is not known. There is increasing evidence that early 
and aggressive use of cysteamine leads to slower progression of glomerular renal 
dysfunction (see chapter 5: "The use of cysteamine and phosphocysteamine"). Since 
cysteamine reduces the lysosomal cystine content, it is likely that the accumulation of 
cystine is involved in the glomerular toxicity. This does not preclude cysteamine 
having another as yet undefined, therapeutic action. 
Renal histology 
Renal biopsy is not routinely undertaken in children with cystinosis. Renal histology 
varies between relatively minor changes and "end-stage" kidneys (Spear, 1974). The 
proximal tubule is involved by epithelial degeneration with characteristic "ballooning 
out" of the cytoplasm. Microdissection may reveal a "swan-neck" thinning and 
shortening of the proximal tubule, a feature seen in many causes of the Fanconi 
syndrome and one that makes distinction between different segments of the nephron 
difficult. Cystine crystals are not always seen but, if visualised, are present in the 
interstitum. 
Changes in the glomeruli are also variable. There may be multinucleate giant cell 
transformation of podocytes (visceral epithelium). The distribution of this change does 
not parallel the site of cystine crystal deposition. There is mesangial cell proliferation 
and changes of hyalWsation may be seen. The basement membrane may be normal, 
thick or split. Interstitial tissue shows fibrosis and Spear reported the presence of dark 
bodies mainly in macrophages but also at other sites (Spear, 1972). These dark 
inclusion bodies were further studied and found to contain an elevated content of 
cystine. They have also been described in biopsies from kidneys transplanted into 
children with cystinosis (Spear et al., 1989). These authors have speculated that 
cystine accumulation may not be localised to the lysosome. 
Other factors leading to deterioration in renal function 
Saleem et al. found that out of 22 children studied, 17 had an increased urinary 
calcium/creatinine ratio and all 22 had features of nephrocalcinosis on ultrasound 
(Saleem et al., 1992). Strife et al. reported the development of gross structural 
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abnormalities of the genitourinary tract in two children with cystinosis (Strife et al., 
199 1). An 11 year old boy was found to have megacystis, grossly dilated ureters and 
hydronephrosis in the absence of bladder outlet obstruction. He had had a normal 
intravenous urogram at 2 years of age. A vesicostomy led to his renal function, which 
had been deteriorating rapidly, returning to a stable state. A 16 year old girl was 
found on ultrasound examination, to have extensive renal cysts which the authors 
postulated might have been related to longstanding hypokalaemia. These reports serve 
to highlight that children with cystinosis require intensive follow-up to minimise the 
progression of their disease. 
Growth 
Short stature is an almost universal feature of patients with cystinosis. Figures 4.2 and 
4.3 demonstrate the growth of 9 pre-transplant children (5 boys, 4 girls) at Guy's 
Hospital (normal data are taken from Tanner et al., 1966). The effects of recombinant 
human growth hormone treatment are shown by the "hatched" lines (for further 
details, see chapter 5: "Hormone replacement in cystinosis"). Figure 4.4 shows the 
same data converted to height standard deviation scores. Most children are growing at 
an approximately normal rate but remain 3 standard deviations below the mean. The 
degree of growth retardation is out of proportion to the extent of renal damage. 
Chronic acidosis, loss of electrolytes as a result of the Fanconi syndrome, rickets and 
the effects of cystine accumulation in bone and other organs (eg. thyroid) may all 
contribute to the poor growth. Nutritional intake is also poor in most children with 
cystinosis. Endocrine abnormalities in cystinosis are discussed below. 
Growth is improved by treatment with cystine-depleting agents (see section on 
treatment). Final height, however, remains short even after renal transplantation. In a 
European review of 123 patients with cysfinosis receiving renal replacement therapy, 
only 8 patients had heights above the third centile for age (Ehrich et al., 1992). Bone 
age was severely retarded in almost all patients. Only 19% of these patients received 
cysteamine or phosphocysteamine and no data on dosage or cystine concentrations 
were reported. In transplanted patients, immunosuppression with steroids is an 
additional factor leading to growth retardation. 
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Endocrine function in cystinosis 
1. Thyroid 
Abnormalities of thyroid function are common in cystinosis and are unrelated to renal 
dysfunction. These may vary from mild elevation of thyroid stimulating hormone 
(TSH) to frank clinical hypothyroidism. Pathologically there is thyroid follicular cell 
atrophy with collapse and condensation of the connective tissue framework (Chan et 
al., 1970). Burke et al. found an exaggerated response of TSH to thyrotropin releasing 
hormone (TRH), suggesting impaired thyroid reserve compared to control children 
with chronic renal failure (Burke et al., 1978). 
The frequency of hypothyroidism increases with age but elevation of the TSH 
concentration has been seen as early as 9 months of age (van't Hoff W, personal 
communication). Fifty-two percent of 123 European children with cystinosis on renal 
replacement therapy (aged 7-25 years) had hypothyroidism (Ehrich et al., 1992). In 
two French reviews, 56% of patients aged 8-16 years and 79% of patients aged 15-26 
years were hypothyroid (Broyer et al., 1981; Broyer et al., 1987). Similar figures 
have been reported in a North American review (Gahl et al., 1986b). 
2. Growth hormone 
Preliminary reports suggest normal growth hormone (GH) secretion in cystinosis. 
Wilson et al. studied physiological and pharmacologically-induced GH secretion in 2 
children (Wilson et al., 1989). GH secretion was stimulated to normal levels after 
glucagon but not arginine. The frequency and maximum peak concentrations of 
spontaneous GH secretion were also normal but the mean integrated concentration was 
slightly lower than normal. In an initial report of the European multicentre study of 
growth hormone treatment in cystinosis, overnight GH concentration profiles in 8 
patients were not statistically different from controls with chronic renal failure (van't 
Hoff et al., 1993). 
Overnight GH profiles have been measured in 4 prepubertal (pre-transplant) patients, 
aged 5-12 years, at Guy's Hospital (see figure 4.5). All 4 patients achieved a peak 
GH concentration of > 20mu/I and the profiles can therefore be regarded as "normal". 
However, the GH level should become virtually undetectable between peaks, and this 
is seen in only one patient (SV) on one occasion (Stanhope R, personal 
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Figure 4.5: Overnight growth hormone secretion in 4 pre-pubertal children (study 
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communication). Growth hormone secretion following an infusion of arginine (a 
pharmacological stimulant of GH secretion) has been measured in 3 of these patients 
(see figure 4.6). Plasma GH should rise above 20mu/I after the arginine dose. Two of 
the three patients tested showed such a normal response whilst the other, RS, had a 
suboptimal profile. 
3. Pancreas 
Hyperglycaemia and diabetes mellitus may occur in the older (transplanted) cystinosis 
patients. There were 7 patients with diabetes mellitus in the European review of 123 
patients on renal replacement therapy (Ehrich et al., 1992). Fivush et al. reported 5 
such patients with insulin levels which were inappropriately low when compared with 
the glucose concentration at the time of the sample suggesting inadequate insulin 
secretion (Fivush et al., 1987). This finding contrasts with the observation of B-cell 
hyperplasia in post-mortem pancreatic tissue from 8 cystinosis patients (Milner and 
Wirdnam, 1982). There has been one case report of a young child of 13 months with 
insulin dependent diabetes mellitus who also had cystinosis (Ammenti et al., 1986). 
4. Gonadotrophins, puberty and pregnancy 
Pubertal development is generally delayed (Gahl and Kaiser-Kupfer, 1987; Winkler et 
al., 1993). In one study of 17 patients, the mean onset of puberty was 15.5y (range 
12-18) in males and 15y (12-18) in females (Winkler et al., 1993). Bone age at the 
onset of puberty was delayed by a mean of approximately 4.5 years in both sexes. 
Females established stable menstrual cycles 2 years after menarche and had 
appropriate cyclical fluctuations in gonadotrophin and oestradiol levels. In males, 
gonadotrophin levels are increased above the normal range. Luck et al. found an 
inappropriately high LH level in an 8 year old boy with cystinosis (Luck et al., 1977). 
Winkler et al. found abnormally high LH and FSH levels but low testosterone levels 
in post-pubertal males (Winkler et al., 1993). The results of these and HCG 
stimulation tests led the authors to conclude that the hypergonadotrophic 
hypogonadism might be due to progressive testicular damage secondary to cystine 
accumulation. 
Reiss et al. reported a successful pregnancy in a woman with cystinosis and a renal 
transplant (Reiss et al., 1988). The patient had developed chronic renal failure at 8 
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years, was transplanted at 9 years and had never received cystine-depleting drugs. She 
had her menarche at 15 years, menstruated regularly thereafter and became pregnant 
at 20 years of age. She developed hypertension, proteinuria and oedema at 35 weeks 
of gestation and on account of cephalo-pelvic disproportion as well as these problems, 
underwent elective caesarian section at 36 weeks. A healthy male infant weighing 
2.79kg was delivered and he remained well at I year of age. His leucocyte cystine 
concentration was 0.95 nmol 1/2 cystine per mg protein, consistent with his expected 
heterozygote status. This report suggests that gonadotrophin and ovarian function in 
adult women with cystinosis may be adequate to allow conception and support a 
pregnancy. 
Neurological manifestations 
Early neurological development and function appears to be normal in cystinosis. 
However in the second and third decades of life, the frequency of neurological 
manifestations of cystine accumulation increase. Ehrich et al. described three children 
aged 9-11 years with seizures in whom computerised tomography (CT) of the brain 
demonstrated generalised cerebral atrophy (Ehrich et al., 1977). The degree of 
cerebral atrophy experienced by patients with cystinosis is greater than that which can 
occur in other patients with renal disease. Cochat et al. demonstrated significantly 
greater cerebral atrophy on CT scans from 10 children with cystinosis compared with 
a similarly aged control group with other renal diseases (Cochat et al., 1986). Nichols 
et al. demonstrated cortical atrophy with magnetic resonance imaging in 10 of II 
patients aged 5-19 years (Nichols et al., 1990). Cognitive test scores were poorer in 
children with the greatest degree of atrophy but the relationship did not reach 
statistical significance (Nichols -et al., 1990). 
In older patients neurological symptoms may include bradykinesia, tremort memory 
loss, dementia, rigidity, weakness, paraesthesiae, dysarthria and dysphagia (Fink et 
al., 1989; Vogel et al., 1990). Neurological examination may be normal or may 
reveal a generalised myopathy (Gahl et al., 1988a), tremor, spasticity and an 
abnormal gait (Fink et al., 1989; Vogel et al., 1990). 
Swallowing dysfunction is a late but serious complication and can lead to fatal 
aspiration (Sonies et al., 1990; Gahl et al, 1988a). In a review of 43 patients, Sonies 
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et al. found that oral motor and swallowing dysfunction increased with age but that 
there were severely affected younger patients. The dysfunction appears to be related to 
impaired neuromuscular activity rather than to neurological damage. Both dry and wet 
swallowing times are prolonged in cystinosis, but the greater differences are seen with 
dry swallows which require more muscular effort (Sonies et al., 1990). 
Neuropathological findings include gyral atrophy, dilated ventricles, cystic necrosis of 
the globus pallidus and lentiform nuclei, patchy demyelination, calcification and 
spongiform changes in cerebral cortex and white matter (Vogel et al., 1990). Cystine 
crystals can be demonstrated in basal ganglia, cortex, thalamus, cerebellum and 
pituitary gland (Fink et al., 1989; Vogel et al., 1990). Gahl et al. described the 
histological changes in muscle in a patient with a striking myopathy (Gahl et al., 
1988a). Frozen sections of skeletal muscle revealed variation in fibre size, selective 
atrophy of type I fibres, presence of ring fibres, absence of inflammatory changes and 
only slight lipid accumulation. Cystine crystals were present in the perimysial and 
endomysial spaces. Several groups have determined cystine concentrations in post- 
mortem brain and muscle tissue (see table 4.3 and Jonas et al., 1987; Gahl et al., 
1988a; Vogel et al., 1990). 
Longitudinal psychometric testing has shown that children with cystinosis usually have 
a normal intelligence quotient (IQ) and can attend normal school (Wolff et al., 1982). 
However other workers have found that whilst overall IQ scores are normal, patients 
with cystinosis had significantly poorer scores in tests of short-term visual memory 
and that this deficit was not due to ocular disease (Trauner et al., 1988). 
Longterm ocular manifestations 
Although the effects of cystine deposition in the eye can be detected early in life (see 
above), visual acuity remains good in childhood. However the longterm prognosis for 
normal vision is poor (Kaiser-Kupfer et al., 1986). Corneal cystine crystal deposition 
progresses with age leading to haziness or clouding in the second decade of life. The 
photophobia increases in severity and corneal erosions develop. Crystal deposition in 
the iris may lead to an inflammatory reaction causing posterior synechiae and 
glaucoma. Crystals may also be seen on the lens surface. Retinal dysfunction also 
occurs. In older patients colour vision may be defective, the dark-adaptation 
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thresholds are increased and electro-refinograms become abnormal. A haemorrhagic 
refinopathy can occur leading to retinal detachment, scarring and angle-closure 
glaucoma (Schneider et al., 1990). 
Gastrointestinal and hepatic manifestations 
Cystine crystals may be found in intestinal mucosa, confined to cells of the lamina 
propria but gastrointestinal function appears to be normal (Morecki et al., 1968). Poor 
feeding is however a frequent complaint and is perhaps related to a feeling of gastric 
fullness due to the large quantities of fluid that the child is obliged to drink. Vomiting 
may be related to chronic acidosis and is exacerbated by medications especially 
cysteamine. Alteration of bowel habit is unusual, if anything there is a tendency to 
constipation as a result of dehydration. One child developed chronic diarrhoea and 
colonoscopy demonstrated features of ulcerative colitis (Treem et al., 1988). 
Pancreatic dysfunction may lead to diabetes mellitus (see above) and malabsorption. 
Fivush et al. reported a 17 year old post-transplant female who developed bulky, 
offensive stools and lost weight (Fivush et al., 1988). Hypoalbuminaemia, excessive 
stool fat excretion and a very low serum trypsinogen all suggested exocrine pancreatic 
dysfunction. The serum amylase remained normal and ultrasound of the pancreas 
showed a marked increase in echogenicity, consistent with chronic pancreatitis. 
Treatment with pancreatic enzyme replacement led to resolution of the symptoms and 
weight gain. 
Hepatomegaly may occur even in young children. Approximately 30% of patients 
under 5 years have hepatornegaly or splenomegaly (Gahl, 1986a). This number rises 
to 42% in patients over 10 years of age (Gahl et al., 1986b). However, biochemical 
tests of liver function are generally normal. Portal hypertension is rare but has been 
reported in French patients with cystinosis, occurring approximately 5 years after 
transplantation and, in 2 cases, requiring a porto-caval shunt operation (Broyer et al., 
1987). Liver biopsy may show normal hepatocytes and portal spaces filled with 
enlarged Kupffer cells containing cystine crystals (Broyer et al., 1987). 
MisceHaneous rmdi gs 
Gahl et al. demonstrated that children with cystinosis have an impairment of sweat 
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production when tested by pilocarpine iontophoresis (Gahl et al., 1984). The 
concentration of sweat chloride was similar to that in normals. Impaired sweat 
production renders cystinosis patients intolerant to prolonged heat exposure. 
Pintos-Morell et al. demonstrated impaired neutrophil migration and adhesiveness in 
cystinotic cells (Pintos-Morell et al., 1985). The authors note that these properties are 
essential for leucocyte-endothelial interactions such as may occur in allograft rejection. 
These workers later reported a decreased production of Ig-containing cells and of Ig in 
stimulated monocytes from cystinosis children (Pintos-Morell et al., 1991). This effect 
was not seen in monocyte-depleted preparations. However no in vivo clinical 
immunological alteration has been described in cystinosis (Pintos-Morell et al., 1991) 
and there is no evidence of increased susceptibilty to infection (Schneider and 
Schulman, 1986). 
Hypercholesterolaemia has been demonstrated in boys but not girls with cystinosis 
(Murphy and Papathalds, 1993). The serum cholesterol concentration was elevated in 
boys by ly of age and the rise was progressive. Renal transplantation led to some 
improvement in cholesterol level. 
There has been a single case report of a patient, transplanted on account of cystinosis, 
who died in respiratory fOure from pulmonary fibrosis (Almond et al., 1993). No 
details of post mortem findings were given. Cystine crystals have been observed in 
interstitial tissue of the lung in one other patient but in this case there were no fibrotic 
changes (van't Hoff W, personal communication). 
Late-onset cystinosis 
In 1971, Goldman et al. described two brothers aged 14 and 15 years, with cystinosis 
(Goldman et al., 1971). The elder brother had a history of polyuria and polydipsia 
from early childhood and had been found to have proteinuria at the age of 4 years. At 
11 years of age cystine crystals were demonstrated in the cornea and conjunctiva. His 
younger brother did not suffer from polyuria but was diagnosed at the age of 10 years 
when his elder sibling was admitted for investigation. Both brothers had a generalised 
aminoaciduria, glycosuria and rickets. This was the first description of what was 
called "adolescent cystinosis" (Goldman et al., 1971). Subsequently there have been 
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further reports of cases of nephropathic cystinosis presenting after infancy, the oldest 
new diagnosis being made in a woman of 26 years of age (Schneider JA, personal 
communication). Patients with intermediate or late-onset cystinosis may develop the 
typical features of the renal Fanconi syndrome or may present with symptoms and 
signs of chronic renal impairment. A 12 year old asymtomatic girl, electively admitted 
for excision of osteochondromata, was found to have glycosuria, proteinuria and a 
plasma creatinine concentration of 265[imol/I (van't Hoff WG, personal 
communication). There had been no history of polyuria or polydipsia. Slit-lamp 
examination of her cornea revealed crystal deposition and her leucocyte cystine 
concentration was 6.92 nmol 1/2 cystine per mg protein. She required haemodialysis 
from the age of 14 years and subsequently received a renal transplant. Cysteamine 
treatment was given from the age of 16 years. 
In general, patients with late-onset cystinosis have a slower progression of renal 
glomerular damage than do infantile-onset patients (Gahl et al., 1989). The degree of 
growth retardation is also less severe than the younger-onset children. These features 
may be related to the findings that the untreated leucocyte cystine concentrations are 
generally lower and fibroblast lysosomal cystine transport generally greater in late- 
onset patients than in the infantile group (Gahl et al., 1989). There is however no 
clear separation between the two groups and it is likely that molecular genetic 
techniques will reveal a continuum of severity related to different gene mutations. 
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Chapter 5: The treatment of cystinosis 
Introduction and historical perspective 
The treatment of cystinosis can be divided into two broad categories: general and 
specific. General measures are those that aim to correct and maintain biochemical 
homeostasis. These include a high fluid intake, electrolyte and alkali supplements and 
Vitamin D. Specific therapies are those that aim to reduce the cystine toxicity in 
tissues. Such measures have included dietary therapy, penicillamine, dithiothreitol, 
ascorbic acid and more recently, cysteamine and phosphocysteamine. 
Renal replacement therapy (dialysis or transplantation) is required for patients in end- 
stage renal failure. In contrast to the use of liver transplantation to correct enzyme 
deficiencies in some other metabolic disorders, neither dialysis nor transplantation 
affect the accumulation of cystine in non-renal tissues. 
Discussion of treatment options formed a small part of the early reports of cystinosis. 
Russell and Barrie describe the therapy given to their first case as "a course of ultra- 
violet light together with vitamin D. " (Russell and Barrie, 1936). McCune et al. 
reviewed the 39 reported cases of the Fanconi syndrome including some with 
cystinosis (McCune et al., 1943). Various therapies had been employed. Insulin had 
been used without benefit. Many workers had given alkali therapy but the results 
seemed disappointing. In contrast, Goldmann and Ekstein reported great benefit from 
a diet rich in potassium (Goldmann and Ekstein, 1939). Vitamin D in conventional 
doses had little effect on the rickets but much higher doses had been beneficial 
(McCune et al., 1943). 
Bickel et al. reviewed the management of 10 cases of cystinosis (Bickel et al., 1952). 
Albright's solution containing sodium citrate 100gms, citric acid 140gms and water to 
1 litre, was used to correct the acidosis. Potassium was given as the chloride salt or as 
part of a modified Albright's solution (substituting 50gms potassium citrate for 50gms 
of the sodium citrate). Very large doses of calciferol (50,000 to 500,000 units daily) 
were given to treat the rickets. The authors wrote "our patients show such obvious 
improvement that we cannot avoid an attitude of cautious optimism". 
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Dietary therapy consisting of a protein intake low in cystine and methionine was 
attempted in the 1940's and remained the only potential specific therapy for three 
decades (Bickel et al., 1972). In the 1960's penicillamine and dimercaprol were tried 
with conflicting but generally ineffective results (Hambraeus and Broberger, 1967). 
The discovery of agents capable of depleting the cystine content of cystinotic 
fibroblasts in vitro led to a new era of therapy. Dithiothreitol was the first of these 
agents and had a beneficial effect on leucocyte cystine concentration but no clinical 
benefit (DePape-Brigger et al., 1977). Ascorbic acid was useful in vitro but not in 
vivo. In 1976, cysteamine was found to be a very effective cystine depleting agent 
(Thoene et al., 1976). This compound together with the derivative, 
phosphocysteamine, are currently the drugs of choice for the treatment of cystinosis. 
General measures in the management of cystinosis 
Introduction 
General measures are those that aim to correct and maintain biochemical homeostasis. 
Most children with cystinosis present in late infancy with features of dehydration, 
potassium and mineral deficiency leading to weakness and rickets., Thus the most 
important aims in early management are adequate replacement of fluids, correction of 
hypokalaemia, acidosis, hypophosphataemia and treatment of rickets. Once these 
measures are underway, attention can be directed towards nutrition and to reducing 
the intracellular cystine concentrations (see below). 
The management of cystinosis requires a multi-disciplinary approach. Close liaison 
between physician, nurse, biochemist, pharmacist and dietician is needed. Specialist 
support is required with ophthalmological, neurodevelopmental, psychological and 
radiological reviews. When there are a sufficient number of patients, these services 
are best coordinated within a specialist, dedicated clinic. As in many genetic and 
chronic conditions, there is a great burden on the family of the affected child. 
Feelings of guilt in relation to passing on a "defective gene" to the child are 
compounded by the child's poor growth, anorexia, nausea and as a result of treatment, 
breath smell. Families find both the "nature" and "nurture" difficult. Growth failure 
becomes an especial problem at school. Children are teased about their height, their 
smell and their need to pass urine frequently. Older children experience difficulties 
with peer relationships and attitudes. Although transplantation has led to longer 
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survival, cystinosis remains a fatal disease. However, there is the hope that the 
current generation of well-treated patients will have a longer lifespan. For these 
reasons, all families should be offered the support of the Research Trust for Metabolic 
Diseases in Children (RTMDC), a parents and professionals group dedicated to all 
metabolic disorders. In addition, supportive counselling is frequently helpful. 
Fluid therapy 
Children with cystinosis may have an obligatory urine output of 2-6 litres per day 
(Gahl et al., 1989). Free access to fluid is therefore required day and night. It is a 
common experience that rehydration of the newly diagnosed patient leads to increased 
urine output and electrolyte losses (see below). The initial therapy will usually need to 
take place in hospital and may take several weeks. 
Illnesses which compromise the child's ability to absorb these volumes, eg. vomiting, 
diarrhoea, or which are associated with further fluid loss, eg. fever, sunstroke, require 
urgent and aggressive intravenous therapy. The calculation of intravenous fluid 
requirements should take into account the "normal" daily urine output for the child. 
Thus a 10kg cystinosis child may require a maintenence volume of 100ml/kg/day 
(1,000ml) plus 2,500ml per day. 
The experience at Guy's Hospital is that most children will only drink water, rejecting 
more nutritious fluids such as milk or carbohydrate drinks. However, much of the 
daily electrolyte requirement can be safely added to bottles of water which can be 
taken over several hours. Children should be encouraged to drink as much as they 
want. It is important to correct -ihe misapprehension that the child is passing a, lot of 
urine because he is drinking so much, rather than the other way round. This becomes 
a particular problem during nursery and schooling. 
Correction of acidosis and electrolyte disturbance 
Correction of acidosis -will lead to massive bicarbonate loss in the urine in the form of 
NaHC03 or KHC03 which leads to further electrolyte deficiencies. Sodium and 
potassium are therefore given with an anion such as bicarbonate or citrate (which is 
metabolised in the liver consuming hydrogen ions) so that both electrolyte disturbance 
and acidosis is corrected. In the UK, potassium is usually given as potassium citrate 
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or chloride and sodium as sodium bicarbonate or citrate. A modified Albright's 
solution (containing sodium citrate, potassium citrate and citric acid) is used in some 
centres. This has the advantage of replacing 3 electrolytes in one concentrated 
solution. Some patients however do not tolerate the taste of citrate formulations. 
Prediction of the doses required for each patient is difficult as they vary enormously. 
Initial doses might be sodium bicarbonate 5-10mmol/kg/day and potassium chloride 4- 
5 mmol/kg/day (or equivalent for compound solutions). Doses are titrated against 
plasma electrolytes, aiming to maintain plasma potassium above 3.5mmol/l (although 
3.0-3.5 is often the best that can be achieved) and the bicarbonate level at 
approximately 22-24mmol/l. 
Treatment of hypophosphataemia and rickets 
Hypophosphataemia is seen in all newly diagnosed children with cystinosis. A variety 
of phosphate supplements are available for use. At Guy's Hospital, neutral sodium 
phosphate, 1.8mmol sodium and I. Ommol phosphate per ml, is used to maintain the 
plasma phosphate concentration within the normal range. This is associated with 
healing of the rickets and a return of the serum alkaline phosphatase level towards the 
normal range. Diarrhoea is a potential side-effect of phosphate therapy but does not 
appear to be a major problem in practice. 
Hypocalcaemia is not a common problem when the child first presents. There is 
however a very significant risk of profound hypocalcaemia leading to tetany following 
correction of the acidosis and hypophosphataemia (see chapter 4: "Metabolic bone 
disease and mineral homeostasis"). This requires correction with oral or intravenous 
calcium and magnesium supplenientation may also be necessary. Some patients require 
longterm calcium supplements. 
Treatment of the rickets also involves the use of vitamin D supplements and these are 
used routinely at Guy's Hospital. 1-ci-hydroxycholecalciferol (Alfacalcidol) is used, 
usually starting at a dose of 25-50 nanogram/kg/day. Very careful monitoring of 
plasma calcium and phosphate together with the serum alkaline phosphatase and 
parathyroid hormone concentrations are required during this therapy. Treatment will 
lead to healing of rickets over several months but there is a risk of hypercalcaemia 
with subsequent renal damage. Hypercalciuria is a feature of the Fanconi syndome and 
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and nephrocalcinosis has recently been described in cystinotic children (Saleem et al., 
1992). 
Other therapies 
Use of thiazide diuretics and indomethacin 
Treatment of the fluid and electrolyte abnormalities in cystinosis can lead to an 
increase in vascular volume, glomerular filtration and thus a further increase in 
urinary salt, bicarbonate and phosphate losses. Some patients have extreme difficulty 
tolerating the volumes of alkali required to correct their acidosis and in these cases, 
additional measures are justified. Thiazide diuretics reduce extracellular volume but 
will cause increased loss of sodium and potassium. 
Indomethacin, a prostaglandin synthetase inhibitor, is a useful adjunct to conventional 
therapy. It can reduce the polyuria and polydipsia thereby reducing the requirement 
for electrolyte replacements. This often has the effect of making the child feel better 
and improving appetite. In some patients indomethacin therapy can improve growth 
rate dramatically even in those who have been well treated with cysteamine (M 
Broyer, personal communication). It acts by reducing renal blood flow with a 
consequent fall in glomerular filtration rate (Haycock et al., 1982). Indomethacin also 
has the effect of increasing tubular sodium reabsorption thereby reducing potassium 
wastage (Haycock et al., 1982). Indomethacin therapy is however potentially 
dangerous. Firstly it causes reduction, albeit reversible over the short term, in 
glomerular filtration rate in a disease characterised by progressive glomerular 
dysfunction (Lemire and Kaplan, 1981). Secondly one patient suffered a duodenal 
perforation during indomethacin therapy (Haycock et al., 1982). 
Indomethacin is not used in the management of cystinosis in North America (JA 
Schneider, personal communication) but is commonly prescribed in European centres 
(Broyer and Tete, 1990). At Guy's Hospital, indomethacin is used in patients in whom 
conventional electrolyte and alkali therapy fails to achieve an adequate biochemical 
response. In June 1993,6 of the 10 pre-transplant patients cared for in the Cystinosis 
Clinic at Guy's Hospital were receiving indomethacin. 
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Camitine therapy 
Bernadini et al. demonstrated that patients with cystinosis have an increased urinary 
excretion of free and acyl carnifine leading to a deficiency of plasma and muscle free 
carnitine (Bernadini et al., 1985). Gahl et al. undertook a trial of L-carnitine 
supplements (25mg/kg every 6 hours) to children with cystinosis (Gahl et al., 1988b). 
This dose of carnitine rapidly corrected the plasma deficiency but within the time of 
the study (up to 18 months therapy) did not correct the muscle deficiency. In a recent 
report, Gahl et al. reported that longterm (approximately 5 years) supplementation 
increased muscle carnitine levels to within the normal range (Gahl et al., 1993). It 
remains unclear whether carnitine treatment has any symptomatic benefits. 
Hormone replacement in cystinosis 
1. Thyroxine 
The need for thyroid replacement therapy increases with age. In one survey, 63% of 
patients aged 10-13 years and 80% of those aged 19-26 years, required thyroxine 
replacement (Gahl et al., 1986b). Following renal transplantation, abnormalities in 
thyroid function can resolve spontaneously (Ehrich et al., 1991). 
2. Imufin 
Patients with cystinosis who develop diabetes mellitus require insulin in standard 
doses. However some patients who have developed diabetes shortly after 
transplantation, only require insulin for a short time (Broyer et al., 1987). Oral 
hypoglycaemic agents have also been used in the management of cystinosis patients 
with diabetes (Almond et al., 1993). 
3. Growth Hormone 
Wilson et al. reported the effect of recombinant human growth hormone (rhGH) 
treatment in two children aged 10 and II years with cystinosis (Wilson et al., 1989). 
Both responded with an increase in growth velocity from approximately 3cm/year to 8 
and 9cm/year respectively. The authors stated that the rate of decline of renal function 
did not appear to be altered by rhGH treatment. 
Andersson et al. reported on the effects of 18-24 months treatment with rhGH in 3 
children with cystinosis, aged 6.6 - 14 years (Andersson et al., 1992). All three 
P 97 
showed an increase in growth velocity but also a sharp increase in plasma creatinine 
concentration. One patient required a renal transplant and the authors cautioned that 
rhGH treatment might increase the rate of progression of renal failure. 
Rees et al. studied two prepubertal children with cystinosis who had been 
transplanted, among a series of children with renal disease given rhGH (Rees et al., 
1990). Both children increased their growth velocities, one suffered a decline in renal 
function (as estimated by plot of reciprocal plasma creatinine concentration) but there 
was no significant change in height standard deviation score (HtSDS) for bone age in 
the group, suggesting that final height would be unaffected. 
A European multicentre trial of rhGH in children with cystinosis is in progress. As of 
August 1993,55 patients have been enroled, 30 have completed 1 year and 12 have 
completed 2 years of therapy (van't Hoff et al., 1993, in press). The median results 
are shown in table 5.1, below. 
Table 5.1: Interim results of rhGH therapy in pre-terminal renal failure (n = 16) 
Baseline 1 year rhGH 2 years rhGH 
Height velocity (cm/y) 3.5 9.0 7.0 
Height SDS (chron. age) -4.5 -3.7 n/a 
Height SDS (bone age) -2.1 -1.6 n/a 
These results suggest that shorrierm, rhGH therapy improves growth. There are 
potential technical inaccuracies in the estimation of bone age in children with rickets, 
however the increase in height SDS when corrected for bone age suggests that final 
height may be improved. No change in the progression of renal disease was observed, 
nor was there any deterioration in the results of serial oral glucose tolerance tests. 
The longterm effects of growth hormone therapy on renal function will take several 
years to evaluate. Its effect on final height can only be judged when the children 
participating in the trial have finished their growth period, 10-15 years from now. 
P 98 
Speciric therapies 
1. Dietary therapy 
Dietary manipulation was the first specific therapy used in cystinosis. Freudenberg in 
an early review, noted that some patients were given a diet based on proteins with a 
low cystine content (eg. lentil preparations), (Freudenberg, 1949). Subsequently some 
groups used an amino acid mixture free of methionine and cystine as the main protein 
source together with a small amount of natural protein. Seip et al. found an 
improvement in "well-being" and a reduction in the polyuria and polydipsia in two 
brothers treated with a lentil diet (Seip et al., 1968). Christensen et al. reported some 
symptomatic improvement in one of two children treated with a similar diet 
(Christensen et al., 1970). 
Crawhall et al. reported that plasma cystine concentrations in children with cystinosis 
were not significantly different to those in controls (Crawhall et al., 1968). These 
workers found that although dietary restriction of cystine and methionine could lead to 
a substantial reduction in the plasma cystine level, there was no concomitant reduction 
in the quantity of cystine crystals seen in the cornea or bone marrow. This work led 
to the realisation that intracellular cystine was not in free equilibrium with 
extracellular fluid and plasma cystine. 
Dietary therapy was unpleasant and associated with serious side-effects. In an 
extensive review of 21 patients receiving dietary therapy, Bickel et al. reported four 
deaths of young children from liver cirrhosis associated with severe methionine 
deficiency (Bickel et al., 1972). No beneficial effect on growth, renal function or 
cystine storage could be demonstrated and the authors concluded that dietary measures 
had no effect on the course of the disease (Bickel et al., 1972). Subsequently, Thoene 
et al. demonstrated that the major source of intralysosomal cystine was from the 
breakdown of endogenous protein (Thoene et al., 1977). Attempts to reduce 
intracellular cYstine by reduction of the extracellular and plasma cystine were 
therefore likely to be in vain. 
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2. Drug therapy 
Peniciflamine 
Penicillamine was used in the treatment of cystinosis initially "in the hope of 
reactivating or maintaining thiol-dependent systems" which were thought to be 
deficient in cystinosis (Clayton and Patrick, 1961). Clayton and Patrick reported a 
reduction in acidosis, aminoaciduria and symptomatic improvement in three children 
treated with penicillamine and dimercaprol (Clayton and Patrick, 1961). Hambraeus 
and Broberger gave penicillamine to one 17 month old child with cystinosis in the 
belief that it might undergo disulphide exchange with cystine (Hambraeus and 
Broberger, 1967) However, there was no clinical improvement nor any change in 
aminoaciduria (Hambraeus and Broberger, 1967). Other groups confirmed the 
ineffectiveness of penicillamine treatment (Crawhall et al., 1968; Bickel et al., 1972). 
Thoene et al. later demonstrated that there was no appreciable cystine depletion when 
cystinotic fibroblasts were incubated in vitro with penicillamine (Thoene et al., 1976). 
Dithiothreitol 
Dithiothreitol (2,3-dihydroxy-1,4-dithiobutane) is a powerful reducing agent capable of 
reacting with disulphides to form an oxidised cyclic derivative. Goldman et al. 
demonstrated that incubation of cystinotic fibroblasts in vitro with ImM dithiothreitol 
led to a marked reduction in the cystine content of the cells (Goldman et al., 1970; 
Aaron et al., 1971). These workers treated one patient in end-stage renal failure for 
two weeks with daily intravenous infusions of dithiothreitol and found a 65% fall in 
cystine content between pre and post-treatment rectal mucosal biopsies. However such 
a fall could be accounted for by sampling error. The child died of terminal uraemia 
one month after the trial of dithiothreitol (Aaron et al., 1971). 
DePape-Brigger et al. gave courses of dithiothreitol in capsule form (at a dose of up 
to 25mg/kg three times a day) to two boys for up to 8 months (DePape-Brigger et al., 
1977). They demonstrated a marked fall in leucocyte cystine concentration during 
treatment. Both children had significant renal impairment prior to dithiothreitol and 
treatment did not appear to affect renal function. One boy died during the study but 
the authors felt that this was not attributable to the drug and there were no other 
serious side-effects (Depape-Brigger et al., 1977). More recently the use of other, 
more effective cystine-depleting agents (cysteamine and phosphocysteamine) has meant 
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that dithiothreitol is no longer widely used. 
Ascorbic acid 
Kroll and Schneider reported that cystinotic fibroblasts were partly depleted of their 
cystine content when incubated in a medium containing high concentrations of 
ascorbic acid (Kroll and Schneider, 1974). A multicentre double-blind clinical trial of 
ascorbic acid (200mg/kg/day) versus placebo was then undertaken in 64 patients 
(Schneider et al., 1979). Both the placebo and ascorbic acid groups were well matched 
prior to treatment. The mean age of both groups was 4y, mean GFR approximately 
39ml/min/1.73M2 and there was no statistically significant difference between the two 
groups in their pre-treatment leucocyte cystine concentrations. After two years the 
study was terminated when there was sufficient evidence that ascorbic acid treatment 
might be harmful. Eight of the eleven patients who left the study on account of death, 
dialysis or transplantation were in the ascorbic acid group. The mean (SD) increase in 
plasma creatinine in the ascorbic acid treated group, 0.52 (0.75) mg/dl, was over 
twice that of the placebo group, 0.24 (0.29), although this difference was not 
statistically significant. No data on the effects of ascorbic acid on leucocyte cystine 
were reported. 
Other agents used to deplete cystine 
Following the report in 1976 of the cystine-depleting property of cysteamine, this drug 
became the treatment of choice in cystinosis. Cysteamine and phosphocysteamine are 
discussed in the next section. 
Nevertheless, other compounds- have been studied. Pantethine is the disulphide of 
pantetheine a naturally occurring precursor of cysteamine (see below: "The occurrence 
of cystearnine in the body"). Pantethine, when incubated with cystinotic fibroblasts in 
vitro, leads to cystine depletion (Butler and Zatz, 1984). It is likely that pantethine is 
reduced to pantetheine once it has entered the cell and that cleavage of pantetheine to 
cystearnine and pantothenic acid occurs by the action of pantetheinase. The cystine 
depletion induced by pantethine is probably mediated by the cystearnine so formed 
(Butler and Zatz, 1984). 
Butler reported that homocysteine had a cystine-depleting effect on cystinotic 
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fibroblasts in vitro (Butler, 1990). Furthermore the addition of cysteamine and 
homocysteine to the culture medium led to a synergistic cystine-depleting effect. This 
finding may lead to new strategies of treatment. 
Renal transplantation 
Prior to the advent of successful renal replacement therapyt children with cystinosis 
died from renal failure. Haemodialysis and subsequently renal transplantation were 
first undertaken in the late 1960's (Mahoney et al., 1970; Goodman et al., 1972). 
There were no technical difficulties specific to children with cystinosis and the results 
were very encouraging. Patients no longer required electrolyte and alkali replacement, 
felt better and in some cases, grew better (Mahoney et al., 1970). 
Broyer et al. commented on the favourable outcome of renal transplantation in 
children with cystinosis compared to those with other causes of renal failure (Broyer 
et al., 1981, Broyer et al., 1987). Graft survival was 86% at 6 years and 76% at 10 
years compared to 58% and 40% for the whole group of paediatric renal transplant 
patients in the H6pital des Enfants Malades, Paris. Other groups in North America 
and Germany have not found a difference in rejection episodes and graft survival 
between cystinosis and non-cystinosis patients (Gahl and Kaiser-Kupffer, 1987b; 
Ehrich et al., 1991). 
Renal transplantation does not correct the metabolic abnormality in cystinosis but the 
grafted kidney does not develop features of cystine toxicity (Goodman et al., 1972). 
Some features of the Fanconi syndrome can occur in transplanted kidneys, probably 
related to episodes of rejection -ýEhrich et al., 1991). Cystine crystals may be seen in 
transplant biopsies but are found in mesangial or interstitial tissue and not (as in the 
native cystinotic Iddney) in the cytoplasm of the renal tubular epithelium (Malekzadeh 
et al., 1977). Such interstitial cystine deposition is consistent with host mononuclear 
cell infiltration. 
There are theoretical risks to the use of live-related donors some of whom, as 
heterozygotes, have impaired lysosomal cystine transport. However the results from a 
live-related donor graft may be better than from a cadaveric graft and the cystine 
content in the two types is similar (Malekzadeh et al., 1977; Gahl and Kaiser-Kupffer, 
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1987). 
Initial impressions of improved growth after renal transplantation have not been 
confirmed and as survival has increased, the spectrum of multisystern failure due to 
cystine accumulation in non-renal tissues has become apparent (see chapter 4: 
"Clinical course and longterm manifestations of cystinosis", also Gahl and Kaiser- 
Kupffer, 1987; Ehrich et al., 1991). 
The use of cysteamine and phosphocysteamine 
Introduction 
The discovery that cysteamine, a naturally occurring compound, was a powerful 
cystine-depleting agent led to a new era in the treatment of cystinosis. It became an 
extremely useful compound for studying cystinotic cells in vitro but, more 
importantly, cysteamine had a dramatic effect on leucocyte cystine concentrations in 
vivo. A series of clinical studies has subsequently demonstrated its potential benefits 
although there are significant problems with administration of the drug. The pro-drug 
phosphocysteamine is better tolerated and is now widely used. 
The occurrence of cysteamine in the body 
Cysteamine is a naturally occurring sulphydryl compound. it is formed by the action 
of pantetheinase on pantetheine, in the formation of coenzyme A (Orloff et al., 1981). 
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Orloff et al. confirmed that there was no defect in pantetheinase activity in cystinotic 
cells and hence no deficiency of cysteamine to account for cystine accumulation in the 
disorder (Orloff et al., 1981). 
Mechanism of action of cysteamine 
Thoene et al. first demonstrated the depletion of cystine that occurs when cystinotic 
fibroblasts are incubated in a medium containing cysteamine (Thoene et al., 1976). A 
range of other compounds were tested for cystine-depleting activity. Thoene et al. 
found that optimal depletion occurred with unsubstituted aminothiols and that the 
presence of an amine group was essential, possibly because it enables passage of the 
molecule through the plasma and lysosomal membranes (Thoene et al., 1976). The 
disulphide cystamine was also effective but is probably reduced to cysteamine prior to 
lysosomal entry and is therefore no betterthan cysteamine itself. 
Thoene et al. postulated that cysteamine reacted with cystine inside the lysosome to 
form the mixed disulphide and cysteine. The mixed disulPhide was then thought to 
either diffuse out of the lysosome on account of its molecular weight (196) being less 
than 200-230 daltons, above which compounds were thought not to be able to diffuse 
out of the lysosome (Thoene et al., 1976). Alternatively, they suggested that the 
mixed disulphide might react with cysteamine to form cystamine and cysteine. 
Cysteine can leave the lysosome freely and cystamine could be converted back to 
cysteamine. 
Subsequent work demonstrated that when lysosome-rich granular fractions of 
cystinotic leucocytes were loaded with labelled cystine and treated with cysteamine, 
high concentrations of the labelled mixed disulphide were recovered (Gahl et al., 
1985b). This work suggested that the mixed disulphide of cysteamine and cysteine left 
the lysosome intact. Work by Pisoni et al. on lysosomal amino acid transport led to a 
better understanding of the mechanism of cysteamine action (Pisoni et al., 1985). 
Granular fractions enriched in lysosomes were loaded with lysine by incubation with 
L-["C]lysine methyl ester (see chapter 2: "Studies of lysosomal transport"). Once 
loaded the lysosomal preparations were incubated in various media and aliquots 
removed at set intervals for determination of radioactivity (and hence lysine efflux). 
The addition of 2mM lysine to the medium led to a 50% reduction in the half-time of 
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lysine exodus -a phenomenon known as counter-transport (or trans-stimulation) and 
accepted as evidence of a carrier-mediated transport system. The lysine carrier was 
found to be specific for cationic amino acids and stereospecific to the L-isomers. 
When either the mixed disulphide of cysteamine and cysteine or 2-aminoethyl-L- 
cysteine (see below for structures) were incubated in the medium, the efflux of lysine 
was greatly increased (Pisoni et al., 1985). 
H3N'-CH-COO- H3N'-CH-COO- H3N+-CH-COO- 
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This work therefore demonstrated that cystine, converted into the mixed disulphide by 
the action of cysteamine, can be transported across the lysosomal membrane on the 
lysine carrier. Once in the cytosol the disulphide is available for reduction. Cysteine 
so formed can participate in protein synthesis or be further degraded to sulphate and 
taurine (see chapter 2: "Degradation"). The other component of the reduced 
disulphide, cysteamine, may be able to re-enter the lysosome and further reduce the 
cystine content. 
Phosphocysteamine 
Thoene and Lemons demonstrated that phosphocysteamine, a phosphothioester of 
cysteamine, was extremely effective in depleting cystinotic fibroblasts of cystine 
(Thoene and Lemons, 1980). Since phosphocysteamine lacks much of the odour of 
cystearnine, it was suggested that it might be a preferable agent for the treatment of 
cystinosis. 
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Smolin et al. confirmed the bioequivalence of cysteamine and phosphocysteamine in 
vivo (Smolin et al., 1988). Equimolar doses of cysteamine and phosphocysteamine 
were given to 6 children with cystinosis. The mean peak plasma cysteamine 
concentration and degree of leucocyte cystine depletion one hour after the dose, were 
not significantly different after cysteamine or phosphocysteamine administration. 
Cluinical studies 
In their paper describing the cystine-depleting action of cysteamine, Thoene et al. 
reported their experience of treating a7 year old girl in end-stage renal failure due to 
cystinosis (Thoene et al., 1976). She was treated for 2 months with increasing doses 
of cysteamine given orally in gelatin capsules. At a dose of 90mg/kg/day she suffered 
generalised seizures for which no obvious cause could be found. These responded to 
anticonvulsant medication and the cysteamine was stopped. Serial measurements of her 
leucocyte cystine concentrations (taken 3 hours after a dose) showed a dose-response 
effect with levels within the. heterozygote range when she was on 90mg/kg/day. 
Thoene et al. also tried an intravenous dose of 10mg/kg cysteamine given over 5 
minutes. Leucocyte cystine concentrations remained suppressed for 48 hours. Neither 
of these trials had any effect on the patient's condition. 
Early clinical experiences were published in the form of case reports (Roy and 
Pollard, 1978; Girardin et al., 1979). Roy and Pollard described the effect of 
cystearnine in reducing leucocyte cystine concentrations in vivo in a5 year old girl. 
However, her plasma creatinine concentration rose from 86/Amol/I to 122JAmol/I over 
the 9 month study period (Roy and Pollard, 1978). Girardin et al. treated a 14 month 
old boy with cysteamine and reýorted an improvement in creatinine clearance. 
Unfortunately he then suffered an episode of severe pyelonephrifis which led to 
further renal damage (Girardin et al., 1979). 
Yudkoff et al. reported their experience of treating 5 cystinosis patients with 
cysteamine for periods of up to 30 months (Yudkoff et al., 1985). The 5 boys, aged 
30-81 months, received increasing doses (up to 90mg/kg/day) of cystearnine as a 5% 
solution. After 30 months therapy, renal function, estimated by creatinine clearanceg 
had stabilised in two of the children and deteriorated in the others. There was no 
effect on renal tubular function nor growth. The mean (SD) leucocyte cystine 
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concentrations decreased from 7.9 (0.9) to 0.7 (0.4) nmol 1/2 cystine per mg protein 
with treatment. 
In 1978 a multicentre, collaborative trial of cystearnine therapy was initiated in North 
America (Gahl et al., 1987c). 93 children were treated with cysteamine (mean dose 
51.3 mg/kg/day in 6 hourly doses) for up to 73 months. Since cysteamine has a foul 
smell and taste, a placebo group was felt to be unacceptable. Instead the treated group 
were compared with 55 historical controls who had participated in the ascorbic acid 
trial (see above: "Specific therapies: Ascorbic acid"). Summary data (mean ± SEM) 
from the trial are shown in table 5.2. 
Table 5.2: Results of US collaborative cysteamine study, 1987 
I 
Cysteamine group Control group 
Age at start (y) 3.89 0.25 4.05 0.26 
Age at finish (y) 6.79 0.27 5.40 0.28 
Creatinine clearance 
at start (ml/min/1.73m') 
38.4 2.0 34.9 1.8 
Creatinine clearance 
at finish (ml/niin/1.73m) 
38.5 2.5 29.7 2.0 
*§* 
Growth velocity in first year 
of trial (% normal) 
73.5 3.4 59.2 3.7 
(*§*: significant difference between groups, p=0.015) 
The mean leucocyte cystine concentration in patients treated for more than one year 
was reduced from 9.3 ± 1.0 to 1.7 ± 0.2 nmol 1h cystine per mg protein. Although 
the use of historical controls is contentious (especially since renal function in the 
group treated with ascorbic acid was worse, albeit not to a significant level, than the 
untreated patients), this study provided further evidence of the efficacy of cysteamine. 
It suggested that longterm cysteamine therapy could reduce the progression of renal 
glomerular disease and improve growth. 
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No effect was seen on tubular function in the small number of patients studied in this 
respect. The only side-effects of note were the foul taste, nausea and vomiting (these 
led to 14% patients becoming non-compliant). 
Gahl et al. re-analysed the data on renal function from this study using a parameter 
they called the "predicted reciprocal creatinine at age 10y (PRCIO)" (Gahl et al., 
1990). Cross-sectional analysis of the patients' reciprocal creatinine concentrations at 
the start of cysteamine therapy plotted against age revealed a linear relationship with 
an intercept on the x axis (ie. equivalent to no renal function or l/creat = co) of 10.5 
years. By analysing each patient's reciprocal creatinine data longitudinally, an 
extrapolated value at age 10 (PRCIO) could be calculated. Values over I would suggest 
excellent renal function (plasma creatinine lmg/dl w 88 timol/1) and values less than 
0.1 would mean terminal renal failure. Patients who had been treated with cysteamine 
had a significantly greater PRCIO than those in the control group (mean values 0.62 vs 
0.33mg/dl respectively, p =. 0.02). Further analyses showed that PRCIO increased 
with the duration of cysteamine therapy and the extent of leucocyte cystine depletion 
(Gahl et al., 1990). This method of analysis has been criticised on the basis that it is 
unreasonable to perform statistical calculations on such extrapolated data (N Gretz, 
personal communication). 
Proesmans et al. reported their experience of treating 3 children with cysteamine and 
phosphocysteamine (Proesmans et al., 1987). The three children aged 2-3 years 
received cysteamine (and later phosphocysteamine) for up to 6 years in a dose of 
60mg/kg/day as a syrup, also containing ascorbic acid and electrolyte solution. All 
three progressed to end-stage renal failure by 10 years. Growth rate remained stable 
or decreased. These results were disappointing but the patients were not monitored 
with serial leucocyte cystine concentrations. These serve not only as an index of 
cystine depletion but also of compliance. Efficacy cannot be judged without this 
information. 
French experience with cysteamine was reported by Broyer and Tete (Broyer and 
Tete, 1990). Eighteen children mean age 3y 4mos (range l0mos-7y) received a mean 
dose of 50mg/kg/day of cysteamine for a mean duration of 4y 8mos (range 6mos-8y). 
As well as conventional alkali and vitamin D therapy, most received indomethacin. 
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Compared with historical controls cared for at the same centre, 65 % of whom 
developed terminal renal failure by 10 years of age, the cysteamine group fared better. 
Only 3 of the patients (all of whom started the drug after 41h years of age) required 
dialysis by 10 years. Children treated before 26 months were 2 standard deviations 
taller than historical controls at age 5 years. 
Clark et al. reported a study of the effects of high dose (1.95g cysteamine free 
base/m'/day) vs low dose (1.30g free base/M2/day), (Clark et al., 1992). (A dose of 
1.30g free base/m2/day is approximately equivalent to 50mg/kg/day). 95 patients were 
studied and data were presented after 2 years of treatment. There was no significant 
difference between the admission and 2 year creatinine clearances (mean ± SEM 63.3 
± 2.3 and 67.7 ± 2.8mls/min/1.73m' respectively). In addition, there was no 
difference in the results between the high and the low dose treatment groups. 
Compared with the previous multicentre trial (see above), both the admission and 
follow-up creatinine clearances were much higher, possibly because the mean age at 
admission in this study was 28 ± 2.1 months compared with 46.7 ± 3.0 in the older 
study. Height standard deviation. score remained stable during the study. The mean 
leucocyte cystine concentrations were 1.7 and 1.3 nmol 1/2 cystine per mg protein in 
the low and high dose groups. 
The most compelling evidence of the efficacy of cysteamine treatment was presented 
in a review of 32 years' experience of the care of children with cystinosis at the 
National Institutes of Health (Markello et al., 1993). In this review, 24-hour 
creatinine clearances were determined in 1217 admissions of 76 children (each 
admitted on at least 2 occasions). Twenty-seven patients were seen prior to the use of 
cysteamine (no treatment group), 32 were considered partly treated (poor compliance, 
cysteamine started after 2 years of age or median leucocyte cystine concentration > 
2nmol 1h cystine per mg protein) and 17 were adequately treated (median leucocyte 
cystine < 2nmol 1h cystine per mg protein and cysteamine started before 2 years Of 
age). The age at diagnosis was significantly less for the adequately treated group 
compared with the untreated group (mean ages 1.0 ± 0.5 vs. 2.2 ± 2. ly, p<0.01). 
The results are summarised in the table 5.3 (below). 
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Table 5.3: Results of NIH experience of cysteamine, 1993 




Duration of treatment (y) 4.5 7.1 
Age at follow-up (y) 8.3±1.9 10.5±2.7 8.3±3.8 
Clcmt (ml/min/1.73m) 8.0±4.8 12.4±7.7 57±20 
Leucocyte cystine 
(nmol cys/mg protein) 
8.8±5.5 1.7±2.1 1.1±0.7 
The mean creatinine clearance for the well treated group was significantly greater and 
the leucocyte cystine concentration significantly less than corresponding values for the 
untreated group (p < 0.001). Creatinine clearances were also analysed by averaging 
the results for each group at yearly age intervals. Partially and well treated children 
demonstrated some increase in creatinine clearance in the first three years of life 
whereas clearance continued to fall in the untreated group. After this age, creatinine 
clearance fell but the slope of this line was the same for the well treated group as that 
for normal unaffected children. The authors extrapolated these data to predict the ages 
at which creatinine clearance would fall to zero. These were calculated as 9.5,20.0 
and 74.3 years respectively, for the untreated, partially and adequately treated groups. 
They further estimated that every one month of adequate cysteamine treatment would 
allow 14 extra months of kidney survival. However, these predictions are based on 
data in children up to the age of 12 years and only time will tell whether they are 
accurate. 
Although there is now overwhelming evidence that cysteamine reduces the progression 
of renal damage there has been concern that the drug would not affect cystine- 
mediated damage to non-renal fissues. Topical cysteamine treatment can prevent or 
reverse corneal cystine crystal deposition (Kaiser-Kupfer et al., 1987; Kaiser-Kupfer 
et al., 1990). Gahl et al. have shown that cysteamine therapy reduces the cystine 
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content in skeletal muscle (Gahl et al., 1988a). These workers have recently found 
that the muscle cystine content in untreated patients increases with age (Gahl et al., 
1992). In contrast the muscle cystine content remained relatively constant in 15 
patients treated with cysteamine for approximately 7 years (Gahl et al., 1992). No 
cystine crystals were seen in a post-mortem study of liver and kidney tissue from a9 
year old boy who had received cysteamine for 8 years (Gahl et al., 1992). This work 
suggests that cysteamine may help to prevent the non-renal manifestations of cystinosis 
and provides support for the contention that treatment should be offered to 
transplanted patients. 
Use of cysteandne and phosphocysteamine in pre-symptomatic patients 
The advent of a treatment for cystinosis led families who had already had an affected 
child, to consider pre-symptomatic treatment. There is clear evidence from the studies 
reviewed above that early treatment is a critical factor in the success of therapy. It 
was therefore very important to study the drug's effect in pre-symptomatic children 
with cystinosis. Siblings affected with cystinosis tend to follow the same clinical 
course and therefore the first child can act as a control for the newly treated patient 
(Gahl et al., 1989). 
Da Silva et al. reported the use of cysteamine in a pre-symptomatic child with 
cystinosis (da Silva et al., 1985). The patient's elder brother was diagnosed as having 
cysfinosis at 16 months of age and at 10 years was in terminal renal failure. The 
patient was born at this time and although clinical examination was normal, leucocyte 
and skin fibroblast cystine concentrations were within the affected range. At 4 weeks 
he was started on cysteamine solution and except for two brief intervals, the leucocyte 
cystine concentration was maintained at < 0.5 nmol 1/2 cystine per mg protein. At the 
age of 4 years, his height was on the 50th centile, creatinine clearance was 
75ml/min/1.73m2and he had no features of the Fanconi syndrome. This report 
therefore provided dramatic evidence of the efficacy of cysteamine if started early and 
maintained at sufficient dosage. In two updates at 5 and 8 years of age, he was 
reported as remaining well with no features of the Fanconi syndrome although he has 
developed corneal cystine crystals (da Silva et al., 1985; Schneider JA, personal 
communication). 
ill, 
This very encouraging evidence is in contrast to other reports of the treatment of pre- 
symptomatic children (Gradus et al., 1985; Reznik et al., 1991). Gradus et al. treated 
a girl with cystinosis from the age of 9 weeks starting with a dose of 10mg/kg/day 
and increasing to 58mg/kg/day by approximately 15 weeks. At this age despite good 
cystine depletion (0.8 nmol 1/2 cystine per mg protein) she had developed glycosuria 
and a metabolic acidosis. All the features of the Fanconi syndrome subsequently 
occurred although at the time of the report (aged 1 year) her glomerular function was 
good and her growth was normal. 
Reznik et al. described three children treated from 12 hours, 9 days and 3 weeks of 
age respectively (Reznik et al., 1991). When re-evaluated at 6 to 8 months old, all 
three had good cystine depletion but all had developed biochemical evidence of the 
Fanconi syndrome (aminoaciduria and reduced phosphate reabsorption) and two of the 
three needed alkali therapy. Compared with their elder affected siblings, their growth 
had been better and their clinical course had been less severe. This may be due to the 
early use of cysteamine or to more aggressive general medical care. 
There may be several reasons for the differences between the first report of pre- 
symptomatic treatment and subsequent cases. Firstly there may be genetic 
heterogeneity between the cases although 0 would be classified as having infantile 
nephropathic cystinosis. Secondly compliance with therapy may be a factor. Thirdly 
there may be differences in the rearing of these infants (eg. nutrition and 
environmental factors) that are as yet of unrealised significance. 
Adverse effects of cysteamine- 
The most common side-effects of cysteamine and phosphocysteamine are nausea and 
vomiting. In the large multicentre trial, 14% of patients became non-compliant on 
account of the foul taste and nausea (Gahl et al., 1987c). However, it must be 
remembered that cystinosis patients are prone to nausea and vomiting, even without 
the addition of cysteamine. 
Corden et al. reported adverse reactions in 3 children treated with cysteamine in 
whom the dose was being rapidly increased (Corden et al., 1981). A 10 year old boy 
developed fever, abdominal pain, headache and a maculopapular eruption after 9 days 
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of cysteamine treatment at which time he was taking 53mg/kg/day. After stopping the 
drug the symptoms resolved over 48 hours. A5 year old girl developed fever, 
vomiting and a rash 8-10 days after starting the drug having reached a dose of 
67mg/kg/day. She became lethargic, an EEG was reported as consistent with a "toxic 
encephalopathy" and she developed neutropaenia. One to two days after stopping the 
drug, she recovered completely. A third child aged 7 years developed fever and a rash 
12 days after starting cysteamine at a dose of 75mg/kg/day. Again all the symptoms 
resolved one day after stopping therapy. 
All three children restarted cysteamine after an interval, built up to a dose of 50- 
60mg/kg/day over a longer interval and remained free of their previous symptoms. In 
retrospect all three cases could easily have suffered a viral illness to account for the 
side-effects. Although rashes and fever can occur with penicillamine treatment (a drug 
structurally similar to cysteamine), the time course of recovery is evidence against 
such allergic phenomena. 
Avner et al. reported a potentially much more serious adverse event during cysteamine 
therapy (Avner et al., 1983). An 8 year old boy developed hepatomegaly 15 months 
after starting cysteamine. Two months later he presented with a severe haematemesis, 
hepatosplenornegaly, ascites and prominent abdominal wall venous distension. After 
recovering from surgery (gastric devascuMsation), he underwent a liver biopsy 
which showed marked sinusoidal fibrosis, most apparent in the centrolobular areas. 
There was severe fibrosis around central veins. Numerous cystine crystals and some 
fatty infiltration characteristic of cystinosis were seen. The authors felt that this 
patient's liver disease was not the same as the hepatic dysfunction sometimes seen in 
(untreated) cystinosis and was therefore likely to be associated with cysteamine. This 
view has been disputed by Gahl et al. who felt that the hepatic damage was a 
manifestation of the disease rather than the treatment (Gahl et al., 1983b). 
The first patient treated with cysteamine developed seizures whist on a dose of 
90mg/kg/day (Thoene et al., 1976). These responded to anticonvulsant medication and 
cessation of cysteamine. Subsequently, cysteamine was reintroduced without ill-effect. 
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Hyperphosphataemia 
Phosphocysteamine is rapidly hydrolysed to cysteamine in the stomach. The phosphate 
released during this process is available for absorption. Changes in plasma phosphate 
were studied in 4 of the 6 patients at Guy's Hospital, undergoing a trial of oral 
phosphocysteamine suspension (see chapter 7: "A study of the effects of a single oral 
dose of phosphocysteamine solution"). Plasma phosphate was determined by standard 
methods in samples taken over a 24 hour period prior to phosphocysteamine and for a 
further 12 hours after a dose of 10mg/kg cysteamine base equivalent. Diet and fluid 
intake was identical on both days. The results, shown in figure 5.1, demonstrate an 
increase in plasma phosphate for several hours after the dose. The small number of 
subjects precludes statistical analysis of this change. 
Clinical experience has confirmed these findings. Patients in end-stage renal failure 
have hyperphosphataemia and require phosphate binding medication. Phospho- 
cysteamine treatment can lead to a substantial additional phosphate load and this has 
led on several occasions to hyperphosphataemia, especially in patients on dialysis. For 
this reason, cysteamine is the preferred formulation for patients in end-stage renal 
failure. 
Other effects of cysteamine 
Cysteamine is used to produce an experimental model of duodenal ulceration in rats, 
although this effect has not been seen in humans (Selye and Szabo, 1973). High doses 
(100mg for a 100grn rat) were used to achieve this effect. This dose is approximately 
20 times higher than the average daily dose in the US multicentre trial. Administration 
of smaller doses (30mg/kg) to rats led to a marked fall in somatostatin in the stomach 
and duodenum, probably by reducing its synthesis or increasing its breakdown at a 
cellular level (Szabo and Reichlin, 1981). 
Tannenbaum et al. demonstrated that administration of cysteamine to rats depleted 
hypothalamic somatostatin concentrations and suppressed pulsatile growth hormone 
release (Tannenbaum et al., 1990). Growth hormone-releasing factor immunoreactivity 
in some tissues was increased but the plasma levels decreased, suggesting that 
cysteamine led to an overall decrease in GRF secretion. 
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Gahl and Bercu studied prolactin secretion in cystinosis patients before and after 
cystearnine therapy (Gahl and Bercu, 1985c). Chronic cysteamine therapy led to a 
lower basal prolactin level and to a blunted prolactin response, abnormalities not seen 
in 12 cystinosis patients who had not received the drug. There was no effect of 
cysteamine on thyroid stimulating hormone. 
Jeitner and Oliver determined the effect of cysteamine on lysosomal enzymes of the 
hyperprolactinaemic rat pituitary (Jeitner and Oliver, 1990). They demonstrated that 
the prolactin-depleting effect of cysteamine was due not to increased prolactin protease 
activity but possibly due to an alterion in the structure of the prolactin molecule. 
Thus cysteamine has marked effects on hormonal secretion in animals and humans. It 
is not clear, however, what the significance of these many actions are in the patient 
with cystinosis. 
Further developments in cysteamine therapy 
Cysteamine or phosphocysteamine remain the specific treatments of choice for 
cystinosis. Research into alternative and improved methods of delivery is in progress. 
Unfortunately, the breath smell occurs even after intravenous dosage suggesting 
pulmonary excretion of sulphides (see chapter 7: "A study of the effects of a single 
dose of intravenous cysteamine"). Cysteamine is very hygroscopic and therefore 
difficult to formulate into capsules. Bergonzi et al. reported on the use of a capsule 
prepared with 2% silicic acid (Bergonzi et al., 1981). Cysteamine has been prepared 
in capsules with a polyethylene glycol base (see chapter 7: "A trial of a new 
formulation of cysteamine in capsules") and these have shown prolonged efficacy and 
stability. Other groups have formulated cysteamine bitartrate and found this to be 
stable and easy to use in capsule form (Schneider JA, personal communication). 
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Chapter 6: Experience with cysteamine in the UK and Eire 
Introduction 
Although there is extensive experience of the use of cysteamine and 
phosphocysteamine reported in the literature, there are no data available from the 
many patients treated in the UK. The objective of this study was to evaluate through 
retrospective data collection, the efficacy of cysteamine and phosphocysteamine in the 
treatment of cystinosis in the UK and Eire. 
Methods 
Patients 
A postal survey was sent to every paediatric nephrologist and those adult nephrologists 
who participate in the care of children with renal disease, in the United Kingdom and 
Eire in February, 1990. The survey asked for the names of every cysfinosis patient 
who had ever received cysteamine or phosphocysteamine. 
Data coUection 
Data were collected retrospectively from the patient records. The data collection form 
was adapted from that used in the United States for patients participating in the US 
National Collaborative Study of Cysteamine (Gahl et al., 1987c). To ensure 
consistency, data were only entered by either myself or by a fellow researcher (Miss 
A Comber). Baseline data included a brief medical history and pre-treatment 
laboratory results. Subsequently, follow-up data were collected as near to 4-monthly 
intervals as possible up to a cut-off date of May 31st 1990. Follow-up data included 
dose information, occurrence of adverse effects or changes in medical condition, 
growth parameters and routine laboratory determinations. 
The data collection forms specifically asked about the occurrence of certain adverse 
effects: vomiting temporally related to cysteamine or phosphocystearnine (occurring 
within one hour of the dose), vomiting unrelated to medication, anorexia, diarrhoea, 
jaundice, rash and fever. For transplanted patients there were questions designed to 
highlight episodes of graft rejection, infection or hypertension. The medical records 
were also scrutinised for other adverse events. 
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Data analysis 
Data were entered into a customised database using SmartwareII (Informix). At the 
start of cysteamine/ phosphocysteamine treatment, results from the preceding clinic 
were used to give the baseline data providing the clinic date was less than 30 days 
beforehand. 
The main parameters of efficacy were renal function and growth. Plasma creatinine 
and hence estimated glomerular filtration rate (Schwartz et al., 1976) were chosen as 
indices of renal function since these measurements were made at most clinic 
attendances. There were few data on formal assessments of glomerular filtration rate 
and these were therefore not used. Growth was assessed by height standard deviation 
score (HtSDS) based on Tanner and Whitehouse standards (Tanner et al., 1966). 
Leucocyte cystine concentration was chosen as a biochemical parameter of efficacy of 
cystine depletion. 
Covariate analysis was used to study whether there were significant differences 
between the pre-treatment and the final values of plasma creatinine, estimated 
glomerular filtration rate (estGFR) and height standard deviation score (HtSDS). This 
allowed the effect of age on renal function and gro wth to be taken into account. Since 
indomethacin affects renal function and may affect growth, 7 patients who received 
indomethacin were excluded at the point that the drug was started. One pre-transplant 
patient treated with recombinant human growth hormone was excluded from the 
analysis. Six patients were excluded from the analysis on account of missing data. 
(Some patients were excluded on more than one count). 
The leucocyte cystine concentration is not affected by age or by renal transplantation. 
All patients in the study were therefore eligible to be included in analysis of cystine 
depletion. The student's paired one sample t test was used to compare these data with 
Bonferroni's correction for multiple analyses. For the purposes of analysis of efficacy, 
cystearnine (C) and phosphocystearnine (PC) were considered as equivalent. 
Results 
Patients 
Fifty-nine patients received C/PC treatment in the UK and Eire. There were 30 
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females and 29 males, studied over a total of 563 clinic attendances. The ethnic origin 
was Caucasian in 45 (76 %), Asian in 12 (20 %) , Middle Eastern in 1 (2 %) and mixed 
(Asian/Caucasian) in I patient (2%). Forty-four (75%) of the patients had been treated 
at either Birmingham Children's Hospital (24 patients) or Guy's Hospital (20 
patients). The number of patients, n, with completed data is given in all further 
analyses. Ages are given as the median value with the range in parentheses. "Renal 
death" is defined as the need for renal replacement therapy in the form of dialysis or 
transplantation. Table 6.1 shows the patient details. 
Table 6.1: Patient details 
All patients 
(n=59) 
Age of onset of symptoms 11.0 mos (4-176) 
(n =5 1) 
Sex: NVF 30/29 
Age at diagnosis 19.6 mos (5-276) 
(n=58) 
Symptom to diagnosis duration 6.0 mos (0-100) 
(n=51) 
"Renal death" 15 
prior to C/PC (n=59) 
Age at "renal death" 8.62 y (5.31-21.39) 
prior to C/PC (n = 15) 
Information on the mode of diagnosis was available for 55 (93%) patients. More than 
one method was used in some patients. The diagnosis was confirmed in 38 (69%) by 
the observation of cystine crystals in the cornea, in 13 (24%) by demonstration of 
cystine in a bone marrow aspirate and in 25 (45%) by an elevated leucocyte cystine 
concentration. 
Forty eight of the patients for whom data were available, developed symptoms under 
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3 years of age. Three patients developed symptoms after 3 years of age (at 3.5,12.5 
and 14.7y). The older two might be considered as having "late-onset" cystinosis 
(Goldman et al., 1971). At the start of cysteamine or phosphocysteamine therapy 15 
(25%) had had a renal transplant. 
Figure 6.1 shows a cross-sectional analysis of reciprocal creatinine concentration of 
each of 36 of the pre-transplant patients (for whom data were available) at the start of 
cysteamine treatment. A line of regression drawn through these values can be 
represented by the equation: 
y= -0.0018x + 0.0019 (r=0.37), 
where y is the reciprocal creatinine and x is age in years. The intercept ot is ine on 
the x axis gives the age of renal death, in this study 10.6 years. 
Other medical history and medication 
Several patients had other medical conditions requiring treatment. Three patients had 
orthopaedic deformities secondary to rickets. Four transplanted patients had developed 
non-renal complications of cystinosis (including diabetes mellitus and cerebral 
degeneration) prior to starting treatment. One transplanted boy had had a parvovirus 
infection 3 months prior to starting phosphocysteamine. This had led to hepatitis and 
bone marrow suppression, but his liver function tests and blood count had returned to 
normal at the start of treatment. 
The pre-transplant patients (n=44) commonly received electrolyte replacements 
(n=31), alkalinising agents (n=32), vitamin D supplements (n=36) or indomethacin 
(n=7). Immunosuppressive ageiýs used after transplantation included prednisolone 
(n = 13), azathioprine (n = 12) and cyclosporin A (n = 8). Thyroxine supplements were 
given to 14 transplanted patients but only one pre-transplant patient. Nine transplanted 
patients were receiving anti-hypertensive agents (including frusemide in 4, atenolol in 
4, hydralazine in 3). Two patients (both transplanted) were receiving growth hormone. 
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Figure 6.1: Cross sectional analysis of reciprocal plasma creatinine concentration at 
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Cysteamine and phosphocysteamine treatment 
Twenty-nine patients were treated with cystearnine and 30 with phosphocysteamine. 40 
patients started treatment with cysteamine, 18 of these changed to phosphocysteamine 
and I changed back. Twenty-two patients started treatment before the age of 2 years. 
The median ages at which C/PC were started and the durations of treatment for the 
different patient groups are shown in table 6.2 and figure 6.2. 
Table 6.2: Duration of cysteamine treatment 
All Pre-transplant Transplant 
patients (n=44) (n = 15) 
(n=59) 
Age at start 3.2y 2.2y 16.3y 
(Y) (0.6-24.8) (0.6-9) (8-24.8) 
Duration (y) 3. Oy 3.6y 0.6y 
(0.01-11.2) (0.01-11.2) (0.2-4.1) 
Four patients had received oral cysteamine prior to entering the study. One patient had 
received cysteamine for several months whilst in Australia but had stopped due to lack 
of improvement. No data were available from that treatment episode. Two patients 
received courses of cysteamine for 5 and 4 months respectively, before stopping. They 
resumed treatment 26 and 32 months later and continued until the cut-off date. Data 
were therefore collected from their second courses of treatment. No baseline data for 
the first cysteamine treatment episode were available for one patient. 
Details of the final doses taken at the cut-off date were available for 38 of the 44 pre- 
transplant patients. Fourteen were receiving cysteamine at a mean dose of 
33mg/kg/day. Twenty-four were taking phosphocysteamine at mean a dose of 84 
mg/kg/day (equivalent to 37mg/kg/day cysteamine base). 
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Adverse events and discontinuation of treatment 
Adverse events were recorded in 54 (92%) of the patient's records and were noted in 
280 (50%) of all clinic attendances assessed. Many (such as an episode of rhinitis, 
gastroenteritis, respiratory infection) occurred once only for any patient and might be 
expected in any longterm study of a paediatric population. Table 6.3 summarises the 
important adverse events, by treatment group for the pre-transplant patients. Data 
refer to the number of patients in whom an adverse effect was noted. 
Other adverse events noted in the pre-transplant patients related to progression of their 
renal disease eg. anaemia, hypertension, fluid overload, rather than to the drugs. Two 
patients developed seizures, one at a time of severe hypertension and the other during 
a high fever. In neither case were cysteamine or phosphocysteamine felt to have 
contributed to the events. 
Table 6.3: Adverse events 





(n = 18) 
Vomiting related to 
C/PC 
27(61%) 14(54%) 13(72%) 
Vomiting not related 
to C/pc 
31(70%) 18(69%) 13 (72%) 
Breath smell 4(9%) 4(15%) 0 
Anorexia 28 ý64%) 18(69%) 10(56%) 
Diarrhoea 11 (25%) 8(31%) 3(17%) 
Fever 23(52%) 16(62%) 7(39%) 
Rash 7(16%) 6(23%) 1 (6%) 
Convulsions 2(5%) 1(4%) 1(6%) 
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Two pre-transplant patients treated at the same centre, developed urticaria and facial 
oedema after starting phosphocysteamine, formulated into capsules at their local 
hospital pharmacy. The symptoms resolved 48 hours after the drugs were Stopped. 
The allergic reaction may have been due to the drug or to an excipient added to the 
preparation. 
In the transplanted patients, 3 of 12 (25 %) receiving phosphocysteamine had vomiting 
related to the medication and many had episodes of fever, headache or hypertension 
which seemed related to problems with their transplant. 
At the end of the study period, 46 (78%) of all the patients were continuing 
cysteamine or phosphocysteamine. Six patients (three pre-transplant) died during the 
period studied. One, aged 2 years, was admitted during a severe infection, 15 months 
after starting cysteamine 10mg/kg/day. Cysteamine was stopped during this episode 
and she died four days later. One girl who had been on cysteamine for one month, 
was noted to have developed features of athetoid cerebral palsy and although it was 
felt that this was probably related to pre- or perinatal events, cysteamine was stopped. 
Her neurological features remained unchanged after treatment was withdrawn and she 
died five years later. One other pre-transplant patient died as a result of acute renal 
failure. 
One patient who had received three Iddney transplants within a period of 12 months, 
died from disseminated fungal infection probably related to immunosuppression. She 
had stopped cysteamine treatment 2 months before her death because of ill health and 
had only ever tolerated a low dose (200mg b. d. ). Two patients died of cerebral 
manifestations of cystinosis. Both had received phosphocysteamine at a late stage in 
their illnesses and treatment had had no appreciable effect on their outcome. 
Three patients participated in a trial of rectal cysteamine (see chapter 7: "A trial of 
longterm rectal cysteamine"). Data from that trial are not included in the present 
analysis. Two of these patients had developed severe nausea on oral cysteamine and 
would have stopped treatment were it not for the rectal preparation. One other child 
stopped on account of nausea and vomiting. Only one patient developed end-stage 
renal failure requiring dialysis, during the study period. Phosphocystearnine was 
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stopped at that point. 
Seven patients experienced a decrease in haemoglobin concentration, associated in six 
of these, by a rise in plasma creatinine concentration. In the other patient the low 
haemoglobin concentration resolved. Two patients were noted to have a fall in total 
leucocyte count during cysteamine therapy but in neither case was this significant. 
There were many changes in plasma electrolyte concentrations during the study period 
but these are expected in children with cystinosis. 
Efficacy 
The main parameters of efficacy (changes in renal function and growth) were assessed 
only in the 44 pre-transplant patients. A number of patients were excluded from the 
analysis, specifically those receiving indomethacin or growth hormone (see "Data 
analysis" for details). The number of remaining (evaluable) patients is given in all 
further analyses. For the purposes of analysis of efficacy, cysteamine (C) and 
phosphocysteamine (PC) were considered as equivalent. 
Renal function (number of evaluable patients: 3 1) 
Figure 6.3 shows individual longitudinal plots of plasma creatinine concentration 
against age for these patients (the hatched area represents longitudinal plasma 
creatinine concentrations in untreated patients (Broyer et al., 1981). Using covariate 
analysis to compare pre-treatment and final values, there was a significant increase in 
plasma creatinine concentration (p < 0.001) and a significant decrease in estimated 
GFR (p < 0.02). 
Growth (number of evaluable patients: 34) 
Figures 6.4 and 6.5 show the growth of boys and girls respectively, plotted with 
centiles from healthy children (Tanner et al., 1966). Figure 6.6 shows individual 
longitudinal plots of HtSDS against age. There was no significant difference between 
the pre-treatment and final values of HtSDS (p > 0.20). 
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Figure 6-3: Change in plasma creatinine concentration in 31 pre-transplant patients 
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Leucocyte cystine concentrations (number of evaluable patients: 34) 
Data on pre-treatment and final values of leucocyte cystine concentration were only 
available in 34 (26 pre-transplant) patients. Table 6.4 summarises the data on mean 
(SD) leucocyte cystine concentrations for the different patient groups. 
Table 6.4: Data on leucocyte cystine concentrations 
All patients Renal function Growth 
n 34 21 22 
Durn. (y) 3.06 3.97 3.87 
Pre-Rx 
cystine 
6.98(4.65) 6.65(5.52) 6.64(5.38) 
Post-Rx 
cystine 
4.79(5.52) 5.58(6.52) 5.39(6.72) 
t statistic 2.01 o. 64 0.78 
p value > 0.2 > 0.2 > 0.2 
Confidence 
interval 
-0.02 to 4.39 -2.43 to 4.55 -2.08 to 4.60 
(units of leucocyte cysfine: nmol 1/2 cystine per mg protein) 
In no group was there a significant difference between pre-treatment and final value of 
leucocyte cystine concentration. The leucocyte cystine concentration was less than the 
accepted upper limit of the treatment range (I nmol 1/2 cystine per mg protein) in only 
21 % of all post-treatment determinations. There were very little data on the timing of 
the sample with respect to the last dose of cysteamine. 
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Discussion 
This is the first study of the UK experience with cysteamine and phosphocysteamine 
in the treatment of cystinosis. The presentation and clinical features of cystinosis are 
sufficiently rare and distinct that it is likely that most patients will be known to a 
paediatric nephrologist. Not all UK patients have been treated with cysteamine or 
phospho-cysteamine. Cysteamine was first used in the UK by Dr Michael Winterborn 
at the Birmingham Children's Hospital. As a result of his subsequent experience and 
more recently of a research interest in cystinosis at Guy's Hospital, these two centres 
cared for 44 of the 79 cystinosis patients in the UK in 1989 (personal 
communications, BAPN survey 1989). In the present study, 75 % of the patients were 
treated at one of these two centres. Experience with cysteamine and phospho- 
cysteamine was much more limited elsewhere. It is therefore likely that the data 
accurately reflect the UK experience with these drugs. 
Data from patients with typical early onset cystinosis were pooled with those whose 
onset of symptoms was later. The division between infantile and late-onset cystinosis 
is not clear cut and the quality of data on age of onset of symptoms in this study was 
too poor to make a qualified classification. Although the study group is very 
heterogeneous, cross-sectional analysis of reciprocal creatinine concentration at the 
start of cysteamine therapy, reveals that the course of the untreated disease in UK 
patients was very similar to that in the rest of Europe and North America. The 
equation of the line of regression for this data closely resembles those published in the 
small study by Yudkoff et al. (Yudkoff et al., 1985) and in the large multicentre trial 
(Gahl et al., 1990). In addition the mean age of renal death of the 15 patients who had 
received a transplant prior to cjiteamine therapy, was 8.6 years, similar to the figure 
of 9.2 years reported from a review of 205 patients with cystinosis, studied before the 
advent of cystearnine (Gretz et al., 1982). 
The occurrence of side effects of cysteamine treatment was difficult to determine. 
Although adverse events were recorded in 54 (92%) of the patient's records, many 
such as fever, vomiting and diarrhoea occur in unaffected young children. Vomiting 
related to the drugs was noted in (61 %) of pre-transplant patients and with a similar 
frequency for cysteamine and phosphocysteamine (see table 6.3). Children with 
cystinosis are prone to vomiting even without cysteamine treatment (Gahl et al., 
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1989). In this study, 70% of pre-transplant patients were noted to suffer from 
vomiting unrelated to the drug treatment. However, the decision to attribute or not to 
attribute vomiting to cysteamine is a subjective one. Prior to the study, the design of 
the data collection form was discussed with the investigators of the US trial. All 
agreed that vomiting that occurred more than one hour after the drug was unlikely to 
be due to the drug. 
One child withdrew on account of nausea although two others would have done so 
were it not for a rectal preparation. Thus 3 of 44 (7%) pre-transplant children stopped 
through an inability to tolerate the medication. However the mean final doses of 
cysteamine and phosphocystearnine are much lower than in the US multicentre trial. 
One explanation might be that UK patients could not tolerate a higher dose. 
Comparison of compliance rates with the US multicentre trial is therefore difficult. 
Retrospective data collection is an imperfect means of acquiring information, since it 
relies on a good standard of clinical note-keeping and is prone to observer bias. In this 
study, only objective data (plasma creatinine, height and leucocyte cystine 
concentration) were used to assess efficacy. The most important criterion of efficacy 
of cysteamine treatment is the effect on renal function. Data on individual changes in 
plasma creatinine for the 205 patients reported in 1982 have yet not been published 
(Gretz, personal communication). Broyer et al. presented data on evolution of plasma 
creatinine with age in 35 French cystinosis patients, none of whom had received 
cysteamine (Broyer et al., 1981). It was not possible to extrapolate these data to the 
present study to act as a control group. In addition, the French study group reported 
children treated between 1959 and 1979, many years before the present study. The 
methods of data collection in the present study precluded analysis of the changes in 
renal function at set intervals after the start of treatment. Therefore analysis of the 
change between pre-treatment and final values of plasma creatinine concentration and 
estimated GFR was undertaken in the pre-transplant children. There was a significant 
increase in plasma creatinine concentration and a significant decrease in estimated 
GFR, despite treatment and this effect could not be accounted for by the effect of age 
on plasma creatinine concentration. Although some patients had only had a short 
duration of treatment (4 patients were treated for <I year) their inclusion in the data 
analysis would be expected to reduce the chance of finding a significant change in 
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plasma creatinine. In this study therefore, cysteamine and phosphocystearnine did not 
prevent the progression of glomerular deterioration. It is not possible to say whether 
treatment affected the rate of deterioration of renal function but some individuals did 
seem to have relatively stable plasma creatinine even after 10 years (see figure 6.3). 
Conversely the lack of significant difference between the pre-treatment and final 
values of HtSDS in the showed that growth rate was maintained although there was no 
"catch-up". There are many factors determining the growth of children with 
cystinosis. These include poor nutrition, frequent episodes of vomiting, electrolyte 
disturbance (including chronic metabolic acidosis and hyponatraemia) and the effects 
of tissue cystine accumulation (eg. in bone and endocrine tissue). Cysteamine 
treatment is therefore only one variable in this equation. Nevertheless, the 
maintenance of a normal growth rate is in contrast to previous experience with 
untreated controls (Broyer et al., 1981). 
The leucocyte cystine concentration is the "gold standard" of biochemical response to 
cysteamine treatment. The results showed that the cystine concentration was less than 
the accepted upper limit of the treatment range (1 nmol 1/2 cystine per mg protein) in 
21 % of determinations. There was no significant difference between pre-treatment and 
final values of leucocyte cystine concentration. Therefore, in this study, there is clear 
evidence that cysteamine treatment did not adequately reduce the leucocyte cystine 
concentration in many patients. It is likely that the poor cystine depletion is related to 
the fact that the mean final doses of cysteamine (33mg/kg/day) and 
phosphocysteamine (37mg/kg/day base equivalent) in this study, are much less than 
the average dose used in the US multicentre trial (51mg/kg/day) (Gahl et al., 1987c). 
These data contrast with the outstanding results of cystearnine therapy at the National 
Institutes of Health, recently presented by Markello et al., see chapter 5: "Clinical 
studies", (Markello et al., 1993). Since the ability of these drugs to deplete cystine 
and reduce the progression of renal disease are now proven, these results suggest that 
cysteamine and phosphocysteamine have not been adequately used in the UK. 
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Chapter 7: The pharmacokinetics of cysteamine and phosphocYsteamine 
Introduction 
Despite their use for over 14 years, the pharmacokinetics, optimal route and 
frequency of administration of cysteamine and phosphocysteamine have yet to be 
determined. Single dose studies of the pharmacokinefics and pharmacodynarnics of 
these drugs were therefore undertaken. 
Methods 
Patients 
Ten patients participated in the pharmacoldnetic studies (see table 7.1). 









1 1.8 M No 79 
2 2.0 F No 40 
3 4.5 F No 79 
4 7.5 F No 132 
5 10.2 M No 186 
6 10.6 M Yes 68 
7 13.9 M Yes 54 
8 14.0 M Yes 131 
9 16.1 F Yes 59 
10 16.5 F Yes 192 
Renal function, assessed by plasma creatinine concentration, was stable at the time of 
studies. None had biochemical evidence of liver disease (plasma bilirubin, aspartate 
transaminase and alkaline phosphatase within normal limits). 
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Study Protocols 
Patients who were already on cystearnine or phospho-cysteamine treatment stopped the 
drug 7 days before each study began to allow an adequate "wash-out" period. Other 
drug therapy was not altered during the study periods because of the hazards of 
withdrawing indomethacin in the pre-transplant group and immunosuppression in the 
transplanted children. Food was withheld for 8 hours before and for the first 3 hours 
of each study but free access to clear fluids was allowed in view of their obligatory 
polyuria. 
Informed, written consent was obtained from the parents and from the older children. 
The study protocols were all approved by the Guy's Hospital ethical review 
committee. 
Blood sampling 
An intravenous cannula was inserted and patency maintained with intermittent bolus 
injections of 2mls heparinised saline (Heplok, lOu/ml). Serial blood samples were 
taken for leucocyte cystine concentration (3mls) and for plasma cysteamine (lml) at 
varying time points after the dose. Leucocyte cystine concentrations were determined 
using the methods in appendix 1. The blood sample for cysteamine determination was 
taken into a lithium heparin tube and placed in wet ice. Plasma was separated 
immediately and frozen at -70T pending derivatisation and analysis by the methods 
detailed in appendix 2. 
Pharmacokinetic and statistical methods 
Pharmacoldnetic parameters were estimated from standard formulae using the 
BIOPAK software package. For each plasma cysteamine profile, the maximum 
cysteamine concentration (C., ) and time at which this occurred (T. ), were noted. 
The area under the plasma concentration time curve (AUCO. ) was determined by the 
linear trapezoidal method. Individual semilog plots of plasma concentration versus 
time were inspected to determine the appropriate data points from which to calculate 
the elimination half-life (to. Statistical analyses were performed using a two tailed 
Student's paired West with Bonferroni's correction for multiple analyses (Altman, 
1991). Significance was assumed if p<0.05. 
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A study of the effects of a single oral dose of phosphocysteamine solution 
Pilot study 
Methods 
A pilot study of the effects of a single oral dose of cysteamine was undertaken in 
patient number 8. He had not previously been treated with cysteamine or phospho- 
cysteamine. As a control, serial blood samples were taken after an overnight fast, at 
08.00,09.00,11.00,14.00,22.00 and 08.00hrs. for determination of any diurnal 
variation in leucocyte cystine concentration. Water was freely allowed at any time of 
the study and food was given after 3 hours. A dietary record of all oral intake was 
kept. After a second overnight fast, he received 20mg/kg of cysteamine base in 
solution. 50mls of water were allowed to "wash down" the drug. Concomitant drug 
therapy (including immunosuppression for his renal transplant) was continued during 
the study. Serial blood samples were taken for measurement of plasma cysteamine at 
0,20,30,40,60,90mins., 2,3,4,6 and 12h and for leucocyte cystine determination 
at 0,1,3,6,12 and 24h after the dose. Intake of diet, fluids and other drugs was 
similar on both the pre-dose (diurnal variation) and oral dose days. 
Results 
The cysteamine dose was poorly tolerated and the patient started vomiting I hour after 
the dose. He vomited a further 5 times during the next 12 hours and required 
intravenous rehydration. Oral fluids were reintroduced after 24 hours and he was 
discharged from hospital 3 days after the study. The plasma cysteamine concentration 
rose sharply (see figure 7.1) reaching a maximum concentration of 92pmol/l, 30 
minutes after the dose. Elimination of the drug was rapid and plasma cysteamine was 
virtually undetectable by 8 hours. Figure 7.2 shows the variation in leucocyte cystine 
concentration during the pre-dose and dosage days. After the dose, the leucocyte 
cystine concentration fell from 6.06nmol Ih cystine per mg protein to 3.37 at I hour 
and 2.07 at 3 hours. Although plasma cysteamine was undetectable after 8 hours, the 
leucocyte cystine concentration remained suppressed during the study period. At the 
end of the study, 24 hours after the dose, the leucocyte cystine concentration was 
4.42nmol Ih cystine per mg protein (73% of the pre-dose value). 
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Figure 7.1: Plasma cysteamine concentrations after a single oral dose of cysteamine 
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Figure 7.2: Leucocyte cystine concentrations before and after a single oral dose of 
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Discussion 
The administration of an oral dose of 20mg/kg cysteamine solution to this patient 
(who had not had previous experience of the drug) was associated with severe 
vomiting. Intravenous rehydration prevented any deterioration in renal transplant 
function (there was no change in his plasma creatinine). 
The plasma cysteamine concentrations achieved in this patient (9211mol/I at 30 minutes 
and 71, umol/I at 1 hour after the dose) were substantially higher than expected from 
reports of previous studies. Jonas and Schneider gave a single oral dose (mean 14 
mg/kg) of cysteamine solution to 5 cystinosis children (Jonas and Schneider, 1982c). 
The mean plasma cysteamine concentration 1 hour after the dose was 34Amol/l. 
Smolin et al. administered equimolar doses of cysteamine (equivalent to 18mg/kg) and 
phosphocysteamine to 6 children with cystinosis (Smolin et al., 1988). The peak 
plasma cysteamine concentrations obtained between 30 mins and I hour, were 
49Amol/I and 54t&mol/I respectively. 
There was no consistent pattern of variation in leucocyte cystine concentration during 
the control (pre-dose) day. After the dose, there was a rapid and sustained reduction 
in cystine concentration over the study period. 
Conclusions 
The results of the pilot study demonstrated that a 20mg/kg oral dose of cysteamine 
solution in a patient with no previous exposure to the drug, leads to very high (and 
toxic) concentrations of cysteamine. Although the plasma is cleared of cysteamine by 
8 hours, the reduction in leucocyte cystine was more prolonged. As a result of this 
pilot study, it was decided to use phosphocysteamine for subsequent patients since this 
form of the drug is generally better tolerated. In addition, the dose was reduced to 23 
mg/kg phosphocysteamine (equivalent to 10mg/kg cysteamine base). 
P 140 
A study of a single oral dose of phosphocysteamine: Methods 
In order to study any diurnal variation in leucocyte cystine concentration (and to act as 
a control), six patients (subjects 3,5,6,7,9 and 10) had serial blood samples taken 
for leucocyte cystine determination over a 24 hour period (at 08.00,09.00,11.00, 
14.00 20.00 and 08.00hours). Seven patients (subjects 2,3,5,6,7,9 and 10) 
received a 23mg/kg single oral dose of phosphocysteamine, given as a suspension in 
50 mls water in the morning (07.30-08.30h). Because of the unpalatability of the 
drug, 50 mls of either juice or milk, were allowed immediately after the drug. Serial 
blood samples were taken for leucocyte cystine concentration at 0,1,3,6 and 12 
hours and for plasma cysteamine at 0,20,30,40mins, 1,1.5,2,3,4,6,8,12 hours. 
Intake of diet, fluids and other drugs was similar on both the pre-dose (diurnal 
variation) and oral dose days. 
Results 
Drug administration and adverse effects 
All the patients in the oral dose study successfully swallowed the phosphocysteamine 
suspension. Patients 5 and 10 suffered vomiting, starting approximately I hour after 
the dose. Patient 10, who vomited 3 times, had the highest peak cysteamine 
concentration (C,,,: 61.4 gmol/1) and largest "area under curve" (AUCo,: 120.1 
14mol. h/1). All the patients were noted to have the characteristic breath smell oi 
cysteamine but there were no other adverse effects. No patient required intravenous 
fluids and there were no changes in plasma creatinine concentration during the study 
(data not shown). 
Diurnal variation in leucocyte7 eystine 
Figure 7.3 shows the mean leucocyte cystine concentrations in the 6 patients in whom 
diurnal variation was studied. There was a trend for the leucocyte cystine to fall 
during the morning but there was no significant change from the baseline 
concentration at time Oh (p>0.3 at all time points). Inspection of diet and drug sheets 
revealed no trend between intake and leucocyte cystine concentration. 
Plasma cysteamine concentrations 
Individual plasma cysteamine profiles after oral phosphocysteamine are shown in 
figure 7.4 and the mean profiles in figure 7.5. 
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Figure 7.4: Individual plasma cysteamine concentrations after a single dose of oral 
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Figure 7.5: Mean plasma cysteamine concentrations after a single dose of oral 
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Leucocyte cystine concentrations 
Individual variation and mean changes in leucocyte cystine concentration after oral 
phosphocysteamine are shown in figures 7.6 and 7.7. After oral phosphocysteamine, 
the mean leucocyte cystine concentration was significantly reduced (p=0.005) to a 
minimum of 40% of the pre-treatment concentration at 3h. The mean leucocyte 
cystine concentration had only reaccumulated to 61 % of the pre-treatment level at 12 
hours after the dose (p=0.032). 
Pharmacokinetic parameters 
Individual derived values of peak concentration (C., J, time to peak concentration 
(T. J, area under the curve from Oh to 8h (AUCo. ) and terminal half-life (t. j are 
shown in table 7.2. 








(; tmol. h/1) 
tý4 
(h) 
2 17.5 40 25.1 1.63 
3 46.5 30 44.5 1.00 
5 28.0 30 44.1 1.90 
6 46.8 40 88.0 4.71 
7 26.5 40 54.3 0.76 
9 29.2 40 39.3 0.24 










Figure 7-6: Individual leucocyte cystine concentrations after a single dose of oral 
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Figure 7.7: Mean leucocyte cystine concentrations after a single dose of oral 
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Discussion 
The single doses of oral phosphocysteamine solution were generally well tolerated. 
Only one patient vomited more than once and she had the highest peak cysteamine 
concentration and area under the curve. There was no difference in patient tolerance 
between those who had received the drug on a longterm basis and those for whom this 
was the first exposure to the drug. 
Since the accumulation of cystine within lysosomes is derived from protein catabolism 
(Thoene et al., 1977), it might be expected that leucocyte cystine concentration would 
vary with diet and time of day. The results show that there is no significant diurnal 
variation in leucocyte cystine levels. 
Cysteamine was rapidly absorbed into the circulation after oral administration of a 
suspension of phosphocysteamine. Pharmacokinetic parameters for cysteamine have 
not previously been described. There was considerable individual variation in C., 
AUCO, and t% but in all cases plasma cysteamine was virtually undetectable after 6h. 
In the absence of data of plasma cysteamine concentrations after intravenous 
administration, it is not possible to calculate the extent of cysteamine absorption after 
an oral dose of phosphocysteamine. However, the rapid absorption and short time to 
peak concentration, are consistent with a high site of gastrointestinal absorption (eg. 
stomach and duodenum). These data are also in keeping with rapid hydrolysis of 
phosphocysteamine to cysteamine in vitro, as suggested by Smolin et al. (Smolin et 
al., 1988). Cysteamine has been prescribed in a6 hourly regimen for two reasons. 
Firstly, Thoene et al. reported that cystine reaccumulated over this period (Thoene et 
al., 1976) and secondly Jonas and Schneider demonstrated that cysteamine was 
undetectable in plasma 6 hours after a dose (Jonas and Schneider, 1982c). The results 
in this study demonstrate that the effect of the drug is more prolonged since the mean 
leucocyte cystine concentration had only risen to 61 % of the pre-treatment level 12h 
after the oral dose. 
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A study of the effects of rectal cysteamine gel 
Introduction 
Cysteamine has an unpleasant taste and following an oral dose, the patient's breath 
smells of free sulphides. A second common side effect is vomiting, typically occurring 
approximately 1/2 hour after the dose. In an attempt to circumvent these problems, an 
investigation of the feasibility and efficacy of rectal administration of cystearnine was 
undertaken. Since palatability was not a concern for the rectal study, and there is no 
information on rectal hydrolysis of phosphocystearnine, cysteamine was used for this 
route. 
Methods 
Six patients (subjects 1,2,3,5,6 and 7) received a dose (10mg/kg) of cysteamine, 
given rectally as a gel. Cysteamine gel was prepared in the Department of Pharmacy, 
Guy's Hospital, with the following constituents: 
- 2-94g cysteamine hydrochloride powder (Idis Ltd. ), 
- 0. Ig disodium edetate, 
- 10mls water, 
- 9% methylcellulose. 
Preliminary dose formulations were prepared with a variety of methylcellulose 
concentrations, from which 9% methyl-cellulose was judged the most suitable. The 
dose of cysteamine was calculated for each patient and dissolved in 9% methyl- 
cellulose gel to a final volume of between 2.5 and 5mls so that the dose volume was 
approximately similar for all patients. The gel was tested for stability and kept at 4T. 
Rectal administration and sampling thnes 
Prior to administration the rectal cysteamine gel was allowed to stand at room 
temperature for 30mins. Get was administered to the patients in either the left lateral 
or supine position, over 2 minutes, using a 5ml syringe (Steriseal) and a fine soft 
plastic quill (Avon Medicals). The children remained supine for 15 minutes after the 
dose. Serial blood samples were taken for leucocyte cystine concentration at 0,1,3,6 




Administration of the rectal cysteamine gel was well tolerated in the younger 3 
children. The older 3 children expressed a desire to expel the dose approximately 15 
minutes after administration, but were able to retain the gel for a further 15 minutes. 
No child in the rectal study suffered vomiting, diarrhoea nor rectal bleeding. The 
smell of cysteamine on the breath was minimal or not apparent after rectal dosage. 
Plasma cysteamine concentrations 
Individual plasma cysteamine, profiles after rectal cysteamine are shown in figure 7.8 
and the mean plasma cysteamine profile is shown in figure 7.9. The 3 children who 
retained the rectal dose had a higher mean peak plasma cysteamine concentration than 
those who expelled the dose (20.1 vs. 14.3gmol/1). Statistical comparison of these 
groups is not possible because of the small numbers. 
Leucocyte cystine concentrations 
Individual and mean leucocyte cystine profiles after rectal cysteamine are shown in 
figures 7.10 and 7.11. There was no significant reduction in mean leucocyte cystine 
concentration at any time point after the rectal dose (p > 0.1 at all time points). Those 
children who had retained the rectal dose had a lower pre-treatment mean leucocyte 
cystine concentration (6.65 vs. 10.23nmol 1h cystine per mg protein) but a greater 
reduction at A (41 % vs. 14 %) than those who expelled the dose. 
Pharmacokinetic parameters 
Individual derived values of peak concentration (C. J, time to peak concentration 
(T., J, area under the curve from Oh to 8h (AUCOJ and terminal half-life (t. h) are 
shown in table 7.3. (Inspection of the plasma cysteamine profile for patient I showed 
a slight rise in cysteamine concentration at 8h, making calculation of pharmacokinetic 
parameters impossible). 
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Figure 7.8: Individual plasma cysteamine concentrations after a single dose of rectal 
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Figure 7.9: Mean plasma cysteamine concentrations after a single dose of rectal 
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Figure 7.10: Individual leucocyte cystine concentrations after a single dose of rectal 
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Figure 7.11: Mean leucocyte cystine concentrations after a single dose of rectal 
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(; tmol. h/1) 
t4 
(h) 
1 15.4 40 See note See note 
2 17.5 40 27 0.73 
3 27.6 30 45 1.46 
5 10.0 20 9 0.45 
6 20.6 20 15 0.29 
7 12.3 30 15 0.98 
Mean (SD) 17.2(6.3) 22.3 (14.3) 0.78(0.46) 
Discussion 
The 3 younger patients who received rectal cysteamine, tolerated the dose without any 
problems. Halitosis was noted in 2 but was minimal compared with that after oral 
dosage. There was marked individual variation in the plasma cysteamine and leucocyte 
cystine profiles after rectal dosage. Although cysteamine was rapidly absorbed from 
the rectum, the extent of absorption was low (table 7.3). There was no significant 
effect on the mean leucocyte cystine concentrations (see figure 7.11) and this is 
probably because the older 3 patients expelled the dose 30 minutes after 
administration. One patient in particular had a marked fall in leucocyte cystine that 
persisted for the study period (see figure 7.10). 
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A trial of longterm rectal cysteamine 
Three young children (patients 1,2 and 3) who became intolerant of oral 
phosphocysteamine were treated for up to 12 months with a once or twice daily 
regimen of rectal cysteamine gel. The gel was formulated and prescribed as in the 
single dose study. The doses were steadily increased according to firstly the effect on 
leucocyte cystine concentration and secondly patient tolerability. The volume of gel 
administered was maintained at approximately 5mls per dose by increasing the 
concentration of cysteamine within the gel. The final rectal doses varied considerably. 
One patient (number 1) required only 20mg/kg/day whereas the other two needed 
higher doses of 50 and 70mg/kg/day respectively. 
Compliance improved not only with the drug but also with their electrolyte 
replacements and dietary intake. Leucocyte cystine concentrations fell to more 
acceptable levels (see figure 7.12), (van't Hoff et al., 1991). Diaries of adverse 
events during therapy revealed that the children tended to defaecate 1/2h after the dose 
in approximately 30% of administrations. Their parents noted that the breath smell 
and nausea were much reduced compared with oral dosage. 
Rectal administration in the three patients was discontinued after 6,8 and 11 months 
respectively. Two stopped on account of side-effects (diarrhoea and minor rectal 
bleeding respectively) and the third wanted to recommence oral dosage. All three 
were able to recommence oral phosphocysteamine without difficulty. For these 
patients rectal cysteamine acted as a "stop-gap" treatment, covering a period of 
complete intolerance to oral therapy. 
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A trial of a new formulation of eysteamine in capsules 
Introduction 
Cysteamine hydrochloride is very hydroscopic, tending to oxidise, to the disulphide, 
cystarnine, in the presence of moisture. It has therefore always been prescribed as a 
solution, formulated with a reducing agent, as follows: 
- Cysteamine hydrochloride 142.25g 
- Disodium edetate 100mg 
- Water to I litre. 
This produces a solution of 100mg cysteamine base per mi of solution. 
Nausea, vomiting and breath smell are common side-effects of cysteamine solution. 
The pro-drug, phosphocysteamine, was developedlo counter these adverse effects. 
Most patients prefer phosphocysteamine to cysteamine. It is prescribed as a powder, 
either in sachets or in capsules which can be dissolved in water just prior to ingestion. 
The Pharmacy Departments of Birmingham Children's Hospital and Guy's Hospital 
have in the past, hand-packed capsules of phosphocysteamine. Although this is very 
time and labour-consuming, the older patients prefer encapsulated drug. 
Phosphocystearnine is obtained in the UK from Idis Ltd, who import the powder from 
Medea Research Laboratories in Westhampton Beach, New York State, USA. This is 
the only commercial source of the drug in the World and is relatively expensive 
(018.35 per 500g, 1989 price). 
For these reasons, research into new formulations of cysteamine has been undertaken. 
Bergonzi et al. reported on the -use of a capsule prepared with 2% silicic acid but no 
pharmacokinetic or pharmacodynamic data were given (Bergonzi et al., 1981). Dr G 
Rowley and colleagues at Sunderland Polytechnic have developed a capsule of 
cystearnine by formulating it in polyethylene glycol. A trial of these capsules was 
undertaken in cystinosis patients since this would give not only pharmacokinetic data 





After an overnight fast, 4 patients (subjects 4,5,6 and 7) received a dose (15mg/kg) 
of cysteamine base in capsule form. The capsules were individually prepared for each 
patient by Dr Rowley and Miss Dixon at Sunderland Polytechnic. The patients 
swallowed the capsules over 1-2 minutes with 50mls water. 
Blood sampling 
Serial blood samples were taken for leucocyte cystine at 0,1,3,6,12 and 24hours 
and for plasma cysteamine at 0,20,30,40,60,75,90mins., 2,3,4,6,8,12 and 24 
hours. 
Results 
All the patients were able to swallow the capsules without difficulty and none 
experienced nausea or vomiting. However the characteristic breath smell was noted in 
all patients. 
Plasma cysteamine concentrations 
The individual and mean plasma cysteamine profiles after the oral cysteamine capsule 
dose are shown in figures 7.13 and 7.14 respectively. The small number of subjects 
precludes statistical analysis but there appears to be a biphasic absorption profile, with 
a secondary peak at 90 minutes. 
Leucocyte cystine concentrations 
The individual and mean leucocyte cystine profiles are shown in figures 7.15 and 7.16 
respectively. Although statistical analysis has not been performed, all the subjects 
demonstrated a marked reduction in leucocyte cystine concentration. One hour after 
the dose, the mean cystine concentration was 47% of the pre-dose level. The greatest 
reduction in mean leucocyte cystine concentration (to 27% of the pre-dose level) 
occurred 3 hours after the dose. At 24 hours after the dose, the mean leucocyte 
cystine concentration had only risen to 51 % of the baseline value. 
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Figure 7.13: Individual plasma cysteamine concentrations after a single dose of 
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Figure 7.14: Mean plasma cysteamine concentrations after a single dose of cysteamine 
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Figure 7.15: Individual leucocyte cystine concentrations after a single dose of 
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Figure 7.16: Mean leucocyte cystine concentrations after a single dose of cysteamine 
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Pharmacokinetic parameters 
Individual derived values of peak concentration (C.., ), time to peak concentration 
(T. J, area under the curve from Oh to 8h (AUC04) and terminal half-life (tj) are 
shown in table 7.5. 








(umol. h/1) W 
4 30.6 30 30.0 0.35 
5 23.6 30 28.4 0.80 
6 42.2 90 92.5 0.77 










The manufacture of a readily available and stable form of cysteamine capsule would 
be a major practical advance in the treatment of cystinosis. The results of this small 
and preliminary study indicate that the formulation of cysteamine in a capsule with 
polyethylene glycol, is both safe and very effective. 
As in previous pharmacoldnetic studies on cysteamine, there was wide variation in 
plasma cysteamine concentrations achieved after an identical (weight-based) dose. 
There was a suggestion of a biphasic absorption profile with an initial mean peak of 
28.9jAmol/I at 30 minutes and a secondary peak (mean 23.31zmol/1) at 90 minutes. The 
secondary peak may indicate absorption of the drug from the small intestine since it 
occurs too early to be due to enterohepatic circulation. 
All the subjects showed a marked and sustained reduction in leucocyte cystine 
concentration. Despite the slower absorption of cysteamine, the profile of leucocyte 
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cystine depletion was similar to that seen after administration of oral 
phosphocysteamine solution. This suggests that total area under the plasma cysteamine 
vs. time curve might be as important a factor in efficacy as peak plasma cysteamine 
concentration. If this is correct, it would allow the development of slower release 
formulations of cysteamine. 
A study of the effects of a single dose of intmvenous cysteamine 
Introduction 
Intravenous cysteamine has been administered to one patient with cystinosis (Thoene 
et al., 1976). In that study, plasma cysteamine was not measured but there was a 
profound reduction in leucocyte cystine that was maintained for 48 hours. No details 
of adverse effects were reported. 
There is much wider experience of intravenous cysteamine in the treatment of severe 
paracetamol poisoning (Prescott et al., 1976; Hughes et al., 1977). Glutathione 
precursors and thiols such as L-cysteine, L-methionine and cysteamine were found to 
be protective against hepatic necrosis in acute paracetamol poisoning. Prescott et al. 
gave intravenous cysteamine to 30 of 121 patients with severe paracetamol poisoning 
(Prescott et al., 1976). The dose regimen was 2g cysteamine base infused over 10 
minutes, followed by a further 1.6g over the next 20 hours. Details of the patients' 
ages were not given, but if an average weight of 70kg is assumed, the initial loading 
dose is approximately 29mg/kg. Early cysteamine treatment (within 10 hours of 
ingestion) was found to be very* effective in preventing severe liver damage, renal 
failure and death when compared with a control group. Cystearnine "regularly" (sic) 
caused flushing, nausea, vomiting, drowsiness and misery. In a further trial , Hughes 
et al. gave intravenous cystearnine to 26 patients after a paracetamol overdose 
(Hughes et al., 1977). The dose used was 2g cystearnine hydrochloride over 10 
minutes with a further 1.2g over 20 hours. The doses in this study are lower than 
those in the study of Prescott et al., since the latter used doses based on cysteamine 
hydrochloride rather than cystearnine base. All 26 patients treated with cysteamine in 
the study of Hughes et al. developed severe nausea and vomiting (Hughes et al., 
1977). Six became drowsy and one developed meningism (although examination of 
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spinal fluid was normal). None had any longterm sequelae of treatment. No mention 
was made in either study of whether the patients had the characteristic smell of 
cysteamine on their breath. In addition in neither study were plasma cysteamine 
concentrations measured. Subsequently, other thiol derivatives such as methionine and 
N-acetylcysteine have replaced cysteamine as protective agents in the treatment of 
severe paracetamol poisoning. 
The assessment of the systemic bioavailability of a drug requires information on the 
plasma concentrations achieved after intravenous dosage in which it is assumed that 
absorption is complete. Comparison of the areas under the curve after enteral and 
intravenous doses allows the bioavailability (F) to be calculated as follows (Rogers et 
al., 1981): 
F =(AUCa / AUCi, ) / (Dosei, x Dose. ) 
where AUCw = area under curve after oral dose 
AUCj, area under curve after iv dose 
Dose,, w oral dose 
Dosei., = iv dose. 
A study of the effects of a single intravenous dose of cysteamine was undertaken to 
provide data on which to calculate systemic bioavailability of the drug and also to 
investigate the suggestion of prolonged cystine depletion after intravenous dosage 
(Thoene et al., 1976). 
Pilot study 
Methods 
After an overnight fast, patient number 5 (see table 7.1) received an infusion of 
2. Smg/kg cysteamine base made up in 50mls of 0.9% Normal saline, given over 30 
minutes. At the end of the infusion, the intravenous line was flushed with 5 mls of 
0.9% Normal saline to ensure that the entire dose of cysteamine was administered. 
Administration by infusion over this time period was designed to mimic the time 
course of the plasma cysteamine profile after oral phosphocysteamine (see figure 7.5). 
It was therefore hoped to avoid very high peak concentrations that might have arisen 
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if the intravenous dose had been given by bolus and thereby reduce the incidence of 
nausea and vornifing. 
Serial blood samples were taken from a second intravenous line placed in the 
contralateral arm, for leucocyte cystine at 0,1,3,6,12,24 hours and for plasma 
cysteamine at 0,10,20,30,40,45,50,60,75,90,105 mins., 2,3,4,6,8,12 and 
24 hours. Pulse and blood pressure were monitored at 30 minute intervals over the 
first 4 hours of the study. 
Results 
The intravenous dose was very well tolerated and there were no adverse effects. The 
characteristic smell of cysteamine was not noted on the patient's breath. There were 
no consistent changes in pulse or blood pressure. 
The plasma cysteamine profile after intravenous infusion of cysteamine is shown in 
figure 7.17. The peak concentration of 20, umol/I was reached at 20 minutes although 
the drug was infused over 30 minutes. Elimination of the drug was rapid and it was 
undetectable in plasma after 3 hours. The leucocyte cystine concentrations are shown 
in figure 7.18. There is no consistent pattern in the cystine results. 
In summary, an intravenous dose of 2.5mg/kg was safely administered by infusion 
over 30 minutes. However, the resulting plasma cysteamine concentrations were low 
and were not associated with any change in leucocyte cystine concentration. The 
absence of halitosis might also be explained by the low plasma concentrations of 
cystearnine. A larger dose would be needed for subsequent studies of the effects of 
intravenous cYsteamine. 
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Figure 7.17: Plasma cysteamine concentrations after an intravenous infusion of 
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Figure 7.18: Leucocyte cystine concentrations after an intravenous infusion of 
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A study of the effects of a single dose of intmvenous; cysteamine 
Methods 
Patients 
After an overnight fast, 4 patients (subjects 2,3,4 and 6), received a 5mg/kg dose of 
cysteamine, given by intravenous infusion in 50mls of 0.9% Normal Saline over 30 
minutes. At the end of the infusion, the intravenous line was flushed with 5 mls of 
0.9% Normal saline to ensure that the entire dose of cysteamine was administered. 
Blood sampling 
Serial blood samples were taken from a second intravenous line placed in the 
contralateral arm, for leucocyte cystine at 0,1,3,6,12,24 hours and for plasma 
cysteamine at 0,10,20,309 40,45,50,60,75,90,105 mins., 2,3,4,6,8,12 and 
24 hours. Pulse and blood pressure were monitored at 30 minute intervals over the 
first 4 hours of the study. 
Results 
As in the pilot study, the intravenous dose was very well tolerated and there were no 
adverse effects. The characteristic smell of cysteamine was noted on the breath of all 
patients but was less noticeable than in the oral study. There were no consistent 
changes in pulse or blood pressure. 
Plasma cysteamine concentrations 
The individual and mean plasma cysteamine profiles after intravenous dosage are 
shown in figures 7.19 and 7.20 respectively. 
Leucocyte cystine concentmflons 
The individual and mean leucocyte cystine profiles after intravenous cysteamine are 
shown in figures 7.21 and 7.22 respectively. Two subjects showed marked and 
sustained reductions in leucocyte cystine concentration following intravenous dosage. 
The other two subjects had no consistent change in cystine concentration. Overall the 
mean leucocyte cystine concentration was reduced to 55% of the mean pre-dose level 
at I hour and had only reaccumulated to 72% of the baseline concentration after 24 
hours. The small number of subjects precludes statistical analysis. 
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Figure 7.19: Individual plasma cysteamine concentrations after an intravenous infusion 
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Figure 7.20: Mean plasma cysteamine concentrations, after an intravenous infusion of 
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Figure 7.21: Individual leucocyte cystine concentrations after an intravenous infusion 
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Figure 7.22: Mean leucocyte cystine concentrations after an intravenous infusion of 
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Pharmacokinetic parameters 
Individual derived values of peak concentration (C,. ), time to peak concentration 
(r. j, area under the curve from Oh to 8h (AUCo-) and terminal half-life (tj) are 
shown in table 7.6. 











2 29.7 20 43 1.45 
3 37.7 30 29 1.89 
4 34.1 20 25 2.45 











Administration of an intravenous dose of cysteamine in the form of a short infusion, 
proved to be safe and in some patients, effective in reducing the leucocyte cystine 
concentration. Since the primary aim of this study was to enable the calculation of 
systemic bioavailability of cysteamine, a low and non-toxic dose was chosen. The 
presence of halitosis suggests that the characteristic breath smell is due to pulmonary 
excretion of free sulphides. As in previous studies, there was marked variation in the 
plasma cysteamine concentrations achieved after an identical (weight-based) dosage. 
There were no technical problems with the intravenous infusions so that delivery of 
the dose can be assumed to be complete. The patient with the highest peak plasma 
cysteamine concentration and area under the curve (subject 6) did not have the 
greatest reduction in leucocyte cystine, as might have been expected. All the 
intravenous studies were completed within a4 week period, a time over which the 
formulation had been shown to be stable (data not shown). 
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The reduction in mean leucocyte cystine concentration was sustained for the 24 hour 
duration of the study. Without data on leucocyte cystine concentrations more than 24 
hours after an intravenous dose, it is not possible to say how long the reduction in 
cystine would last. As was observed in the oral dose study, the duration of leucocyte 
cystine depletion (24h) far outlasted the presence of cysteamine in the plasma 
compartment (8h). 
Discussion of the pharmacokinetics of cysteamine and phosphocysteamine 
There has been little work on the pharmacokinetics and administration of cysteamine 
and phosphocysteamine. Such information will almost certainly increase efficacy, 
reduce side effects and thereby improve compliance. This investigation is the first 
formal study of the pharmacokinetics of cysteamine and phosphocysteamine in patients 
with cystinosis. 
All the pharmacokinetic studies were undertaken in patients with cysfinosis rather than 
in animals or healthy human volunteers. Animals were not used mainly because 
pharmacokinetic data are often species-dependent. Patients were studied in preference 
to healthy volunteers since this provided data not only on the pharmacoldnetics but 
also on the pharmacological response (ie. a change in leucocyte cystine). The 
leucocyte cystine concentration in a normal healthy person is less than 0.3nmol 1/2 
cystine per mg protein. This level approaches the lower limit of detection of the 
assay. Thus it would not be feasible to measure an effect of cysteamine on the 
leucocyte cystine concentration in healthy volunteers. 
Since cystinosis is a very rare condition, the number of patients at any one centre is 
relatively small. From this point of view, it was fortunate that there were a group of 
patients at Guy's Hospital who felt able to participate in these studies. Inevitably the 
number of subjects in any one trial was small. Many patients underwent several 
studies, although none took part in more than one in every six months. Each study 
involved stopping longterm phosphocystearnine treatment for 7 days and entailed a 
two day hospital admission (generally arranged in school holidays or at weekends). 
Practical and ethical considerations therefore limited the research. 
Preliminary data on the metabolism of cysteamine came from the studies of its 
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radioprotective effects. Eldjarn and Nygaard studied the distribution of cysteamine and 
cystamine after administering S35 -labelled capsules of each compound to 2 healthy 
human volunteers (Eldjarn and Nygaard, 1954). Peak serum radioactivity occurred 
between 30 and 60 minutes after the doses, with rapid fall-off thereafter. Urinary 
excretion of radioactive products demonstrated that very little cystamine or cysteamine 
was excreted in unchanged form. Most of the S35 -labelled products were in the form 
of sulphate and taurine. Further animal work from the same group demonstrated that 
in mice, cystamine and cysteamine are extensively protein bound in the form of mixed 
disulphides (Eldjarn and Pihl, 1956). 
At the time of the first description of the depletion of cystine by cysteamine, a 
clinically applicable assay for cysteamine was not available (Thoene et al., 1976). 
There were therefore no data on plasma cystearnine concentrations after the oral and 
intravenous doses in the first treated patient. Jonas and Schneider measured plasma 
cystearnine concentrations after an oral dose (mean 14 mg/kg) of cysteamine solution 
in 5 cystinosis children on longterm treatment (Jonas and Schneider, 1982c). The 
mean plasma cysteamine concentration I hour after the dose was 34, umol/l. Urinary 
cysteamine excretion was also measured and was found to vary between 0.3 and 1.7% 
of the total daily dose. 
Smolin et al. compared equimolar doses of cysteamine (equivalent to 18mg/kg) and 
phosphocysteamine in 6 children with cystinosis (Smolin et al., 1988). These children 
were on longterm treatment although it had been stopped for I day (in 2 patients) and 
7 days (in 4 patients). The peak plasma cysteamine concentrations obtained between 
30 mins and 1 hour, were 49pthiol/i and 5414mol/I after cysteamine and phospho- 
cystearnine, respectively. In their study, plasma cysteamine concentrations and 
leucocyte cystine levels were not reported more than 6 hours after the dose. In all 
cases cysteamine had been virtually cleared from the plasma by this time. In the 2 
patients in their study who had stopped longterm cysteamine treatment 7 days 
beforehand, the leucocyte cystine concentrations 6 hours after the dose remained 
lower than the pre-dose levels. - 
Cysteamine is prescribed in a6 hourly regimen since, in vitro, cystine reaccumulated 
over this period (Thoene et al., 1976). In addition Jonas and Schneider demonstrated 
P 177 
that cysteamine was undetectable in plasma 6 hours after a dose (Jonas and Schneider, 
1982c). The results of the oral phosphocysteamine study demonstrate that the effect of 
the drug is more prolonged since the mean leucocyte cystine concentration had only 
risen to 61 % of the pre-treatment level 12h after the oral dose. Since this was a single 
dose study, undertaken in patients with "untreated" cystine levels, it is not surprising 
that the cystine level remained well above the upper limit of the therapeutic range 
(lnmol 1/2 cystine per mg protein). Whilst some patients in the UK can tolerate 6 
hourly dosage, many can only manage to take the drug twice a day (Winterborn M, 
van't Hoff W, personal communications). The demonstration that 12 hourly dosage is 
efficacious is of great importance to these patients. It is not possible to say from these 
results whether the rate of cystine re-accumulation will be the same after multiple 
doses. Longterm therapeutic monitoring will provide information in this respect (see 
chapter 8: "Monitoring of leucocyte cystine concentrations"). 
Even with such a reduction in the frequency of dosage, there remain patients who are 
unable to tolerate therapy. This is a particular problem in the youngest children since 
they usually require larger quantities of electrolyte supplements at this time. These 
young, recently diagnosed cystinosis children are prone to vomiting, even before 
cysteamine is started (Gahl et al., 1989). It can therefore be difficult to introduce 
cysteamine or phosphocysteamine therapy with the expectation of nausea and vomiting 
as common side effects. For these reasons, alternative routes of administration of 
these drugs have been studied. 
Rectal administration of cysteamine in the form of a gel, proved to be feasible and 
safe. Although some individuals showed a reduction in cystine concentration, the low 
dose used and the fact that 3 subjects expelled the dose after 30 minutes, resulted in 
there being no significant reduction in mean leucocyte cystine. There was no 
significant difference between the mean elimination half lives, t1/2, in the oral and 
rectal dose studies (p > 0.2), see table 7.7, below. 
As a result of this preliminary study, the 3 younger subjects participated in a study of 
longterm rectal cysteamine treatment (see chapter 7: "A trial of longterm rectal 
cysteamine"). For these three patients, rectal cysteamine proved to be a "stop-gap" 
treatment, covering a period in which they were completely intolerant of the oral 
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medication. 
For the older patient, new formulations of oral cystearnine are required. Although a 
cystearnine capsule has been prepared and used in clinical practice (Bergonzi et al., 
1981), there has been no previous description of the pharmacokinetics and 
pharmacodynamics of a capsule formulation. Although the number of patients was 
small, all showed a marked and sustained reduction in leucocyte cystine concentration. 
There was a suggestion of a biphasic absorption profile after administration of the 
cysteamine capsule. After the capsule dose the mean peak cysteamine concentration 
was less than that after the oral phosphocysteamine suspension, although the AUCO, 
was comparable, see table 7.7. 
Table 7.7: Summary of pharmacoldnetic parameters 
Drug (dose) Cmax AUCO., t4 
(UM01/1) (; tmol. h/1) (h) 
Phosphocysteamine 36.4 59.4 1.59 
soln., 10mg/kg 
Rectal cysteamine 17.2 22.3 0.78 
gel, 10mg/kg 
Intravenous 41.4 40.9 1.79 
cysteamine, 5mg/kg 
Cysteamine 30.6 61.0 0.70 
capsule, 15mg/kg 
Notes: 
1. Doses are given as the equimolar dose of cysteamine base. 
2. A secondary peak plasma cysteamine concentration occurred after the capsule 
dosage. 
Administration of the intravenous (IV) dose was designed to mimic the plasma 
cysteamine profile after oral phosphocysteamine. After IV dosage, three of the 
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subjects had a peak concentration at 20 minutes, the fourth occurring at 30 minutes. 
This suggests rapid distribution of the drug out of the vascular compartment. The 
results of the single dose intravenous cysteamine study enabled calculation of the 
bioavailability of these drugs when administered in different formulations and by 
alternative routes. The systemic bioavailability of a drug is that amount of the 
compound reaching the vascular compartment. For orally administered drugs, a low 
bioavailability may reflect either poor absorption from the gastrointestinal tract or an 
extensive first-pass extraction by the liver. A drug given by the rectal route should 
avoid the first-pass effect, since there is a porto-systemic anastomosis with the inferior 
rectal vein. The systemic bioavailabilities of cystearnine after oral and rectal 
administration, corrected for the different doses used, are shown in table 7.8 (see 
below): 
Table 7.8: Bioavailability of. cysteamine and phosphocysteamine 
Route of administration E Bioavailability 







Oral cysteamine cmafleL 50 
The calculation of bioavailability requires a number of assumptions (Rogers et al., 
1981): 
1. that the apparent volume of distribution M and elimination rate constant (k) of the 
drug are independent of the route of administration, 
2. that the principle of superposition applies, ie. that the phamacoldnetics of 
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cysteamine may be described by a first-order model. The values of systemic 
bioavailability, F, in table 7.8 above, show that cysteamine is absorbed very well 
from a dose of phosphocysteamine solution and rather poorly from rectal gel. Poor 
rectal absorption is in part explained by the elimination of the dose in three cases. The 
high bioavailability of oral phosphocysteamine suggests that first-pass extraction of 
cysteamine must be relatively minor. Cysteamine is moderately well absorbed from 
the capsule formulation in comparison to the oral phosphocysteamine solution. 
Despite the greater absorption of cysteamine from oral phosphocysteamine solution, 
the leucocyte cystine depletion was greater 3 hours after the capsule dose (27% of 
pre-dose level) than after the suspension (40% of pre-dose level), see figure 7.23 
(above). The small numbers and marked variability preclude statistical analysis of this 
difference. It is possible that cystine depletion depends as much on the area under the 
curve as on the peak concentration achieved after cysteamine administration. Since 
there is a suggestion that the peak concentration is a major factor in determining 
toxicity (Schneider JA, personal communication), further work is required to 
investigate whether cysteamine could be formulated into slow-release preparations. 
It has been estimated that the manufacture of a cysteamine capsule is five times 
cheaper than the equivalent dose of phosphocysteamine (M Coulthard, personal 
communication). Furthermore cysteamine is widely available whereas 
phosphocysteamine is supplied by only one source in the world. As a result of this 
pharmacoldnetic study, a trial is being prepared by the British Association of 
Paediatric Nephrologists, comparing the acceptability and efficacy of cysteamine versus 
phosphocysteamine capsules in -cystinosis patients. 
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Chapter 8: Personal experience and recommendations for treatment 
At Guy's Hospital, children are seen in a specialist cystinosis clinic, held fortnightly 
and supported by a senior liason nursing sister. As of August 1993, there are 10 pre- 
transplant children were attending the clinic. A protocol for their care has been 
developed with the benefit of 5 years of experience in the clinic and based on the 
results of the studies described in chapter 7: 
Management of newly-diagnosed child - 
1. Newly-diagnosed children require admission to hospital, usually for a period of 2 
weeks, to correct the biochemical abnormalities, start cysteamine treatment and to 
allow detailed discussions with the parents. 
2. In addition to the standard clinical history and examination, the following details 
are recorded: 
- detailed family tree 
- height, weight and head circumference 
- blood pressure 
- formal dietary assessment. 
3. Initial investigations should include: 
- urea, creatinine and electrolytes, acid base 
- calcium, magnesium, phosphate, albumin 
- liver function tests 
- haematology (including differential leucocyte count) 
- urine biochemistry, pH 
- urine tubular proteins and enzymes 
- thyroid function tests 
- parathyroid hormone level 
- bone age 
- Inutest 5-point single injection estimation of GFR 
- blood for subsequent DNA analysis 
- plasma quantitative amino acids, trace elements and vitamins (as from September 
1993) 
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4. Management of fluid and electrolyte imbalance varies between patients but the 
following guidelines are helpful: 
- allow free access to fluid, day and night 
- vomiting or fluid refusal are indications for nasogastric or intravenous therapy 
- most patients require nasogastric feeds or oral calorie supplementsin the first few 
months after diagnosis 
- initial doses are in the range shown in table 8.1: 
- aggressive correction of the acidosis and hypophosphataemia can lead to tetany 
secondary to hypocalcaemia and/or hypomagnesaemia 
- phosphocysteamine is started according to the guidelines detailed in the section 
"Clinical use of cystearnine and phosphocystearnine" 
Table 8.1: Doses of electrolyte and vitamin D supplements 
Drug Initial dose 
Sodium bicarbonate 5- 10 mmol/kglday 
Potassium chloride 4-5 mmol/kg/day 
Phosphate Sandoz 1/2 tab (8mmol) twice a day 
Neutral sodium phosphate 5 -10 mmol/day 
1-ot calcidol 200 nanograms once a day 
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ClWcal use of cysteamine and phosphocysteamine 
Introduction 
There is now therefore overwhelming evidence of the efficacy of cysteamine treatment 
in cystinosis. Therapy should be started as soon as possible since longterm outcome is 
directly related to the age at which cysteamine is introduced. There is not yet evidence 
that renal tubular dysfunction can be corrected but early treatment may lead to an 
improvement in glomerular filtration rate (Markello et al., 1993). It follows that early 
diagnosis is of paramount importance if therapy is to be successful. 
Dosage and frequency of administration 
My practice is to start at a dose of approximately 10mg/kg/day cysteamine base. 
(10mg/kg cysteamine base is approximately equivalent to 23mg/kg 
phosphocysteamine). Phosphocysteamine is generally preferred to cysteamine. The 
dose is increased steadily over a period of weeks aiming for a pre-dose leucocyte 
cystine concentration of <I nmol Ih cystine per mg protein. The dose needed to 
achieve this level of cystine depletion varies considerably. Some need as little as 
20mg/kg/day whereas others need 75mg/kg/day. The dose should not normally exceed 
90mg/kg/day. 
In the UK, phosphocysteamine is prescribed in 200mg capsules (equivalent to 87mg 
cysteamine base). The phosphocysteamine powder can be dissolved in a small volume 
of water or juice, so that small children can take it in liquid form (orally or via a 
nasogastric tube). Older children can swallow the capsules. At each dose increase, a 
re-emergence of nausea and vomiting can be expected but tolerance usually develops 
after one week. In North America, the drug is usually given in divided doses every 6 
hours. This is a reasonable method of administration if the child is able to tolerate it. 
The results of the pharmacoldnetic and pharmacodynamic studies suggest that 12 
hourly dosage is probably as efficacious (van't Hoff et al., 1991). Clinical experience 
suggests that these results can be extrapolated to chronic therapy thus allowing 12 
hourly administration. This frequency of dosage is often better tolerated especially in 
those patients who find the breath smell socially disadvantageous (eg. at school or 
work). 
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Monitoring of leucocyte cystine concentrations 
Whatever the formulation, route and frequency of dosage, careful monitoring of the 
leucocyte cystine concentration is essential since the response to cysteamine is 
unpredictable. Leucocyte cystine concentrations should be determined just prior to the 
next dose. Patients receiving 12 hourly doses are advised that on the night before their 
clinic appointment, they should take a dose as late as possible. At the clinic, a pre- 
dose level is measured in the morning, approximately 12 hours after the last dose. 
Figure 8.1 shows the results of 179 leucocyte cystine determinations in 18 patients 
(mainly at Guy's Hospital) treated for up to 44 months. Only leucocyte cystine levels 
measured 9- 15 hours after the last dose are shown. These data demonstrate that 
effective cystine depletion can take at least 12 months to achieve and that good control 
can be interrupted by high results. Table 8.2 (below) summarises the leucocyte cystine 
concentrations (n = 109) in 14 of these patients, taken after at least 12 months of 
therapy. 
Table 8.2: Summary of leucocyte cystine concentrations during cysteamine treatment 
Cystine concentration 
(mol 1/2cystine per mg protein) 
Mean ± SD 1.69 ± 1.25 
Median 1.28 
Inter-quartile range 0.82-2.20 
Range 0.16-6.66 
72% of these concentrations were < 2nmol 1/2 cystine per mg protein, a value 
considered to reflect good control (Markello et al., 1993) and 33% were < Inmol 1/2 
cystine per mg protein. However unexplained high cystine concentrations in seemingly 
well controlled patients are a common phenomenon. There may be several 
explanations including poor compliance, intercurrent illness and batch-to-batch 
variation in the medication. 
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Care of the cystinosis patient in the outpatient cl*uu*c 
The following protocol has been formulated: 
Each visit: 
Height and weight 
Plasma electrolytes, Ca, P04, Astrup 
FBC including differential leucocyte count 
Spot urine for tubular proteins 
Other tests as indicated, eg. CyA if renal Tx 




Leucocyte cystine concentration 
Liver function tests 
Thyroid function tests 
6 monthly: 
3-day dietary assessment (sent by parent) 




Plasma amino acids, trace elements and vitamins* 
Bone age 
Neurological review - 
IQ/Developmental scale & psychometric tests* 
Inutest 5-point single injection estimation of GFR 
Ultrasound of liver, spleen and pancreas* 
' To be considered as part of a prospective study 
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Treatment during dialysis and after renal transplantation 
Whereas there are clear parameters by which to judge the efficacy of treatment prior 
to end-stage renal failure, it is much more difficult to determine whether cysteamine 
treatment after renal transplantation is successful. In a recent European review, only 
19% of post-transplant patients were treated with cysteamine (Ehrich et al., 1992). 
My practice is to continue therapy during dialysis and after transplantation. Care is 
needed with phosphocysteamine treatment when the patient is in end-stage renal 
failure since this drug provides a considerable phosphate load (see chapter 4: 
"Adverse effects"). During the immediate post-transplantation period, cysteamine 
therapy is often witheld. At this time there are more immediate concerns of graft 
rejection, infection and recovery from surgery. Once stable, the patient can 
recommence cysteamine. There are clear theoretical benefits to continuation of therapy 
after transplantation, but only time will tell whether this approach is correct. The 
possibility of teratogenic effýcts preclude its use in pregnancy. 
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Chapter 9: The genetics of cystinosis 
Incidence 
Nephropathic cystinosis is an extremely rare condition but has been reported 
throughout the World. The true incidence varies according to the community studied. 
Studies of incidence have relied on retrospective surveys of paediatric admissions. 
This method is fraught with problems. Firstly, since no evidence of a systematic 
database of cases has been presented, it relies on the recall of the paediatricians 
studied. Secondly there is evidence that children with cystinosis die prior to the 
diagnosis being confirmed (see chapter 4: "Clinical features"). Thirdly, although most 
patients are followed in a paediatric nephrology centre, some remain in the care of the 
local hospital. Surveys of paediatric nephrology centres alone may therefore miss 
cases (Bois et al., 1976). However, accepting all these reservations, the incidence of 
cystinosis varies between 1 in 26,000 and 1 in 326,000 as shown in table 9.1 (see 
below). 
The highest incidence described so far occurred in 3 Departments of France 
(Finist6re, Morbihan, C6tes-du-Nord). This area has a high consanguinity rate but 
Bois et al. found no such marriages in the Breton families studied. However they did 
find that the distance between the parental birthplaces was considerably smaller for the 
Breton families than for the rest of France (mean 84km vs 146km). This may be 
indirect evidence of inbreeding. Manz and Gretz found an increased incidence in 
isolated rural communities with low populations (5.9 patients per million population) 
compared to the rest of Germany (0.9 patients per million), (Manz and Gretz, 1985). 
There is also a cluster of cystinosis families in the region of Saint-Jean Lake in 
Quebec, whose ancestry can be traced to Brittany and Normandy (Bois et al., 1976). 
In a survey of UK paediatric nephrologists, undertaken in 1989,1 found 79 cases of 
cystinosis. In view of the reservations detailed above, I have not presented an estimate 
of the incidence. Combining the incidence figures from the three national surveys of 
France, Germany and Denmark and assuming these to be representative of the rest of 
Europe, the incidence of cystinosis in this area is approximately 1/175,000 births. 
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Table 9.1: Incidence of cystinosis in Europe 
Area Incidence 6: 9 Reference 
Nfidlands, England 1 in 40,000 1: 1 Bickel et al. 1952 
West Brittany I in 26,000 Bois et al. 1976 
Rest of France I in 326,000 1.2: 1 Bois et al. 1976 
France (overall) I in 230,000 Bois et al. 1976 
West Germany 1 in 179,000 1.4: 1 Manz & Gretz 1985 
Denmark I in 115,000 1.75: 1 Ebbesen et al. 1976 
Gene frequency 
The gene frequency for cystinosis can be calculated from the Hardy-Weinberg 
equation: 
pý + 2pq + q2 =1 
where: p= frequency of the normal allele 
q= frequency of the cystinosis allele. 
Since cystinosis is an autosomal recessive disorder, qý is equal to the disease 
frequency, approximately 1/175,000 births. The gene frequency (q) is therefore 
0.00239 and the carrier frequency (2pq) approximately 0.00478 (equivalent to 1/210). 
Sex mtio 
The sex ratio for cystinosis shows a slight preponderance of males (see table 9.1). 
There is no obvious explanation for this finding but Bois et al. noted that the male 
preponderance was no different than that of the general population (Bois et al., 1976). 
Inheritance 
Cystinosis is inherited in an autosomal recessive manner. Evidence for this conclusion 
comes from the following observations: 
I. Cystinosis can occur in more than one family member, but always in a sibling and 
never in more than one generation. 
p 191 
2. The incidence of consanguinity and possibly of inbreeding, is raised in cystinosis 
families. 
3. Both males and females are affected. 
Parents of cystinosis patients are obligate heterozygotes and are entirely 
asymptomatic. However, studies of lysosomal cystine transport have shown that the 
rate of efflux of cystine is 0% for affected patients and 50% for heterozygotes (Gahl 
et al., 1982b). This gene dose effect is further evidence of recessive inheritance. 
Heterozygote diagnosis 
The impaired rate of cystine transport and subsequent moderate lysosomal cystine 
accumulation in heterozygotes permits carrier diagnosis. Studies of cystine transport 
can distinguish heterozygotes from normals but are difficult to perform (Steinherz et, 
al., 1982c). The most convenient method of heterozygote detection is to determine the 
cystine concentration in a polymorphonuclear (PMN) cell preparation (Smolin et al., 
1987). Using this method, Smolin et al. found no overlap between the values in 29 
obligate heterozygotes and those in 18 individuals, presumed to be normal (Smolin et 
al., 1987). Subsequently, many more individuals have been tested and some overlap 
has been seen (Schneider JA, personal communication). The measurement of PMN 
cell cystine concentration is described in appendix 1. Using this assay, the cystine 
concentrations were measured in 24 obligate heterozygotes (ie. parents of cystinosis 
patients) and 33 healthy individuals. The results, expressed as nmol Ih cystine per mg 
protein, are shown in figure 9.1 and summarised in table 9.2 below. 
Table 9.2: Polymorphonuclear leucocyte cystine concentrations in obligate 





Mean 0.67 0.12 
SD 0.41 0.08 
Median 0.55 0.10 
Range 0.23-1.79 0.04-0.38 
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Figure 9.1: Polymorphonuclear leucocyte cystine concentrations in obligate 
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Smolin et al. calculated a cut-off value of 0.30 nmol Ih cystine per mg protein, 
between normal and heterozygote cystine concentrations (Smolin et al., 1987). From 
the results above, the upper limit of the normal range could be defined as 0.28 (mean 
+ 2SD). Using this value, the results can be further analysed to calculate the 
following parameters (Altman, 1991): 
a. sensitivity (the proportion of true positives that are correctly identified by the test), 
b. specificity (the proportion of true negatives that are correctly identified by the test), 
c. positive predictive value (the proportion of individuals with a positive test who are 
correctly diagnosed), 
d. negative predictive value (the proportion of individuals with a negative test who are 
correctly diagnosed). 
Table 9.3: Effect of a "cut-off' value of 0.28nmol 1/2 cystine per mg protein on the 




Carrier 21 2 23 
Non-carrier 3 31 34 
Totals: 24 33 57 
Sensifivity = 21/24 * 100% = 88% 
Specificity = 31/33 * 100% = 94% 
Positive predictive value = 21/23 * 100 %= 91 % 
Negative predictive value = 31/34 * 100 %= 91 
The 3 obligate heterozygotes with low PMN cystine concentrations (0.23,0.23 and 
0.24 respectively) fall into the "normal range", but were all mothers, thus eliminating 
the question of "non-paternity". Figure 9.2 shows the PMN cystine concentrations for 
controls and carriers transformed into probability density curves (Dennis and Carter, 
1978; Altman, 1991). 
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Figure 9.2: Probability density curves derived from PMN leucocyte cystine 
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Prenatal diagnosis 
Prenatal diagnosis was initially performed with a pulse-labelling technique (Schulman 
et al., 1970d). Schneider et al. confimed the diagnosis of cystinosis following 
amniocentesis in an 18 week old foetus using this technique (Schneider et al., 1974). 
Prenatal diagnosis using chorionic villous sampling was reported simultaneously by 
two groups (Smith et al., 1987; Patrick et al., 1987). Patrick et al. incubated the 
chorion sample with IIS-cystine, separated the products with thin-layer 
chromatography and assessed the uptake by autoradiography. Smith et al. determined 
the cystine content of chorionic villi using the cystine binding protein (CBP) assay and 
reported one positive (affected) case (Smith et al., 1987). Their group have performed 
a number of prenatal diagnoses on chorionic villous (by direct assay and in cultured 
cells) or amniotic fluid samples and the cystine contents (in nmol 1/2 cystine per mg 
protein) are shown below (Smith ML, personal communication): 
Table 9.4: Prenatal diagnosis results from Smith et al. 
CVS (direct) CVS (culture) Amniocyte 
Cystinosis 9.5 3.9 
34.7 9.7 
17.9 7.3 
Unaffected 0.11-0.64 0.12-0.24 0.10 0.04 
(n = 4) (n = 4) (n 8) 
Control 0.09-0.70 0.04-0.26 
(n = 9) (n = 8) 
Only one amniocentesis test has given a positive (affected) diagnosis of 3.9 nmol 1/2 
cystine per mg protein, measured (in 1974) by a radio-labelling technique. 
In view of our experience with the CBP assay, this method was chosen as the 
preferred method at Guy's Hospital (see appendix I for methods). Prenatal diagnosis 
has been undertaken in 7 pregnancies from 6 at-risk couples, 4 by chorion villous 
sampling (CVS), 2 by amniocentesis (Amnio) and I by foetal blood sampling (FBS). 
Foetal blood sampling was undertaken at 20 weeks gestation because an amnio- 
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centesis performed at 16 weeks had failed in culture at another laboratory. A mixed 
leucocyte pellet was prepared from 1.5mls of umbilical cord blood using standard 
methods (see appendix 1). The results of the prenatal tests are shown in table 9.5 
below: 




(nmol Ih cys/mg protein) 
Comment 
I (CVS) 0.12 Confirmed normal 
2 (CVS) 0.40 Child healthy 
3 (CVS) 0.21 Baby healthy 
4 (CVS) 0.65 Baby healthy 
5 (Amnio) 1.63 Termination, no post 
mortem 
6 (Amneo) 0.06 Pregnancy 
continuing 
7 (FBS) < 0.03 Child healthy 




One foetus was terminated on the basis of an amniocyte cystine content of 1.63nmol 
1/2 cystine per mg protein. Although this level seems low, it is IN higher than the 
mean of the unaffected amniocyte cystine concentrations from Smith's group. 
Although requested, foetal specimens were not collected after the termination so that 
the result could not be further validated. 
The most convenient method of prenatal diagnosis in cystinosis is chorion villous 
sampling at approximately 9- 10 weeks gestation. Using the CBP assay, direct . 
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measurement of the cystine content in the sample is straightforward and accurate. It is 
possible to provide an answer within 24 - 48h of receiving the sample. Wherever 
possible, a control CVS should be analysed at the same time and it is advisable to set 
up half of the CVS for culture. This allows a second (fafl-back) specimen to analyse 
and will also provide material for chromosome analysis if needed. 
The eystinosis gene 
Introduction 
The location of the gene responsible for cystinosis is unknown and attempts to isolate 
the human cystine transport protein have so far been unsuccessful. Using somatic cell 
hybrids between cells from patients with the different clinical variants of the disorder 
(infantile, late-onset and benign), Pellet et al. found that no complementation occurred 
(Pellett et al., 1988). This strongly suggests that the three forms of cystinosis are 
allelic. 
Very rarely, children with cystinosis have had an additional genetic disorder raising 
the potential of linkage between the two disorders. However, molecular genetic 
analysis of a pedigree containing a child with both cystic fibrosis (CF) and cystinosis 
showed no linkage between the CF gene and the proband (Smith et at., 1991). There 
has been no report of a child with cystinosis who also has a chromosomal disorder 
(deletion, translocation etc. ). Thus there are no candidate chromosomes for the 
cystinosis gene. 
A project group has therefore býen set up to determine the site of the cystinosis gene. 
The project has received a grant from the Medical Research Council to fund the work. 
Formal collaboration has been established with Dr. Gahl, National Institutes of 
Health, Bethesda, Dr. Taylor (previously the late Dr. Winterborn), Birmingham 
Children's Hospital and Dr. Schneider, University of California, San Diego. 
Strategy for determining the location of the cystinosis gene 
Since the chromosomal location of the cystinosis gene or genes is unknown, a 
systematic search of all autosomes for a linked marker will have to be carried out. 
Although this seems a formidable task, several groups have shown that it is feasible 
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(for example, Mathew et al., 1987). Furthermore, several major recent advances have 
facilitated this approach. First, a substantial number of probes for variable numbers of 
tandem repeats (VNTRs) or minisatellite type sequences are now available (Nakamura 
et al., 1987; Wong et al.; 1987). Microsatellites are di- or trinucleotide repeats which 
are very abundant and widely distributed throughout the genome. The lengths of 
individual microsatellite loci are highly polymorphic and therefore much more 
informative for linkage analysis than restriction fragment length polymorphisms 
(RFLP). Secondly, the polymerase chain reaction (PCR) can be used to amplify 
polymorphic loci from genomic DNA, so that large numbers of samples can be 
amplified in a single day (White et al., 1989). Thirdly, detailed linkage maps of all 
human chromosomes have now been established, such that a set of probes spaced at 
20 centiMorgan intervals along a chromosome can be used to test whether a 
disease locus lies within a particular interval (White et al., 1985; Lander and Botstein, 
1986; Weissenbach et al., 1992). 
In 1990 a postal survey of all the paediatric nephrologists in the UK and Eire, 
identified 79 patients from 66 families. Thirteen of the families are particularly 
suitable for linkage analysis (9 families with 2 affected children and 4 with a 
consanguinous marriage). Details of some of the most informative families are given 
in table 9.6. Two pedigrees, B and C, contain more than one nuclear family; details 
of the pedigrees of families A, B and C are shown in appendix 3. 




A 2 Yes 3 
B 2 Yes 3 
C 3 Yes 3 
D I Yes 3 
&J 2 No 3 
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Two factors significantly increase the linkage information content of these families: 
1. Several families contain a consanguinous marriage. Lander and Botstein have 
shown that since each offspring from such a marriage will be homozygous by descent 
around the disease locus, they provide the same linkage information as a nuclear 
family with 3 affected siblings (Lander and Botstein, 1987). 
2. The ability to distinguish heterozygotes from normal individuals significantly 
increases the linkage content of each pedigree. Although there is some overlap 
between normal and heterozygote cystine concentrations, a probability of an individual 
being heterozygous can be calculated (see above "Heterozygote diagnosis"). This 
probability will then be incorporated into the linkage calculations. 
Heterozygote detection can be used to establish whether the cystinosis gene is of 
grandpaternal or grandmaternal origin, and hence the phase in the parents. 
Furthermore, unaffected siblings yield significant information. Dr. Farrell (Clinical 
Research Centre, Northwick Park) has calculated maximal LOD scores and equivalent 
number of meioses, for the 3 most informative families (pedigrees A, B and 
assuming a highly polymorphic marker which is perfectly linked (see table 9.7 below). 
Calculations have been performed for both "completely recessive" (non-carriers and 
carriers indistinguishable) and "carrier detection" situations. 
Table 9.7: Logarithm of the odds (LOD) scores and number of meioses for pedigrees 









A 1.9 6.2 4.2 14.0 
B 1.4 4.5 5.8 19.4 
C 3.1 10.0 3.9 13.0 
TOTAL: 
:- 









The genetically most informative families have been approached through the paediatric 
nephrologist loolcing after them. Families A, B and C have been extensively studied. 
A further 70 DNA samples have been obtained from UK families and DNA from 12 
North American pedigrees has been sent from Bethesda. 
Heterozygote determination 
Heterozygote determination has been performed on members of pedigrees A, B and C 
according to the methods detailed in appendix I (see appendix 3 for results). Some 
members of family C also suffer from an inherited haemolytic anaemia which led to 
difficulties in the preparation of PMN leucocyte pellets. Many members of family C 
have been studied twice. Individual PMN leucocyte cystine concentrations were 
similar on each occasion and the phenotypic status was confirmed. Borderline PMN 
cystine concentrations (ie. between 0.25 - 0.35 nmol 1/2 cystine per mg protein) were 
found in 3 members of the family on both occasions. These results serve to underline 
the reproducibility of the method. 
LUkage studies 
A systematic search for co-segregation of polymorphic DNA markers with the 
cystinosis phenotype is in process. The linkage search is based on a set of markers 
from every autosome, which are spaced at intervals of approximately 20 
centiMorgans. Probes which detect highly polymorphic sequences and PCR systems 
which detect simple tandem repeats are used wherever possible. 
DNA segments are amplified by PCR, detected using a fluorescent labelling system 
and separated by polyacrylamide gel electrophoresis (PAGE). This is a more rapid 
process than Southern blotting. Fluorescent labelling is used rather than a 
radiolabelling technique for the following reasons: 
1. No exposure to radioactivity 
2. Fluorescent labels are available in 4 colours so that many more markers can be run 
than with monochrome autoradiographs. 
3. A molecular size standard can be labelled with a different colour and thus run with 
each track, reducing sizing errors. 
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4. Fluorescent labels are stable in contrast to the short half-life of P" primers. 
5. Data-analysis is aided by a computerised laser system that rapidly analyses the gels 
directly (without the need for making an autoradiograph). 
6. Since the computer can distinguish different colours even when they overlap, 
several markers can be run in the same track. 
Interim Results 
As of August 1993, The research group has established sets of fluorescently labelled 
primers to microsatellite markers from chromosomes 5 (primers kindly supplied by 
June Davies, John Radcliffe Hospital), 6q, 9,10 and 20. Using the fluorescent 
detection system, 112 microsatellite markers have been analysed in 13 cystinosis 
families but no significantly positive LOD scores have been found. 
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Chapter 10: Conclusions 
Diagnosis and therapeutic monitoring 
The determination of cystine in biological samples using a cystine binding protein 
assay (CBP), (Oshima et al., 1974), has been further studied. The method has been 
improved by the development of a semi-automated assay for protein, using a Cobas- 
Mira autoanalyser. The cystine assay has a lower limit of detection of 0.0314mol/I 
cystine and is linear to a concentration of 1.5/4mol/l. Binding is highly specific and no 
interference is found ftom free thiols or other amino acids. The differential leucocyte 
count in mixed leucocyte pellets is broadly similar to that in the whole blood from 
which the pellets were prepared. 
Clinical applications of this assay have been described. Determination of the leucocyte 
cystine concentration is the most appropriate method of biochemically confirming the 
diagnosis of cystinosis. In a series of 32 patients (not receiving cystine-depleting 
drugs) the mean ± SD leucocyte cystine concentration was 5.78 ± 2.49 nmol 1/2 
cystine per mg protein (controls 0.10 ± 0.05). Besides confirmation of the diagnosis, 
the leucocyte cystine concentration is used to monitor the efficacy of cysteamine and 
phosphocysteamine treatment. As of May 1993, over 700 leucocyte cystine samples 
have been processed. Data on 109 samples from 14 patients treated for at least 12 
months have been presented. The median leucocyte cystine concentration in this group 
was 1.28 (range 0.16 - 6.66) nmol 1/2 cystine per mg protein. Seventy-two percent of 
these concentrations were < 2nmol 1/2 cystine per mg protein, a value considered to 
reflect good control (Markello et al., 1993) and 33% were < Inmol 1/2 cystine per 
mg protein. The CBP assay has also been used to determine the cystine concentration 
in post-mortem tissue samples, amniocytes and chorion villous material. 
In recognition of the practical difficulties of determining leucocyte cystine 
concentration in other laboratories, the effect of storage of blood samples on leucocyte 
cystine concentration was studied. Although pellet preparation of samples stored for 
48 hours was technically more difficult, no significant difference was found between 
the results from samples prepared immediately and those stored for up to 48 hours in 
either acid citrate dextrose-dextran solution or in lithium heparin tubes. Ideally, a 
leucocyte pellet should be prepared immediately and storage of the blood sample 
P 203 
cannot normally be recommended. However, there is negligible loss of accuracy when 
samples are sent to a specialised centre and prepared within 48 hours. It is hoped that 
such work will make the diagnosis and therapeutic monitoring of cystinosis more 
accessible. This is of importance since the prognosis is clearly related to the age at 
which treatment is started. 
A study of tubular proteinuria in 10 newly-diagnosed cystinosis patients was 
undertaken prior to their starting cysteamine. The grossly elevated excretion of retinol 
binding protein, 82-microglobulin and N-acetylglucos-amininidase in these patients was 
confirmed. In 5 patients, the excretion of the tubular brush border enzyme, alanine 
aminopeptidase, was also determined and was found to be markedly elevated. Low 
molecular weight proteinuria is considered to be a very early marker of the renal 
Fanconi syndrome (Tomlinson, 1992). These urine markers are relatively easy to 
determine in random urine samples and could be used to screen children suspected of 
having a renal tubular disorder, prior to the more complicated measurement of 
leucocyte cystine concentration. With the development of urine testing strips for 
NAG, tubular dysfunction could be diagnosed at the bedside or in the clinic. 
Use of cysteamine and phosphocysteamine 
Single dose studies of the pharmacoldnetics and pharmacodynamics of cysteamine and 
phosphocysteamine in patients with cystinosis have been undertaken. The results have 
led to the development of rational and proven dosage guidelines. There is no 
appreciable diurnal variation in leucocyte cystine concentration so that therapeutic 
monitoring is not dependent on the time of day that the sample is taken. Oral 
cysteamine and phosphocysteamine are prescribed on a 12 hourly basis. Different 
routes of administration and formulations of cysteamine have been studied. The data 
show that rectal administration with higher doses may be a feasible alternative for 
patients unable to tolerate the oral route. It is hoped that a suppository of cysteamine 
will be developed as a more convenient form of administration. This may be a more 
acceptable alternative to older children and adults. The intravenous study has yielded 
essential pharmacoldnetic data on the bioavailability of cysteamine and 
phosphocysteamine. Finally, the development of a cysteamine capsule has led to a 
viable oral alternative to phosphocysteamine. Cysteamine was moderately well 
absorbed from the capsule and led to'substantial cystine depletion. Further studies of 
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the pharmacokinetics of new formulations can be expected to improve efficacy, reduce 
side-effects and improve compliance. 
Fifty nine patients with cystinosis have received cysteamine and/or phosphocysteamine 
in the UK and Eire in the period up to May 1990. In the 44 pre-transplant patients, 
the median age at start of treatment was 2.2 years (range 0.6 - 9) and the median 
duration of treatment was 3.6 years (range 0.01 - 11.2). Nausea and vomiting were 
frequent side-effects. There was no difference in this respect between cysteamine and 
phosphocysteamine. There were no serious adverse events that could be attributed to 
these drugs. The mean dose of cysteamine used was much lower than that reported in 
the US multicentre trial (Gahl et al., 1987c). Cysteamine treatment did not prevent a 
progressive decline in glomerular renal function. However in the absence of control 
data, it is not possible to prove whether cysteamine treatment affected the rate of 
progression of renal damage. The mean height SDS remained stable during treatment 
indicating that a normal growth rate was maintained. The inability to demonstrate a 
significant reduction in leucocyte cystine concentrations suggests that monitoring of 
therapy needs to be improved. These data contrast with the excellent results being 
achieved in North America (Markello et al., 1993), and highlight the need for more 
aggressive use of cysteamine in the UK. 
Growth in children with cystinosis 
Data on growth in children with cystinosis at Guy's Hospital have been presented. In 
a group of 6 newly-diagnosed patients, whose mean age was 15.3 months, the mean 
height standard deviation score was -3.1. Growth remains poor throughout childhood 
although some have responded well to cysteamine treatment. Growth hormone 
secretion as measured by overnight profile, was normal in 4 prepubertal children. 
When maximal growth hormone secretion was determined following an infusion of 
arginine, one of three patients had a sub-optimal response. It is likely that growth 
failure in cystinosis is primarily related to the severity of the renal disorder rather 
than to deficient growth hormone secretion. 
A trial of high dose recombinant human growth hormone (rhGH) therapy in cystinosis 
has been described. In the short-term, rhGH treatment has led to an improvement in 
height velocity and height standard deviation score (HtSDS), without any significant 
P 205 
effect on renal function or glucose tolerance. Longterm data are required to establish 
the role of rhGH treatment in cystinosis. 
Genetics of cystinosis 
A strategy for determining the cystinosis gene by linkage analysis has been described. 
The most genetically informative cystinosis families in the UK have been identified. 
Determination of the polymorphonuclear leucocyte cystine concentration enabled 
heterozygotes for cystinosis to be distinguished from normal individuals in 
approximately 90% cases. The median polymorphonuclear leucocyte cystine 
concentration in a group of 24 obligate heterozygotes was 0.55 (range 0.23 - 1.79) 
nmol 1/2 cystine, per mg protein (controls 0.10, range 0.04 - 0.38). A method for 
searching the genome using a fluorescent labelling technique has been described and a 
collaborative study is now in progress. Interim results have been presented. It is 
hoped that the location of the cystinosis gene will be found within the next few years. 
This will lead to a study of the gene mutations in cystinosis, an attempt to isolate the 
gene product and perhaps ultimately a possibility of gene therapy. 
Although cystinosis is extremely rare, prompt diagnosis and early treatment with 
cysteamine or phosphocysteamine are required to ensure a good prognosis. Even in 
the 1990s, children have died prior to the diagnosis being made and there are children 
in the UK who still do not receive cysteamine treatment. It is to be hoped that the 
work in this thesis will contribute towards an improvement in the diagnosis, treatment 
and future for children with cystinosis. 
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Appendix 1: Analytical methods 
Mixed leucocyte cell pellet preparation 
Chenfleals required: 
a) ACD-Dextran solution: 
3g Dextran (Sigma D-7265, MW2xlOl' - 2.75xl0l), 
2.1 g Dextrose, 
0.33g Sodium Citrate, 
O. llg anhydrous Citric Acid 
made up to 100ml of 0.9% Sodium Chloride. 
b) 0.9% Sodium Chloride 
c) 3.6% Sodium Chloride 
d) Distilled water 
e) 12% 5-Sulphosalicylic Acid 
(All solutions were filtered through a 0.22liM Millipore filter in a vacuum flask prior 
to use and were kept at 40C between assays) 
f) Wet Ice 
Procedure 
1.3mls of ACD-Dextran solution in a 15ml. test tube (Elkay Products, Inc. 000-2087- 
000) were allowed to stand at room temperature prior to use. Other solutions were 
kept on wet ice. 
2.3mls. venous blood were taken into a syringe primed with a small amount of 
heparin (1000iu/ml). 
3. The blood was immediately added to the ACD-Dextran solution and inverted gently 
until well mixed. The tube was stood in ice for 45 minutes to allow the red cells to 
precipitate. 
4. After 45 minutes the supernatant was transferred to another 15ml test tube. The 
tube was spun in a pre-chilled centrifuge at 50C, at 450 xg for 10 minutes to 
precipitate the leucocytes. 
5. The supernatant was discarded using a water vacuum aspirator, leaving a red pellet. 
6.0.8 mls. of 0.9% sodium chloride were added and the tube held on a vortex mixer 
until the pellet was resuspended. 2.4 mls. of distilled water were added and the tube 
was vortexed continuously for 90 seconds. 0.8 mls. of 3.6% sodium chloride were 
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then added to restore the suspension to isotonicity and briefly vortexed to ensure 
mixing. The tube was centrifuged at 450 xg for 3 minutes at 5*C. 
7. The supernatant was discarded using a water vacuum aspirator and the hypotonic 
lysis step was repeated, usually once but twice if the resulting pellet remained 
contaminated with red cells. 
8. After the supernatant had been discarded the pellet was washed by adding 3-OmIs 
of 0.9% sodium chloride and briefly vortexed to resuspend the leucocytes. The pellet 
was precipitated by centrifugation at 450 xg at 5C for 3 mins. 
9. The supernatant was discarded and the pellet taken to dryness with a water vacuum 
aspirator. 150, ul of distilled water were added and the tube was vortexed briefly. 
10. The leucocYte suspension was lysed by ultrasonication using a Sonipen High 
Power Cell Disrupter (Technic International, Inc. ). 5 short (I second) bursts of 
sonication were used to disrupt the leucocyte cell membranes. 
11. The suspension was transferred to an Eppendorf/Microfuge tube to which has 
been added 501AI 12% 5-sulphosalicylic acid to precipitate the protein fraction. The 
tube was vortexed briefly to ensure mixing. 
12. The pellets were stored at -7OoC pending determination of the cystine and protein 
contents. 
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Polymorphonuclear leucocyte cell pellet preparation 
Chemicals required: 
a) 0.9% Sodium Chloride in 5mM EDTA 
b) 0.9% Sodium Chloride 
c) 3.6% Sodium Chloride 
d) Distilled water 
e) Phosphate buffered Saline (PBS): 
800mg sodium chloride, 
200mg potassium chloride, 
1.15gm di-sodium hydrogen phosphate 
made up to I litre with distilled water and buffered to pH7.2. 
f) 12% 5-Sulphosalicylic Acid 
g) 0.2 M Sodium EDTA 
h) lOmM Potassium phosphate buffer 
(All solutions were filtered through a 0.2214M Millipore filter in a vacuum flask prior 
to use and were kept at 4"C between assays) 
i) N-Ethylmaleimide (Sigma E-3876) 
2.6mg NEM in 4. Omls of potassium phosphate buffer was prepared on the day 
of the assay. 
j) Histopaque-1077 (Sigma 1077-1) 
k) Histopaque-1119 (Sigma 1119-1) 
All solutions (except the Histopaque gradients) were kept at VC between assays or on 
wet ice during the pellet preparation. The Histopaque gradients were kept at VC 
between assays but were allowed to stand at room temperature for I hour prior to use. 
Procedure 
1. Three 15 ml test tubes (Elkay Products, Inc. 000-2087-OW) were marked for each 
patient. The first (gradient tube) was marked at 3,4.5 & 6mls. The second (blood 
collection tube) was marked at 4.5 &9 mls. The third tube was marked at 12mls. 
2. A Pasteur pipette was used to carefully add 3 mls. of Histopaque- 1119 to the 




3.0.25mls of 0.2M sodium EDTA were added to the second (blood collection tube). 
4.5 - 5mls of venous blood were taken into a heparinized syringe and immediately 
added to the blood collection tube. The tube was gently inverted several times to mix 
and placed on ice until all the blood samples had been taken. 
4.4.5mls PBS were added to the blood and the tube mixed by inverting several times. 
Gradient preparation 
5. A Pasteur pipette was used to very slowly (over 3-5 mins) add 3mls of Histopaque- 
1077 to the gradient tube. The two layers of Histopaque were seen to be separated by 
a meniscus. 
6. A Pasteur pipette was used to very gently pipette the blood onto the Histopaque 
gradient. 
Isolation of polymorphonuclear cell: 
7. The tube was spun at 450 xg for 20 mins at room temperature (20*C), and 
allowed to decelerate without any centrifuge brake so as not to disturb the gradient 
layers. 
8. The centrifuge was run at 450 xg at 5*C for 10 minutes to chill it in preparation 
for the next stage. 
9. A vacuum aspirator was used to carefully discard the supernatant down to the 
4.5ml mark, removing at the same time the lymphocyte layer. 
10. A Pasteur pipette was used to transfer the layer containing the polymorphonuclear 
leucocyte cells to the third test tube, being careful not to take up any red cells. 
CeH wash 
11. The polymorphonuclear leucocyte cells were diluted with 0.9 % sodium chloride 
containing 5mM EDTA up to the 12ml mark. The tube was spun at 450 xg at VC 
for 10 minutes and allowed to decelerate with the centrifuge brake in the off position. 
Hypotonic red cell lysis 
12. A vacuum aspirator was used to remove the supernatant down to the pellet. 
0.8mls. of 0.9% sodium chloride were added to gently resuspend the pellet. 2-4mls- 
of distilled water were added and the tube vortexed briefly. After 90 seconds 0.8mls. 
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of 3.6% sodium chloride were added to restore isotonicity. The pellet was precipitated 
by centrifugation at 450 xg for 3 minutes at 50C. 
CeU wash 
13. A vacuum aspirator was used to remove the supernatant down to the pellet. 
Occasionally, if the pellet still appeared to be contaminated with red cells, the 
hypotonic red cell lysis step was repeated. 4. Omls. of 0.9% sodium chloride 
containing 5mM EDTA were added and the pellet resuspended and centrifuged as 
before. 
Polymorphonudear leucocyte cell lysis 
14. A vacuum aspirator was used to remove the supernatant and dry the leucocyte 
pellet. 150jul of the N-ethylmaleimide solution were added and the pellet resuspended 
by briefly vortex mixing. 
15. The leucocyte suspension was lysed by ultrasonication using a Sonipen High 
Power Cell Disrupter (Technic International, Inc. ). 5 short (I second) bursts of 
sonication were used to disrupt the leucocyte cell membranes. 
16. The suspension was transferred to an Eppendorf/Microfuge tube to which has 
been added 50, ul 12% 5-sulphosalicylic acid to precipitate the protein fraction. The 
tube was vortexed briefly to ensure mixing. 
17. The pellets were stored at -70oC pending determination of the cYstine and protein 
contents. 
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Determination of cystine in cultured cells and tissue specimens 
Chemicals required: 
a) 0.9% Sodium Chloride 
b) Distilled water 
c) 12% 5-Sulphosalicylic Acid 
(All solutions were filtered through a 0.22, uM Millipore filter in a vacuum flask prior 
to use and were kept at 4oC between assays) 
f) Wet Ice 
Procedure 
1. The sample was washed to remove blood (and in the case of cultured cells, 
extraneous cystine in the medium) in 0.9% sodium chloride by vigorous pipetting 
using a wide mouth pipette. 
2. The tissue was pelleted by centrifugation at 450 x, g for 5mins at VC and the 
supernatant discarded. 
3. The tissue was disrupted in a centrifugal micro-homogeniser system (Hearse, 
1984). 
4.200til of dH20 were added and the suspension was lysed by ultrasonication using a 
Sonipen High Power Cell Disrupter (Technic International, Inc. ). 5 short (I second) 
bursts of sonication were used to disrupt the leucocyte cell membranes. 
5.67AI 12% 5-sulphosalicylic acid were added to precipitate the protein fraction. The 
tube was vortexed briefly to ensure mixing. 
6. The supernatants and protein pellets were stored at -700C pending determination of 
the cystine and protein contentg respectively. 
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Preparation of the sample for determination of the cystine and protein contents 
0 Chemicals required: 
a) 1.66M Sodium hydroxide 
b) 1M Sodium acetate, pH5 
c) O. lM Sodium hydroxide 
(All solutions were filtered through a 0.22jim Millipore filter in a vacuum flask prior 
to use and kept at 4"C between assays) 
Method 
1. The samples were thawed on a rollermixer and the protein fraction pelleted by 
centrifuging the sample in a microcentrifuge for 2 mins. 
2. Using a 200jil pipette and noting the exact volume, the protein free supernatant was 
removed into a microfuge tube for cystine determination. 
3.5001410. IM Sodium hydroxide were added to the protein pellet and the tube 
vortexed over 2-3 mins. The protein sample was then frozen at -70*C pending 
determination of the protein concentration. 
4.25141 1.66M Sodium hydroxide and 25jul 1M Sodium acetate were added to the 
cystine sample tube and the mixture briefly vortexed. 
5. The pH of the sample was measured by testing a 3-5, ul aliquot on a pH paper strip. 
51A aliquots of either 1.66M Sodium hydroxide or 25, ul IM Sodium acetate were 
added to the cystine sample tube until the sample measured pH 5. The volume of 
buffer added was noted. Samples were either used directly or frozen at -70*C pending 
determination of the cystine concentration. 
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Determination of the protein concentration 
Introduction 
The protein concentration was determined by the method of Lowry et al., modified 
for use on a Cobas-Mira autoanalyser (Lowry et al., 1951). The Lowry method uses 
two steps, firstly the protein sample is incubated with alkaline copper solution. 
Secondly, Folin-Ciocalteu reagent is added and the sample incubated for 30 minutes, 
after which the resulting colour change is determined by a spectrophotometer. Clifton 
et al. described a modification of the Lowry assay for use on a Cobas-Bio centrifugal 
analyser allowing rapid multiple analyses (Clifton et al., 1988). Clifton et al. found 
that the colour reaction was accelerated threefold at 37*C compared with 25*C, 
allowing a reduction in the time of the second incubation. Further they found a linear 
relationship between the time of the first incubation and final absorbance values, so 
that the first incubation could be reduced to 60 seconds without any detriment in 
accuracy. 
The methods of Clifton et al. were adapted to a Cobas-Mira Centrifugal analyser. 
Chemicals required: 
a) 2% Cupric sulphate (CuS04.51120), (BDH Analar) 
b) 3% Anhydrous sodium carbonate (BDH Analar) in OAM sodium hydroxide, 
containing 8AI Sodium dodecyl sulphate (BDH Prod-44215) per 100mls 
c) 4% Sodium tartrate dihydrate (Sigma S8640) 
d) 2M Folin Ciocalteu phenol reagent (Sigma F2952) 
e) lmg/mI Protein standards (Sigma P0914) 
Methods: 
1. The protein pellet samples were thawed on a rollermixer, spun briefly in a 
microcentrifuge and inspected to ensure that the pellet had dissolved in the sodium 
hydroxide. (Occasionally, more than 500, ul of 0. IM sodium hydroxide were added to 
the protein sample to dissolve the pellet. The exact volume of sodium hydroxide 
required was noted). 
2.501AI protein sample were pipetted into a Cobas-Mira sample cup. 
3. The sample cups were placed in a rack, interspersed every 5 samples, with 2 
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sample cups containing 501AI dH20 and 50/Al protein standard (Img/ml) respectively. 
4. Lowry reagent C was prepared by mixing 20mls 3% Sodium carbonate, 200AI 4% 
Sodium tartrate and 200til 2% Copper sulphate. 
5. Main reagent (Lowry reagent Q and start reagent (2mls Folin Ciocalteu reagent) 
were placed in cups in the appropriate positions in a rack "5". 
6. A sample needle dedicated to the protein assay was used. Prior to starting, the 
needle was primed for 30 seconds. 
7. The Cobas Mira settings were as shown on the menu (enclosed). Samples were run 
in duplicate and the blank and standard results reviewed to check for drift during the 
assay run. 
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Determination of the cystine concentration using the cystine binding protein assay 
(Based on the methods of Oshima et al., 1974) 
Chemicals required: 
a) 100mM Sodium acetate, pH5 
b) Cystine binding protein "cocktail" (see below for composition) 
c) Cystine standards (see below for composition) 
d) Scintillation fluid (0.5% Butyl PBD, (Sigma B 8378), in toluene) 
Cystine binding protein "cocktail" 
Chemicals required: 
Bovine serum albumin (Sigma A 7888) 
Cystine binding protein (CBP), (Riverside Scientific Enterprises, Bainbridge Island, 
WA 98110, USA)o 
"C-Cystine (65jAM, NEN Research Products NEC-465) 
IM Sodium acetate pH 5.0 
lOOmM Sodium acetate pH 5.0 
(The sodium acetate solutions were filtered through a 0.22ym Millipore filter in a 
vacuum flask prior to use and kept at OC between assays) 
1.6514M "C-Cystine was diluted to a final concentration of MkM with 100mM 
sodium acetate (typical volumes used were 251A 14C_Cystine with 4.19mls of acetate). 
20141 of the 0.4; tM 14 C-Cystine were spotted onto 2 nitrocellulose filters (24mm 
diameter, Schleicher and Schueft BA 80,0.45, um, Ref No 401104) and dried under a 
heat lamp. The dry filters were placed in 6mls of scintillation fluid and the counts 
measured over 10 minutes in a liquid scintillation counter (Beckman LS 1800). The 
counts needed to be between 4100 and 5000 to ensure an appropriate slope for the 
standards in the cystine assay (see below). The diluted 0.4, UM 14C_Cystine was frozen 
in aliquots at -70*C until required. Each dilution of 65juM 14 C-Cysfine was checked in 
this way. 
2.10mls of a solution of 0.4mg/ml BSA in lOOmM sodium acetate were prepared and 
filtered through a 0.221&m Millipore filter. The CBP was diluted I in 6 with 0.4mg/ml 
BSA in sodium acetate solution by adding 1.2ml CBP to 6. Omls of BSA solution. The 
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albumin acts as a stabiliser to the CBP. The CBP in albumin was divided into aliquots 
and frozen at -70*C until required. 
3. Cystine binding protein "cocktail" was prepared prior to the assay by adding 
0.4, uM 14C_Cystine and 1M sodium acetate to the diluted CBP according to the 
volumes given in table Al. I below: 
Table Al. 1: Dilution of cystine binding protein 








0.4 0.16 0.4 12 
0.8 0.32 0.8 28 
1.2 0.48 1.2 41 
1.6 . 0.64 1.6 60 
The cocktail was used directly or kept frozen for a maximum of 2 weeks. 
Cystine standards 
Stock solution of 50014M Cystine in 0.1 M Hydrochloric acid was kept in aliquots, at - 
70"C. Standards were prepared as follows: 
1.50jul of 500juM Cystine in 0. IM Hydrochloric acid were added to 4950jul of 
100mM sodium acetate, pH5 giving a 514M Cystine solution. 
2. Standards were prepared in 100mM Sodium acetate, pH5, as detailed in table Al. 2 
below: 
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Table AI. 2: Composition of cystine standards 
Cystine 
standard CuM) 
Volume of 100mM 
Sodium acetate Ws) 
Volume of 514M 
Cystine solution 
0 1.00 0 
0.05 0.99 10 
0.1 0.98 20 
02 0.96 40 
0.3 0.94 60 
0.4 0.92 80 
0.5 0.90 100 
0.6 0.88 120 
The cystine standards were kept at -70"C between assays. 
Methods 
1. The samples were thawed to room temperature on a rollermixer and centrifuged in 
a microcentrifuge for 1-2 mins. 
2. The samples were diluted to fall within the worldng range for the cystine binding 
protein assay using 100mM Sodium acetate, pH5. The dilutions used were determined 
by the following factors: 
a. whether the patient is on cysteamine or phosphocysteamine treatment (and if so, the 
time of the sample in relation to the last dose), 
b. the size of the sample pellet as judged by the protein concentration and 
c. the dilutions used for that patient in previous assays. 
For samples from individuals suspected of having cystinosis, initial dilutions were as 
follows: neat, I in 2,1 in 20 and I in 50. 
3. Using forceps one nitrocellulose filter (24mm diameter, Schleicher and Schuell BA 
80,0.45jAm, Ref No 401104) for each sample and standard were placed in a petri dish 
containing lOmM Sodium acetate to ensure hydration. 
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4.501AI of the standards and diluted samples were pipetted into microfuge tubes. 
5.60,41 of CBP cocktail were added to each sample tube at 20 second intervals and 
the tube vortexed briefly to ensure mixing. When CBP cocktail had been added to all 
the tubes, they were briefly spun in a microcentrifuge and incubated at room 
temperature for 30 minutes. 
6. The "wash" syringe was primed with lOmM Sodium acetate and a vacuum pressure 
of 5 inches Hg maintained by a water vacuum aspirator. 
7. Following incubation, a nitrocellulose filter was carefully placed on the filter holder 
causing the vacuum pressure to increase to 10 inches Hg. At this pressure, 1001AI of 
the incubated sample were carefully pipetted onto the centre of the filter. 
8. The filter was immediately washed with 6001A lOmM Sodium acetate, delivered by 
the "wash" syringe. The filter was then taken off and placed on a clean piece of 
aluminium foil in a tray. 
9. When all the samples had been pipetted, the filters were dried under an infra-red 
heat lamp for 45 minutes. 
10. The filters were then placed in 20ml scintillation vials to which were added 6mls 
scintillation fluid. 
11. The radioactivity remaining on the filters was determined by using a Beckman LS 
1800 liquid scintillation counter. Counts were accumulated over 10 minutes or until 
10,000cpm. 
P 243 
Calculation of the leucocyte cystine concentrations 
Taking the counts for the zero standard as CPM.., the ratio 
CPM.. 
. i.. 
/CPM,, b,,,,,, was calculated for each standard and sample. A linear 
regression of CPM.,,, /CPM,, b, on standard cystine concentration was performed. The 
slope of this regression line was normally 4.5 - 5.0 and the y intercept approximately 
1.0 ± 0.1. If the values of slope and intercept fell outside these ranges, the assay 
was repeated with a fresh CBP cocktail. The values of CPM. /CPM,, b. were plotted 
against cystine standard concentration as a visual check on the assay. "Raw" cystine 
concentrations in each sample were calculated from the regression curve. These values 
were then adjusted to take into account the volume of supernatant in the sample, the 
volume of buffers added and the dilution performed. The adjusted values were 
factored by the mean protein concentration for the pellet to account for cell recovery 
and expressed in nanomoles 1h cystine per milligram protein. 
These calculations were incorporated into a spreadsheet using SmartWare II (Informix 
Software, Inc. ), allowing rapid generation of the regression plot and providing a 
hardcopy of the data. 
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Appendix 2: Determination of plasma cyst ie 
Reduction of plasma cysteamine 
Chemicals required: 
a) 7M Urea in water (Sigma U-1250) 
b) 100mg/ml Sodium borohydride (Sigma S-9125) in 0.1M sodium hydroxide 
c) 10% Trichloroacetic acid (Sigma T-4885) 
Methods 
1. Plasma samples were thawed on a rollermixer and briefly microcentrifuged. 
2. Cysteamine standards were freshly prepared as follows: 
50AI of lmM cysteamine in OAM HCI (stock solution stored at -70*C) were added to 
150, ul dH20 to give a 2501AM solution. 501AI of the 250, uM cysteamine solution were 
added to 200jAI dH20 to give a 501AM solution. 201AI of the 501AM cysteamine solution 
were added to 180, ul of dH20 to give a solution of 5jAM cysteamine. 
3.10141 of dH20,5,50 or 250, uM cysteamine were added to one of four 15ml 
polypropylene test tubes containing 40, ul of the patient's pre-drug plasma to give 
standards of 0,2,20 and 100AM cysteamine respectively. 
2.40AI patient plasma were pipetted into a 15ml polypropylene test tube, to which 
were added IOAI dH20. 
3.250, ul 7M Urea and I drop Octanol (Sigma 0-4500) were added and the tube 
vortexed briefly. 
4.25/Al Sodium borohydride solution were added to each tube which was then covered 
with Parafilm and briefly vortexed. 
5. The tubes were incubated and agitated at 50*C in a water bath for 30 minutes. 
6. The reduction was stopped by the addition of 2501AI of cold 10% trichloroacetic 
acid. 
7. The tubes were centrifuged at 3000 xg for 15 minutes at room temperature to 
precipitate the protein fmction. 
8. The supernatant was transferred to a 22tiM filter cup in a microfuge tube 
(Millipore Ultrafree-MC, UFM OGV 00) and centrifuged for 5 mins. 
9. The filtered protein-free samples were frozen at -70*C pending analysis. 
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Preparation of mobile phase for high pressure liquid chromatography 
Chemicals required: 
a) Monochloroacetic acid (Sigma C-0266) 
b) Ethylamine (70%, w/v), (Sigma E-3754) 
c) Octyl sulphate (Sigma 0-4003) 
Methods 
1.4.73g of monochloroacetic acid (MCA) were made up to 1 litre with dH20 to 
form 
a solution of 0.05M MCA. 
2.3mls of Ethylamine (70%, w/v aqueous) and 60mg Octyl sulphate, were added. 
3. The solution was buffered to pH 3.10 by the addition of further monochloroacetic 
acid or IM Acetic acid. 
4. The mobile phase was filtered through a 22tiM filter on a vacuum flask prior to 
use. 
5. A Waters 501 HPLC pump set at Iml/hr was used to recycle mobile phase for 7 
days prior to use to reduce the effect of impurities on the analyte response. 
High pressure liquid chromatography 
Principles of electrochemical detection 
Electrochemical detection (ECD) is based on the measurement of a current generated 
by the oxidation or reduction of the analyte when it is exposed to a voltage applied to 
an electrolysis cell, as a function of elution time. The electrolysis cell consists of a 
test electrode at which the electrolysis of the analyte occurs, an auxillary cell at which 
the complimentary electrolytic reaction occurs and a reference electrode which 
provides a constant potential used in measuring the potential at the test electrode. 
Amperometric measurement requires both an electrolysis cell and a potentiostat which 
adjusts the voltage of the control amplifier until the signal potential and the difference 
in potential between the test and reference electrodes are equal. The potential applied 
to the test electrode will affect sensitivity and background noise (due to electrolysis of 
other components and contaminants in the eluent). The optimal test potential must 
therefore be individually derived for the mobile phase and substance being analysed. 
An amperometric detector produces a current signal proportional to the analyte 
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concentration. In most systems between I and 5% of the analyte is electrolysed. When 
the proportion of analyte being electrolysed approaches 100%, the detector is said to 
be coulometric and the response is directly proportional to the analyte concentration. 
The advantages of coulometric detectors are: 
1. Enhanced signal stability (since impurities on the electrode surface will not affect 
response until > 95% area is covered) 
2. The signal due to analyte electrolysis is maximised 
3. Dual electrodes in series can further enhance selectivity. 
The ECD used in this work was the ESA Model 5100A Coulochem. The electrolysis 
cell has two electrodes in series. The second (downstream) electrode is used as the 
test electrode. The first (upstream) electrode can be used in "screen" or in "redox" 
mode. Once the optimal working potential to apply to the test electrode is known, a 
second potential selected from the lower end of the response vs. test potential curve, 
can be applied to the screen electrode. This will serve to reduce background current 
and prevent unwanted peaks from impurities that are electrolysed at potentials lower 
than the working potential. Redox mode is used when the electrolysis of the substance 
being analysed can be reversed. For instance, reduction is caused at the first electrode 
and then oxidation at the second electrode (set at an opposite polarity to the first). Use 
of the redox mode can improve selectivity and reduce noise. 
The mobile phase serves to maintain conductivity of the solution, controls the pH and 
minimises ionic migration of the analYte. Purity of the mobile phase is of paramount 
importance since the current created by analyte electrolysis will be significantly 
affected by electrolysis of contaminants. The noise thus created can be reduced by 
using only "high grade" purity components and organic solvents, by filtering the 
mobile phase prior to use and by recycling it prior to use. Recycling allows impurities 
to be electrolysed sequentially as they pass through the cell so that after some time, 
the mobile phase is "purer". 
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Procedure 
1. Reduced plasma samples were thawed and microcentrifuged prior to use. 
2. Nitrogen was bubbled through each sample for 1 min. to maintain cystearnine in its 
reduced state. 
3.60, ul were injected via an injection port onto a Hichrorn S50DS2 -2879 column. 
4. The chromatography of cysteamine varied from run to run but generally eluted at 
approximately 5 minutes. 
5. The analytes were detected using an ESA Model 5011 Analytical cell, controlled by 
the ESA Coulochern 5100A electrochemical detector. 
6. Typical operating settings were as follows: 
Electrode 1: Operating potential +0.10V 
Electrode 2: Operating potential +0.60V 
Gain xIO 
Response time 0.4s 
7. The output from the Coulochem detector was integrated using a Spectra Physics 
SP4270 integrator. 
8. Samples were run in duplicate and as far as possible, in ascending concentration 
order. 
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Appendix 3: Cystinosis pedigrees 
EI 
II 
Key to pedigrees 
: Homozygous affected 
: Heterozygous 
: Hornozygous unaffected 
rmm 
LA : Borderline result 
Mn 
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